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Summary
GABAg receptors are G-protein-coupled receptors for gamma-aminobutyric acid 
(GABA), the main inhibitory neurotransmitter in the brain. Functional GABAg 
receptors are formed by the assembly o f GABAg] and GABAg: subunits. Genetic 
deletion of either subunit in mice abolished GABAg receptor-mediated inhibition 
resulting in epilepsy and shortened life-span. The two main isofbrms o f the GAB Agi 
subunit, GABAgia and GABAgib, form two receptor subtypes GABAg(%a, 2) and 
GABAg(ib, 2), and show differential synaptic localisation in several brain areas. In the 
amygdala, hippocampus, thalamus, and neocortex, the GABAgia containing receptors 
have been demonstrated at presynaptic glutamatergic terminals, whereas, GABAgib 
containing receptors were fbund at postsynaptic sites. In addition, both GABAgi 
isofbrms may function as autoreceptors on GABAergic terminals. This study aimed to 
further understand the roles of GABAg receptor subtypes in modulating synaptic 
inhibition and neuronal excitability.
Receptor subtype expression was examined in the brain nuclei o f GABAgia"' and 
GABAgib'^' mice by immunohistochemistry using antibodies selective fbr the GABAgi 
and the GABAg2 subunits. The modulation of synaptic inhibition by GABAg receptor 
subtypes was investigated in the dentate gyrus o f the GABAgia" ' a^id GABAgib"^" mice 
by perfbrming electrophysiological recordings in brain slices. The net effect of 
GABAg receptors on neuronal excitability was then compared by scoring seizure 
activities induced by a chemoconvulsant in GABAgia"^" and GABAgib"^" mice.
GABAgi staining was fbund to be widely reduced in both GABAgia"^" and GABAgib"^" 
brains. However, expression of GABAg2 was selectively reduced in the caudate 
putamen and amygdala in the GABAgia"^" mice and in the thalamus o f GABAgib"" 
mice, suggesting a predominant expression of the GABAgia and GABAgib subtypes in 
different brain nuclei. As the caudate putamen neurons were shown previously to have 
no intrinsic expression of GABAg2 transcripts, the GABAgia containing subtypes are 
likely to be expressed on terminals of afferent projections to this region. The lack of 
GABAgia may, therefore, also affect the interaction between different brain nuclei. The 
lack of GABAgib subtypes, predominantly in the thalamus of GABAgib"^" mice, may 
affect postsynaptic inhibition and result in increased neuronal excitability.
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In the hippocampal formation, glutamatergic pathways in the CAl and CA3 are mainly 
modulated by the GABAgia subtype. The dentate gyrus, a key region involved in 
seizures and epilepsy, receives excitatory inputs via the perforant pathway and the 
associational/commissural pathways and sends glutamateric outputs to the CA3 via 
mossy fibres. However, no GABAg heteroreceptor-mediated inhibition was fbund at 
the perfbrant pathway-dentate gyrus granule cell terminals. In agreement, staining in 
the dentate gyrus molecular layer associated with perfbrant pathway input to the 
granule cells was fbund not to differ between the genotypes. Staining of the 
glutamatergic associational/commissural pathway terminals showed GABAgia 
containing receptors demonstrating a differential localisation fbr the receptors in the 
dentate gyrus. In contrast to the CAl and CA3, activation o f either the GABAgia or 
GABAgib receptors induced disinhibition via inhibition of GABAergic tramsission in 
the dentate gyrus. This excitatory effect was enhanced in the GABAgib" ' mice and was 
likely due to loss o f GABAg-mediated postsynaptic inhibition.
Finally, acute seizure models were implemented to study the role of each receptor 
subtype in the control of excitability. GABAgia' " mice were fbund to display higher 
seizure activity invoked by the chemoconvulsant pentylenetetrazol, demonstrating that 
GABAgia isofbrm exerts a greater overall inhibitory effect in the brain than the 
GABAgib isofbrm. Pre-treatment with baclofen, a GABAg receptor agonist, decreased 
seizure activity in GABAgia" ", with little effect in GABAgib"^" mice. Activation of the 
GABAgia containing receptors causes excitation in the dentate gyrus, which is 
subsequently responsible fbr inhibition in the CA3 and CA l. In addition, the GABAgia 
subtype is important fbr modulating excitatory communication between brain nuclei, 
their loss may promote spreading o f seizure activity and reduction of seizure 
thresholds.
Overall, the results o f this study show differential expression of GABAg receptors 
subtypes in brain nuclei and between synaptic pathways. Collectively, it was fbund 
that the absence of GABAg(ia, 2) receptors increased the net excitability of the brain and 
enhanced chemoconvulsant-induced seizure activity. Genetic mutation and 
autoimmunity to the GABAg(ia, 2) may therefbre underlie certain types o f epilepsy and 
seizures observed clinically.
-IV-
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1 General Introduction
1.1 GABA and Inhibition
1.1.1 GABA Mediated Inhibition
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the 
central nervous system and has been shown to bind to two distinct receptor subtypes, 
the ionotropic GABAA and the metabotropic GAB As. At postsynaptic sites, GABA 
hyperpolarises neurons with inhibitory postsynaptic currents (IPSC) consisting of fast 
and slow components that inhibit synaptic transmission (Solis and Nicoll, 1992). The 
GABAA receptor forms ion channels facilitating the conductance of chloride ions 
across the plasma membrane and these are responsible fbr the fast IPSC (Figure 1.1). 
Whereas, GABAg receptors are guanine nucleotide-binding protein (G-protein) 
coupling receptors (GPCRs), mediating their effects via second messenger systems, 
giving a slower but longer lasting IPSC (Figure 1.1). In addition to these postsynaptic 
effects, GABAg receptors are also located at presynaptic terminals, acting as either 
autoreceptors or heteroreceptors, to decrease neurotransmitter release (Bettler g/ ar/., 
2004).
A Control B CGP35348
200 ms
Picrotoxin
CGP35348 + 
Picrotoxin
Figure 1.1 -  GABAa mediate fast synaptic inhibition and GABAg m ediate slow 
synaptic inhibition
The slow component inhibitory postsynaptic potentials (IPSPs; A), mediated by 
GABAg receptors, were blocked by the GABAg antagonist CGP35348 (B). The fast 
component, mediated by GABAA receptors, was blocked by the GABAA receptor 
antagonist picrotoxin (C) in hippocampal CAl pyramidal cells. Both fast and slow 
IPSPs were blocked by application o f both CGP35348 and picrotoxin (D). Figure 
adapted from Solis and Nicoll (1992).
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1.1.2 GABAa Receptors
The GABAA receptor is part of the Cys-loop superfamily along with nicotinic 
acetylcholine, 5-hydroxytryptamine type 3 and glycine receptors (as reviewed by 
Miller and Smart, 2010). These receptors are ligand-gated ion channels vshth a 
heteromeric pentamer structure around a central pore. In GABAA receptors this pore is 
selective fbr chloride ions and when activated it hyperpolarises the neuron resulting in 
an inhibition o f action potential generation. However, in neonatal animals up to two 
weeks postpartum, GABAA receptor activation can depolarise the neuron, causing 
excitation, due to a difference in the chloride ion gradient across the plasma membrane 
(as reviewed by Ben-Ari, 2002). Classically defined GABAA receptors are blocked by 
the antagonist bicuculline, however, another GABA binding ionotropic receptor which 
was not blocked by bicuculline has been identified (Drew g/ a/., 1984). This receptor 
was initially termed the GABAc receptor, however fbr unifbrmity it has been 
reclassified as a sub-type of the GABAA receptor, GABAA-p, due to its shared 
evolutionary history, structure and function with these receptors (as reviewed by 
Barnard g/^  a/., 1998). Expression of GABAA-p subunits has been demonstrated at the 
messenger ribonucleic acid (mRNA) level in the ovary, testis, spinal cord, cerebellum, 
denate gyrus and hippocampus (Rozzo g^  n/., 2002). These receptors have been shown 
to be present in the neonatal spinal cord and have some functions in spinal neurons in 
electrophysiological recordings (Rozzo et al., 2002), but were without a physiological 
effect in whole cord recordings (Schmitt gr a/., 2004). In addition, GABAA-mediated 
effects in the mouse retina were mediated by the bicuculline-sensitive GABAA 
receptors and not the GABAA-p subtype (Feigenspan and Weiler, 2004). Due to the 
lack of significant function at the physiological level, the GABAA-p receptors will not 
be discussed further. This thesis will use the terms GABAA henceforth to refer to the 
bicuculline-sensitive GABAA receptor subtype.
1.1.3 GABA B Receptors
7.73.7 T(ggg^ 7or Dz.ycovg/y
The GABAg receptor was first discovered by Bowery g/ a/. (1980; 1981) in 
experiments using isolated tissue preparations which showed that GABA and baclofen 
reduced radiolabelled noradrenaline release independently &om the GABAA receptor. 
GABAg-mediated activity was fbund to be blocked with analogues o f guanosine
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triphosphate (GTP) demonstrating that this receptor is a GPCR (Hill g/ a/., 1984; 
Asano gr n/., 1985). These findings therefbre suggested a novel receptor mediated the 
effects o f GABA.
7 . 7 . 3 . 2  T ^ g g ^ 7 o r  .H g / g r W z T M g r z
The gene encoding fbr the GABAg receptor was first identified by Kaupmann g/ a/. 
(1997) following the isolation of two proteins using high-affinity radioligands. This 
gene has been demonstrated to have two start codons producing two splice variants, 
G7\BAgia and GABAg ly, both having the seven transmembrane domain structure o f the 
GPCR (Kaupmann g/^  a/., 1997). Both isofbrms displayed binding sites associated with 
the GABAg receptors, however, the binding affinities (Kaupmann gr nZ., 1997) and 
coupling to the second messenger pathways were lower than those fbund with native 
receptors (Kaupmann gr n/., 1998a). The expression of the GABAgi protein in cell 
lines was retained within the endoplasmic reticulum and not transported to the cell- 
surface (Couve gZ z^/., 1998), due to the presence o f an endoplasmic reticulum retention 
signal in the intracellular COOH-terminus (Margeta-Mitrovic gZ nZ., 2000; Pagano gZ 
nZ., 2001; Grünewald gZ aZ., 2002). This suggested that additional proteins were 
required fbr the maturation and trafficking of the receptor. Database searching using 
the nucleotide sequence of the GABAg] receptor identified another G7\BAg receptor, 
GABAg], displaying similar sequence homology and predicted structural similarities 
(Jones gZ nZ., 1998). Expression patterns o f GABAg], revealed by zzz .yzZzz hybridisation, 
were fbund to be highly correlated with GABAgi in areas with GABAg receptor 
binding (Jones gZ aZ., 1998). GABAg] expression in cell lines was stable and shown to 
be trafficked to the cell surface, although no measurable binding was seen with 
GTkBAg pharmacological agents (Kaupmann gZ aZ., 1998b). Co-expression o f either 
GABAgia or GABAgi y with GABAg] restored the ligand binding, however the 
coupling to the Kir3 channel was close to, but still below, that seen with the native 
receptors (Kaupmann gZ aZ., 1998b). These findings demonstrated that the GABAgi 
receptor is responsible for GABAg ligand binding, whereas GABAg] couples to the 
second messenger systems, indicating that both receptor subunits heterodimerise to 
fbrm the functional G7\BAg receptor. This hypothesis was further supported by 
immunoprécipitation o f both receptors from brain tissue using specific antibodies 
raised either to GABAgi or GABAg] (Jones gZ nZ., 1998; Kaupmann gZ aZ., 1998b;
-4-
Chapter 1 - General Introduction
White gZ a/., 1998; Kuner gZ aZ., 1999; Martin gZ aZ., 1999; Ng gZ aZ., 1999). The 
GABAgi and GABAg] receptor subunits interact via a coil-coil interaction (White gZ 
nZ., 1998) which masks the GABAgi endoplasmic retention signal and allows fbr the 
receptor to be trafficked to the cell surface (Margeta-Mitrovic gZ aZ., 2000). The 
discovery that the GABAgi subunits fbrm a heterodimer with the GABAg] subunits 
was reported over two years by six independent laboratories (Jones gZ nZ., 1998; 
Kaupmann gZ (zZ., 1998b; White gZ zzZ., 1998; Kuner gZ aZ., 1999; Martin gZ aZ., 1999; Ng 
gZ û[Z., 1999). These reports were the first to show that GPCRs are dependent on 
heterodimerisation to produce the functional receptor (Marshall gZ aZ., 1999).
7.7.3.3 T^gg^Zoz" z^zZzzznzZj^  &
The GABAgia and GABAgiy isofbrms differ in their extracellular domains (Figure 
1.2), the GABAgia has two sushi domains within the extracellular NHg-terminus, 
whereas these sushi domains are absent in the G7\BAgiy isofbrm (Kaupmann gZ aZ., 
1997). Several additional GABAgi isofbrms have been identified from mRNA 
extracted from mouse, rat and human tissue, however, few have been fbund at the 
protein level and to be conserved between the species (Bettler gZ aZ., 2004). GABAgia 
and GABAg lb were highly conserved between species and had predominant expression 
within the nervous system (Bettler gZ nZ., 2004). In contrast, GABAg le has been 
identified in rats and humans and was identified to be expressed exclusively in the 
peripheral nervous system (Schwarz gZ aZ., 2000). GABAg ij is a truncated isofbrm 
which has an identical extracellular domain to the GABAgia isofbrm (Figure 1.2), but 
lacks the transmembrane domains. As such it does not interact with the GABAg] 
receptor subunit (Tiao gZ 6zZ., 2008). This isofbrm has recently been identified by real­
time polymerase chain reaction (PCR) to be present at a low level, compared to 
GABAgia and GABAgib, in brain tissue from mice, rats and humans (Lee gZ nZ., 2010). 
While the PCR findings only provide evidence at the mRNA level this protein has 
been identified using protein extraction h-om rat brains (Tiao gZ aZ., 2008). These 
findings suggest that if  GTkBAgij isofbrm is expressed in the mouse it is likely to be 
present at low levels compared to the GABAgia and GABAgly isofbrms. However at 
present, GABAgia and GABAgi y remain the only isofbrms that have been identified at 
the protein level in mice (Prosser gZ aZ., 2001; Queva gZ nZ., 2003; Gassmann gZ nZ., 
2004). The gene encoding fbr the GABAg] receptor subunit has been shown not to
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undergo alternative splicing, thus has no other isoforms (Martin et a l, 2001). This 
suggests that two main functional receptor subtypes exist as GABAeda, 2) and 
GABAB(ib, 2).
GABAgia
SDSD 7TM CC R SR R
G A B A g ^ [ j  C T
7TM CC R SR R
I I I I I I I
GABAg^e
SD SD
SDSD
GABAgij 1 1
Figure 1.2 -  Key regions of species conserved GABAbi isoforms
GAB Asia and GABAeib are the main isoforms present in the mammalian central 
nervous system and are strongly conserved between species. These isoforms differ in 
their extracellular domains, with GABAeia having two sushi domains (SD). Both 
isoforms have identical intracellular structure sharing the seven transmembrane (7TM), 
coil-coil (CC) and endoplasmic reticulum retension (RSRR) domains. GABAbie and 
GABAbij are truncated forms of the receptor lacking the intracellular domains. 
GABAbie is exclusively expressed in the peripheral nervous system, whereas GABAbij 
has been suggested to be conserved between species, but expressed in the central 
nervous system at relatively low level compared to GABAbi a and GABAbi b- Figure 
adapted from the review article by Bettler et al (2004).
1.1.3.4 Receptor G-Protein Coupling
The G ABA b receptors couple to the Gia/GoU G-proteins and the Gpy complex (Asano 
et a l,  1985; Morishita et a l, 1990). The GPy complex links activation of the G ABA b 
receptor to the inhibition of voltage gated calcium channels at presynatpic terminals 
and the inwardly rectifying potassium channels at postsynaptic sites (Luscher et a l, 
1997; Schuler et a l, 2001). The Gitt/GoU G-proteins inhibit adenylyl cyclase activity 
and as a consequence reduce concentrations of cyclic adenosine monophophate 
(cAMP). Cyclic AMP activates protein kinase A (PKA), which has down-stream 
effects on receptor targets {see section 1.1.3.16). In addition, the Gpy complex can also 
activate some adenylyl cyclase isoforms and therefore increase cAMP concentrations 
in the presence of the G§a G-protein via ‘cross-talk’ with other GPCRs (As reviewed 
by Bowery et a l, 2002; and Bettler et a l, 2004). Whether activation of G ABA b 
receptor will enhance cAMP production and promote PKA activation is dependent on
-6-
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the expression of adenylyl cyclase isofbrms and the additional activiation of G§a 
(Bettler e/ a/., 2004). Recently it has been shown that the GABAg receptors form a 
heteromnltimer with potassium channel tetramerisation domain-containing (KCTD) 
proteins via interaction with the COOH-terminus of the GABAgi receptor subunit 
(Schwenk gt a/., 2010). More importantly the introduction o f the KCTD proteins into 
cell lines restored coupling o f the GABAg receptors to both voltage gated calcium 
channels and the inwardly rectifying potassium channels to the level seen in native 
tissues (Schwenk gt a/., 2010). The onset and desensitisation of the GAB As responses 
was altered by the presence o f different KCTD subtypes in the complex interacting 
with the GABAs receptor, demonstrating a novel mechanism for receptor diversity at 
the molecular level (Schwenk gt a/., 2010). This complex was found to be constructed 
from KCTD proteins 8, 12, 12b and 16 (Schwenk gr a/., 2010). The KCTD proteins 
were recently demonstrated to have differential localisation vGthin the mammalian 
brain (Metz gt a/., 2011). Expression o f the KCTD proteins was also seen in tissues not 
associated with GABAs receptor expression, which suggests that they have a wider 
role than with the GABAg receptor alone (Metz gf uA, 2011).
A. 7..^ . j
At presynaptic terminals GABAg receptors mainly act to inhibit either the N type or 
the P/Q type voltage gated calcium channels resulting in a reduction in 
neurotransmitter release (Newberry and Nicoll, 1985; Scholz and Miller, 1991; Amico 
gt a/., 1995; Takahashi gt a/., 1998). While presynaptic inhibition is caused 
predominantly via the inhibition o f the calcium channels, GABAg receptors have been 
shown to activate potassium channels at presynaptic terminals (Thompson gt uA, 1992; 
Ladera gt aA, 2008). GABAg receptors are located at terminals that release GABA to 
function as autoreceptors and at terminals releasing glutamate and other 
neurotransmitters to function as heteroreceptors (Bettler gt aA, 2004) (Figure 1.3). 
Stimulation o f the GABAg receptors at extrasynaptic locations has been demonstrated 
to occur from the ‘spillover’ of GABA release during repetitive GABAergic neuronal 
activity, by saturating the reuptake o f GABA, during physiological relevant activity in 
the hippocampus (Scanziani, 2000).
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1.1.3.6 Postsynaptic Inhibition
GABAb receptors at postsynaptie sites produce a slow IPSC by the activation of 
inwardly rectifying potassium channels (Luscher et a l, 1997; Schuler et a l, 2001). 
This has been confirmed by the absenee of GABAg-mediated currents in mice lacking 
functional GABAg receptors (Schuler et a l, 2001) or the Kir3.2 channel (Luscher et 
a l, 1997). In addition, activation of the GABAg reeeptors has been shown to interact 
with the T-type voltage gated ealeium channel (Futatsugi and Riviello Jr, 1998; Bettler 
et a l, 2004). These channels are associated with paeemaker activity and are thought to 
be linked to the occurrence of absence epilepsy (Chang and Lowenstein, 2003).
GABAb 
auto receptors
G A B A g  
hetero receptors
spillover 
.  I G A B A  %
; K+ ■ K+ ' . A : . . .  K+ sp m èv  K+ K+
soma
Cl- Cl-
0 ©  
@ © ©
dendritic shaft
IGABA.areceptor GABAgreceptor K*-channel UU channel NMDAreceptor
Figure 1.3 -  Presynaptic and postsynaptic locations of the GABAg receptor.
GABAg receptors are loeated at presnaptic loeations on the glutamatergic and 
GABAergic terminals to act as heteroreceptor and autoreeeptors, respeetively. At these 
presynaptic locations, GABAg receptors predominately inhibit voltage gated calcium 
channels resulting in a reduetion of neurotransmitter release. At postsynaptic locations, 
GABAg receptors aetivate inwardly rectifying potassium channels producing 
inhibitory postsynaptic currents. Activation of extrasynaptic GABAg receptors is 
caused by the ‘spillover’ of GABA release from the GABAergic terminals. Figure 
adapted from the review artiele by Bettler and Tiao (2006).
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1.1.3.7 Synaptic Location in the cerebellum
Purkinje cells are large GABAergic neurons in the cerebellum that project to the deep 
cerebellar nuclei to provide an inhibitory input (Apps and Garwicz, 2005). Granule 
cells are glutamatergic neurons which are innervated by the mossy fibre o f the 
precerebellar nucleus (Apps and Garwicz, 2005). Axons from the granule cell form the 
parallel fibres of the cerebellar molecular layer and provide excitatory synapses with 
the Purkinje cells (Apps and Garwicz, 2005). In addition to the parallel fibres, Purkinje 
cells receive excitatory glutamatergic stimulation from climbing fibres of the inferior 
olive (Apps and Garwicz, 2005). Both the mossy and parallel fibres have been 
demonstrated to have GABAb heteroreceptors (Dittman and Regehr, 1997; Mitchell 
and Silver, 2000), however GABAg appears not to be present at the climbing fibre 
terminals (Hashimoto and Kano, 1998). In situ hybridisation for the GAB Agi isoform 
mRNA demonstrated that Purkinje cells display a near-exclusive expression of 
GABAg lb mRNA, conversely the granule cells predominatly expressed GABAg i a 
mRNA (Billinton et a l, 1999; Bischoff et a l, 1999; Liang et a l, 2000). These finding 
suggest differential presynaptic and postsynaptic locations for the GABAg]a and 
GABAg lb isoforms (Figure 1.4).
ML
Presence of GABA, 
' heteroreceptors
PCL
cGC
mf
Figure 1.4 -  Synaptic locations of the GABAg receptor in the cerebellum.
GAB Agi a mRNA has been shown to be expressed by cerebellar granule cells (cGC) 
forming the parallel fibre (pf), whereas GABAgib mRNA has been shown to be present 
in Purkinje cells in the cerebellum. GABAg heteroreceptors have been shown in
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electrophysiological investigations at parallel and mossy fibres (mf). Abbreviations: cf, 
climbing fibre; ML, molecular layer; PCL, Purkinje cell layer. Figure redrawn and 
adapted from the review article by Apps and Ganvicz (Apps and Garwicz, 2005).
7.7.d. ATzcg
Genetic deletion of the GABAgi (Prosser g/ a/., 2001; Schuler gr a/., 2001; Queva er 
a/., 2003) and GABAgi (Gassmann gf a/., 2004) receptor subunits ( G A B A g a n d  
GABAg2' '^) abolished the presynaptic and postsynaptic responses to GABAg 
pharmacological agents, providing further evidence that heterodimerisation is essential 
for functional receptors. Removal o f either the GABAgi or GABAgi subtypes also 
prevented GABAg receptor-mediated muscle relaxation and hypothermia (Schuler g/ 
6z7., 2001; Queva gf a/., 2003; Gassmann gr a/., 2004). Although immunohistochemical 
staining for the GABAg i subunit was present in GABAg]'^' mice the staining was 
observed to be retained within the cell soma (Gassmann gr a/., 2004). This suggests 
that these receptors are retained within the endoplasmic reticulum and not present at 
the cell surface in agreement with the loss o f GABAg receptor binding with knockouts 
of either receptor subunits (Schuler et a l, 2001; Gassmann et a l, 2004). Loss of 
functional GABAg receptors resulted in hyperlocomotion, hyperalgesia and impaired 
memory in passive avoidance tasks (Schuler gr a/., 2001; Gassmann gr a/., 2004). In 
addition, these transgenic mice developed recurrent spontaneous seizures (Prosser gr 
a/., 2001; Schuler g^  a/., 2001; Queva g^  a/., 2003; Gassmann gr a/., 2004). These 
seizures were mainly clonic-type seizures, however atypical absence and tonic-clonic 
seizure were also observed (Schuler gf aZ., 2001). Loss o f GABAg-mediated inhibition 
was also seen with mice expressing a C-terminus truncated version of the GABAg] 
(Thuault gZ a/., 2004). In these mice GABAg receptor complexes were not detected at 
the cell surface (Thuault gZ a/., 2004), presumably due to the lack o f masking of the 
endoplasmic reticulum retention signal by the truncated GABAg] protein.
GABAgi'^' mice had an exaggerated response to stimulation during GAB A A receptor 
blockade (Prosser gZ a/., 2001). Further investigation showed that the G A B A g m i c e  
and animals expressing the C-terminal truncated GABAg] protein had enhanced N- 
methyl-D-aspartic acid (NMDA) receptor activation (Brown gZ aZ., 2003; Thuault gZ 
aZ., 2005) presumably due to the loss o f the hyperpolarising action of the GABAg 
receptor (Davies and Collingridge, 1993). In addition, the sustained activation o f the
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GABAA receptor will shiA the chloride equilibrium -  switching effects o f GABAA 
channel activity Aom hyperpolarising to depolarising (Davies and Collingridge, 1993; 
Brown gZ aZ., 2003). This change in equilibrium fits with the onset o f seizure in these 
mice as it occurs during the developmental period when GABAA receptors shiAs Aom 
depolarising to hyperpolarising (Brown gZ aZ., 2003; Chudotvorova gZ aZ., 2005). As 
these findings were not fully replicated in wild-type animals with GABAg receptor 
antagonism. Brown gZ uZ. (2003) proposed that plastic enhancement of response were 
provoked during development in GABAg mice. However, investigations since this 
publication have demonsAated the interaction of GABAg receptors with other 
receptors (Chang gZ aZ., 2007; Boyer gZ ürZ., 2009; Rives gZ aZ., 2009; Chalifbux and 
Carter, 2010; Guetg gZ uZ., 2010; Tu gZ uZ., 2010). Therefore, the seizure activity may 
be the consequence o f the loss of these receptor interactions at critical locations and 
during developmental periods, or the absence o f the interactions may promote synaptic 
plasticity.
7.7. j .  P Zyq/brzM A^noc^wZ MZgg
Due to the lack of GABAg subtype selective pharmacological agents Vigot gZ uZ. 
(2006) created GABAgia and GABAgiy knockout mice (GABAgia'^' and GABAgib'^'), 
which allowed for the investigation o f the GABAg ib and GABAgia isofbrms in 
isolation, respectively. ElecAophysiological studies in these mice demonstrated that 
the GABAgia containing receptor subtype acted exclusively as presynaptic 
heteroreceptors at glutamatergic Schaffer collateral terminals in the hippocampal 
Cornu Ammonis region 1 (CA l) (Vigot gZ aZ., 2006). Whereas, the GABAgib 
containing receptors were shown to be present at post synaptic sites opposite 
glutamatergic and GABAergic terminals at the ulAastructure level and were 
responsible for coupling to the Kir3 channels (Vigot gZ aZ., 2006). Due to the 
inAacellular structural similarities between these GABAg i isofbrms it was suggested 
that these effects were due to the localisation o f the receptor subtypes rather than 
differences in second messenger coupling. Tagging of the GABAgia and GABAgib 
proteins in CAl pyramidal neurons demonsAated that both proteins diffused into the 
dendritic spines, however only GABAgia was located Avithin the axon (Vigot gZ aZ., 
2006). Further electrophysiological investigations confirmed that the GABAgia acts as 
presynaptic heteroreceptors at glutamatergic terminals in the lateral amygdala (Shaban
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gZ 6z/., 2006), hippocampal Cornu Ammonis region 3 (CA3) (Guetg gZ a/., 2009), 
thalamus (Ulrich gZ a/., 2007) and neocortex (Perez-Garci gZ <3/., 2006). Both GABAgia 
and GABAgib receptor subtypes were found to act as autoreceptors within the CAl 
subfield (Vigot gZ ar/., 2006) and thalamus (Ulrich gZ <3/., 2007). In contrast, 
autoinhibition was mainly mediated by GABAgib containing receptors in the neocortex 
(Perez-Garci gZ a/., 2006).
Long term potentiation (LTP) can be induced in the CA3-CAl synapses and this 
enhancement o f synaptic strength was facilitated by the activation o f the GABAg 
autoreceptor (Davies gZ a/., 1991; Davies and Collingridge, 1993). LTP was absent in 
the complete GABAgf^' and the GABAgia  ^ mice (Vigot gZ <3/., 2006). The 
investigators suggested this change was due to the decrease in silent synapses present 
at the CA3-CA1 in the GABAgia'^' mice which are necessary for the formation o f LTP 
(Vigot gZ arZ., 2006). These changes were found to Aanslate into changes at the 
behavioural level as the GABAgia'' mice lacked the ability to distinguish between 
novel and familiar objects, while novel object recognition was present in the 
GABAgib'' mice (Vigot gZ aZ., 2006). GABAg receptors at glutamatergic terminals are, 
therefore, implicated in the cellular mechanisms for learning and memory.
Further behavioural investigations showed that unlike the G A B A g mice (Schuler gZ 
aZ., 2001) both GABAgia'^' or GABAgib'^' showed impaired memory in passive 
avoidance tasks (Jacobson gZ üfZ., 2007a; Jacobson gZ aZ., 2007b). In contrast to the 
complete GABAg knockout mice (Schuler gZ aZ., 2001; Gassmann gZ (zZ., 2004) the 
GABAg agonist baclofen induced hypothermia and muscle relaxation in both GABAg 1 
isofbrm knockout mice, however the changes were less than those seen in wild-type 
mice (Jacobson gZ aZ., 2006a). Locomotor activity was also found to differ as 
GABAgib'' mice displayed increased activity (Jacobson gZ üfZ., 2006a). GABAgia"' 
mice failed to acquire conditioned taste aversion to LiCl, whereas, GABAgib'^' did not 
show an extension o f the aversion to the non-reinfbrced conditioned stimuli (Jacobson 
gZ aZ., 2006b). Investigation of conditioned fear using audiogenic stimuli with electric 
foot shocks showed that GABAgia'' mice displayed a generalised fear to both paired 
and non-paired stimuli (Shaban gZ uZ., 2006). While presynaptic GABAg autoreceptors 
have a role in the development of hearing (Takesian gZ aZ., 2010), GABAgia' ' mice 
were reported to discriminate between the electric foot shock-paired and non-paired
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stimuli at lower electric shock intensities (Shaban gZ a/., 2006), suggesting the 
generalisation was not due to a loss o f stimulus differentiation. Spontaneous seizures 
were initially reported not to occur in both GABAgi isofbrm knockout mice (Jacobson 
gZ aZ., 2006a), however a recent publication by Vienne gZ aZ. (2010) reported the 
GABAgia'^' mice to display clonic-type seizures. Investigations using the GABAgia'^' 
and GABAgib'^' mice have allowed the identification of the differential synaptic 
localisation, functional and behavioural roles o f the GABAg receptor subtypes.
7.7.3.70 & 7hZgmgZZoMj wZzZz OzZzgr CgZZwZar fmZgZM.y
GABAgia and GABAgib isofbrms have been shown to be differentially located within 
glutamatergic neurons, with GABAgia localised in the soma and GABAgib is present 
in the dendrites (Vigot gZ aZ., 2006). As both GABAgia and GABAgib isofbrms have 
very similar structures, except fbr the inclusion of two sushi domains within the 
extracellular domains in the GABAgia, it is suggested that both receptors isofbrms 
contain a dendritric targeting signal in the intracellular C-terminus. In a recent study by 
Beirmann gZ aZ. (2010) it was demonstrated that the sushi domains o f the GABAgia 
isofbrm were responsible fbr targeting the receptor to the axonal compartment in 
glutamatergic neurons. The GABAgij isofbrm has been shown to scavenge the sushi 
binding sites at presynaptic glutamateric terminals and to impair the function o f the 
presynaptic GABAg hetroreceptors, but not the GABAg autoreceptors (Tiao gZ aZ., 
2008). These findings suggest that targeting the sushi domains may give rise to 
pharmacological agents selective fbr the GABAg la-containing heteroreceptor.
7.7.3.77 T^gg^Zor 5'ZrwgZwrg
GABAg ligands bind to the extracellular domain of the GABAg i subunit (Malitschek 
gZ zzZ., 1999b). This binding site consists of two lobes connected by a hinge region, 
where GABA and other ligands cause the two lobes to close in this 'Venus flytrap 
module' (Pin gZ aZ., 2009). Due to the heterodimer structure of the GABAgi and 
GABAg] subunits it is suggested that the induced closure o f the 'Venus flytrap 
module' in the GABAg i subunit evokes a confbrmational change in the receptor 
complex resulting in the activation state o f the GABAg receptor (Figure 1.5) (Pin gZ 
grZ., 2009).
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Figure 1.5 -  Conform ational changes in the GABAg receptor during ligand 
binding.
G ABA b receptor ligands bind to the extracellular domain in the ‘Venus flytrap 
module’ (VFT) of the G ABA bi receptor subunit. This binding site is situated between 
to lobes (lobe 1 and lobe 2), ligand binding (red) induced closure of the VFT evoking a 
conformational change in the G ABA bi (blue) and G A BA b2 (yellow) receptor subunit 
heterodimer forming the active state of the G A BA b receptor. Figure is taken from the 
review article by Pin et al (2009).
1.1.3.12 Modulation o f  the GABAb Receptor
Positive allosteric modulators bind to receptors and act by enhancing the function of 
ligand activation. In contract to receptor agonists, positive allosteric modulators alone 
lack intrinsic efficacy and will only enhance endogenous GABA activity thus 
discriminating between active and non-active receptors (Bettler et a l, 2004). The first 
posititive allosteric modulator of the G A BA b receptor, CGP7930, was first described 
in a study by Urwyler et al. (2001). In this investigation, the GTPy[^^S] binding signal 
measured in the presence of GABA and CGP7930 was greater than the maximum level 
seen with GABA alone. Although, the ligand binding site is present in the G ABA bi 
receptor subunit (Malitschek et a l, 1999b), CGP7930 binds to the G ABA b2 receptor 
subunit to enhance receptor activity (Binet et a l, 2004). Binding to the G ABA b2 
receptor subunit is also necessary for the positive allosteric modulator GS39783 
(Dupuis et a l, 2006). Both positive receptor modulators have been demonstrated to 
have effects in both in vitro (Urwyler et a l, 2001; Urwyler et a l, 2003; Chen et a l.
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2006) and m vzvo systems (Smith gZ czZ., 2004; Liang gZ aZ., 2006; Jacobson and Cryan, 
2008; Paterson gZ aZ., 2008; Brusberg gZ aZ., 2009). Using ZM vZvo systems positive 
modulation o f the GABAg receptor has been shown to decrease drug seeking 
behaviour fbr drugs o f abuse (Smith gZ aZ., 2004; Liang gZ aZ., 2006; Paterson gZ aZ.,
2008) and psychosis (Wieronska gZ a Z ., 2011), as well as, having analgesic (Brusberg 
gZ aZ., 2009) and anxiolytic properties (Jacobson and Cryan, 2008). These positive 
allosteric receptor modulators show fewer side effects in comparison to the GABAg 
receptor agonists and display a greater potential fbr use as a pharmacotherapy.
7.7.3.73 T^gggpZor TTq^ ÿzgArZMg
GABAg receptors are internalised from the cell surface into clathrin-coated vessels in a 
dynamin-dependant process (Grampp gZ aZ., 2007; Vargas gZ aZ., 2008). Endocytosis o f  
the GABAg receptors has been reported to be both an agonist-dependent (Gonzalez- 
Maeso gZ aZ., 2003; Wilkins gZ aZ., 2008) and an agonist-independent response (Fairfax 
gZ aZ., 2004; Grampp gZ aZ., 2007; Vargas gZ aZ., 2008). These contrasting findings have 
been suggested to be due to the cell line used in the investigations and the method used 
to label the receptors (Vargas gZ aZ., 2008; Wilkins gZ aZ., 2008), however it is currently 
accepted that GABAg receptor internalisation can be an agonist-independent process 
(Terunuma gZ aZ., 2010a). Endocytosed GABAgi and GABAg] receptor complex has 
been demonstrated to recycle back to the cell surface under normal conditions (Fairfax 
gZ aZ., 2004; Vargas gZ aZ., 2008). Internalisation o f  the GABAg receptor occurs in the 
dendrites rather than axon (Terunuma gZ aZ., 2010a), possibly suggesting a 
predominant involvement o f  the GABAgiy-containing receptor subtypes. However, 
glutamate treated cells showed a reduction o f  both cell surface and intracellular 
GABAg receptors suggesting that glutamate can enhance GABAg receptor 
internalisation and degradation o f  the receptors (Vargas gZ aZ., 2008; Wilkins gZ aZ.,
2008). The cell surface expressions o f  the GABAg and NMDA receptors have been 
shown to directly influence each other (Chalifbux and Carter, 2010; Guetg gZ aZ., 2010; 
Terunuma gZ aZ., 2010b). Activation o f  the GABAg receptor has been shown to directly 
reduce Ca^^ current from the NMDA receptor via activation o f  the PKA pathway in the 
prehontal cortex (Chalifbux and Carter, 2010). Whereas, activation o f  the NMDA 
receptor has also been shown to modulate the cell surface expression o f  the GABAg ly- 
containing receptor at postsynaptic sites in dentritic spines o f  hippocampal pyramidal
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cells by activation o f the calcium calmodulin-dependent kinase type II (Guetg eZ a/., 
2010; Terunuma gZ a/., 2010b).
7.7.3.7^ Dgvg/ap/MgMZaZ
The GABAg 1 and GABAg] receptor subunits are expressed from embryonic day 14 at 
extrasynaptic sites in the regions associated with the hipocampal formation and are 
present at presynaptic and postsynaptic locations at birth (Lopez-Bendito gZ aZ., 2004). 
The relative expression o f  each isofbrm has been shown to alter during postnatal 
development by western blot analysis o f  the protein extracted from rat whole brains 
(Fritschy gZ aZ., 1999). At birth the GABAgia isofbrm was fbund to be more 
prominently expressed than the GABAgib isofbrm and had a higher expression in the 
neonatal animals compared to adults (Fritschy gZ aZ., 1999). At postpartum day 10, the 
expression o f  the isofbrms was equal and fbllowing postpartum day 21 GABAgib was 
more highly expressed than GABAgia (Fritschy gZ aZ., 1999). These findings indicate 
that the presynaptic GABAg ia-containing receptors have an important role during 
postnatal development. This increased expression may be due to the greater need o f  
GABAg receptor fbr inhibition during this period as a result o f  the excitatory effects o f  
the GABAa receptors at this time. The expression o f  the KCTD proteins in the 
hippocampal fbrmation o f  neonatal mice was comparable to that displayed in the adult 
mice (Metz gZ arZ., 2011).
7.7.3.73 7(ggZo»aZ ZocaZZoM
Expression of the GABAg receptor has been investigated using receptor 
autoradiography, Z» .yZZw hybridisation (Bischoff gZ aZ., 1999; Liang gZ aZ., 2000) and 
immunohistochemistry (Margeta-Mitrovic gZ aZ., 1999; Charles gZ aZ., 2001). GABAg 
receptors show a widespread distribution within the mammalian brain, with the 
receptor being detected in most neurons (Bischoff gZ aZ., 1999). These studies 
demonstrated that the highest level of expression was in the cerebellum, hippocampus 
and thalamus (Bischoff gZ aZ., 1999; Margeta-Mitrovic gZ aZ., 1999; Liang gZ aZ., 2000).
The expression o f mRNA fbr the GABAgib isofbrm was higher in the habenula and 
laterodorsal nucleus of the thalamus in comparison to the GABAgia mRNA (Bischoff
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gZ uZ., 1999). In contrast, the thalamic reticular nucleus demonstrated a moderate 
expression of the GABAgia isofbrm compared to the low expression o f the GABAg i y 
mRNA (Bischoff gZ <^Z., 1999). However, all the thalamic nuclei demonstrated equal 
immuno-positive staining fbr both GABAg receptors isofbrms (Charles gZ afZ., 2001). 
These differences in findings may be due to the differences in regulation of mRNA 
translation to proteins or may result from the poor sensitivity of the qualitative scoring 
used in the immunohistochemical investigation.
The basal fbrebrain, the caudate putamen and the globus pallidus were fbund to 
demonstrate relatively equal expression and staining fbr the GABAgi isofbrms 
(Bischoff gZ orZ., 1999; Charles gZ aZ., 2001). Similarly, in the nuclei of the amygdala 
little regional differentiation between the GABAgia and GABAgib isofbrms was 
reported (Bischoff gZ aZ., 1999). However, an immunohistochemical investigation has 
suggested higher levels of the GABAgia staining compared to the GABAgib in the 
basolateral and central nuclei (Charles gZ 6zZ., 2001).
In the cerebellum, the GABAgia and GABAgib isofbrms are expressed by the granule 
cells and Purkinje cells, respectively (see section 1.1.3.7 and Figure 1.4). Staining in 
the cerebellum with antibodies directed against the GABAgib isofbrm indentified the 
presence o f this protein in the molecular layer o f the cerebellum and demonstrated a 
zebrin-like staining pattern (Fritschy gZ aZ., 1999; Chung gZ aZ., 2008). Zebrin-like 
staining fbrms alternating bands of intense and weak immuno-positive staining, which 
is proposed to functionally regulate parallel fibre stimulation (Chung gZ aZ., 2008). 
These finding may indicate that the GABAgib receptor is exclusively responsible fbr 
this zebrin-like staining, although low levels o f GABAgia have also been reported in 
the Purkinje cells (Billinton gZ aZ., 1999).
The hippocampal fbrmation is fbrmed of two interlocking C-shaped layers o f cell 
bodies termed the dentate gyrus and Ammon’s horn (also known as Cornu Ammonis; 
CA). Ammon’s horn is the larger of the two cell layers and is divided into the subfields 
CAl to CA4, with the CA4 field situated in the hilar region of the dentate gyrus. The 
dentate gyrus and the hippocampus proper have a well defined series of glutamatergic 
connections between the subfield of the hippocampal fbrmation, termed the trisynaptic 
circuit (Witter gZ aZ., 2000). The dentate gyrus acts as the gateway into the
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hippocampal formation and is mainly innervated by the projections of the perforant 
pathway, originating from the entorhinal cortex (Witter et a l, 2000). The granule cells 
of the dentate gyrus region project via the mossy fibre to the CA3 pyramidal neurons 
and the CA3 neurons project via the Schaffer collateral pathway to the CAl region 
(Witter et a l, 2000). These CAl pyramidal cells project to the subiculum which 
provides input back to the entorhinal cortex (Witter et a l, 2000). G ABA b 
heteroreceptors have been demonstrated to be present on the perforant pathway, mossy 
fibre and Schaffer collaterals (Lanthom and Cotman, 1981; Ault and Nadler, 1983a; 
Isaacson et a l, 1993). These presynaptic receptors on the mossy fibre (Guetg et a l,
2009) and Schaffer collaterals (Vigot et a l, 2006) have been demonstrated to be 
G ABA b la-containing receptors (see section 1.1.3.9; Figure 1.6). Expression levels and 
staining intensity for the G ABA bi isoforms has been demonstrated to be similar in the 
dentate gyrus and hippocampus (Bischoff et a l, 1999; Charles et a l, 2001). However, 
immunohistochemistry in the G ABA bla’^ ’ mice revealed an absence of G ABA bib 
staining in the stratum lucidum of the CA3 subfield, a region associated with 
presnaptic terminals of the mossy fibre (Vigot et a l, 2006). Further 
immunohistochemical investigation using the G ABA bi isofbrm knockout mice may 
identify other regional differences.
G A B A g i a  o n  P r e s y n a p t i c
T e r m i n a l s
P r e s e n c e  o f  G A B A ,  
h e t e r o r e c e p t p f s
sc
D G
C A 3
Figure 1.6 -  Synaptic locations of the GABAb receptor in the hippocam pus.
GABAb la receptors have been shown to be responsible for GABAB-mediated synaptic 
inhibition at the mossy fibre (mf) terminals of the dentate gyrus (DG) granule cells and 
the Schaffer collaterals (sc) o f the CA3 pyramidal cells. Electrophysiological studies 
have shown the GABAb heteroreceptors to be present that the presynaptic terminals of 
the preforant pathway (pp), although the GABAbi isoforms present in this receptor 
have yet to be identified.
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7.7. j. M  7^gc^/or
As previously mentioned GABAg receptors can cross-talk with other receptors via 
interactions ^vith adenylyl cyclase to increase cAMP levels (Bowery g/ 2002; 
Bettler g/ a/., 2004), however recent publications have shown that the GABAg receptor 
can, additionally, directly interact with other receptors. The study by Boyer et al. 
(2009) demonstrated that the GABAg] recepor subunit can heterodimerise with the 
muscarinic type 2 receptor (M]) which can restore internalised M] back to the cell 
surface in cell lines. Co-precipitation o f the GABAg and the metabotropic glutamate 
type la  (mGlula) has been demonstrated in the cerebellum (Tabata e/ a7, 2004), 
however, co-localisation o f the receptors may not necessarily imply a cross-talk 
between these receptors (Rives gr (z/., 2009). Both the co-localisation o f the 
GABAg/mGlula receptors and activation o f the Gi/o G-proteins GABAg receptor can 
paradoxically enhance calcium release from the m G lula activation o f the inositol 
trisphosphate pathway (Tabata gr <2/., 2004; Rives g/ a7, 2009). In addition, co- 
precipitation has also been seen with the GABAg and the insulin-like growth factor 
type 1 (lGF-1) receptor and produce an anti-apoptotic signal via GABAg activation of 
IGF-1 receptor (Tu et a l, 2010). Transactivation o f the lGF-1 receptor, via down- 
stream effects of the G^y complex, produced the anti-apoptotic action o f Akt (Tu gr 
a/., 2010). The fbrmation o f a complex containing the extracellular calcium sensing 
receptor (CaR) and the GABAg] receptor subunit has also been identified by co­
precipitation (Chang gr a/., 2007). Binding with GABAg] caused the masking o f the 
endoplasmic reticulum retention signal present in the CaR (that is normally masked by 
CaR homodimer fbrmation) and promotes cell surface expression o f the GABAg]/CaR 
complex (Chang g/ a7, 2007). Although the GABAg]/CaR complex was fbund to be 
disrupted by co-expression o f the GABAgi receptor subunit raising questions whether 
it would be seen in native tissues (Chang gr a/., 2007), the CaR may have an increased 
surface expression in the GABAg f^' mice.
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1.2 GABAb and Neurological Disorders
1.2.1 Neuropathic Pain & Spasticity
The GABAg receptor agonist baclofen is used as a centrally acting muscle-relaxant fbr 
spasticity associated with cerebral palsy, multiple sclerosis, stiff man syndrome and 
tetanus (Bowery, 2006). In addition, baclofen has also been demonstrated to have 
analgesic properties and is used clinically fbr the treatment o f trigeminal neuralgia 
(Bettler gr a/., 2004). Baclofen shows poor penetration in the brain from systemic 
administration (Balerio and Rubio, 2002b) its use is often limited due to side effects 
and rapid development o f tolerance developed centrally (Bowery, 2006). Adverse 
effects associated with systemically administered baclofen include hallucinations, 
hypotension, mental confusion, muscle weakness, sedation, seizures and nausea 
(Bowery, 2006). Implanted pumps are used to infuse baclofen intrathecally thereby 
reducing the required dose and to lessen the development of tolerance (Penn et a l, 
1989). However, tolerance is reported to also develop with this route of administration 
(Nielsen gr aZ., 2002; Hefferan gr aZ., 2006). The analgesic effects of baclofen have 
been indicated in both the brain and the spinal cord, probably via inhibition in the 
rostal agranular insular cortex (Jasmin gZ aZ., 2003) and the dorsal horn in the spinal 
cord (Malan gZ ürZ., 2002). Projections of the rostal agranular insular cortex extend to 
the amygdalae, which are involved in pain and fear associated behaviours (Jasmin gZ 
aZ., 2003), and the dorsal horn.
1.2.2 Psychiatric Disorders
Alterations in GABAg receptor expression have been demonstrated in psychiatric 
disorders including autism (Fatemi gZ aZ., 2009; Oblak gZ aZ., 2010), bipolar disorder 
(Ishikawa gZ üfZ., 2005), depression (Sequeira gZ aZ., 2009), obsessive compulsive 
disorder (Zai gZ aZ., 2005b) and schizophrenia (Mizukami gZ z^ Z., 2000; Mizukami gZ aZ., 
2002; Ishikawa gZ aZ., 2005; Fatemi gZ aZ., 2011). Receptor autoradiography in post 
mortem tissue taken from the anterior and posterior cingulate cortex and the fusifbrm 
gyrus o f autistic individuals showed a reduction o f GABAg receptor density compared 
to controls (Oblak gZ aZ., 2010). In addition, western blot densitometric analysis of 
cerebellum tissue from autistic patients demonstrated a decrease in both GABAgi and 
GABAg] receptor expression (Fatemi gZ aZ., 2009). Over a quarter o f autistic
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individuals present with epilepsy as co-morbidity with a wide spectrum of seizure 
types (Tuchman and Rapin, 2002). As alterations in GABAg receptor expression has 
been shown fbllowing seizure activity (Billinton gZ aZ., 2000) the changes in GABAg 
receptor expression in autistic individuals may be due to the seizure activity. However, 
no difference between the GABAg receptor density was demonstrated between autistic 
suffers with and without a history o f seizures (Fatemi gZ aZ., 2009; Oblak gZ aZ., 2010).
Studies o f GABAgi receptor immunohistochemistry in post mortem brains from 
schizophrenic patients revealed decreased labelling in the dentate gyrus granule cells, 
hilar mossy cells and the pyramidal cells o f the hippocampus compared to control 
brains (Mizukami gZ aZ., 2000). In addition, the GABAgi receptor staining intensity 
was observed to be decreased in the entorhinal cortex and inferior temporal cortex in 
schizophrenic patients (Mizukami gZ aZ., 2002). Western blot densitometric analysis o f 
GABAg protein levels in the preffontal cortex demonstrated decreased expression of 
GABAgia in schizophrenic patients compared to controls, whereas patients with bi­
polar disorder demonstrated decreased expression o f GABAgia, GABAg]y and 
GABAg] (Ishikawa gZ aZ., 2005). Expression of both GABAgi aJid GABAg] is 
decreased in the lateral cerebellum of patients with bipolar disorder, major depression 
and schizophrenia (Fatemi gZ aZ., 2011). Genetic polymorphism in the (Zai gZ
aZ., 2005a) and genes (Zhao gZ aZ., 2007), coding fbr the GABAgi and
GABAg] receptor subunit respectively, were identified in schizophrenic patients. 
However, additional investigations failed to establish linkage between the 
gene and schizophrenia (Imai gZ aZ., 2002; Zhao gZ aZ., 2007). Interestingly, a recent 
investigation has demonstrated that a GABAg receptor agonist and positive allosteric 
modulator had anti-psychotic effect in animal models (Wieronska gZ aZ., 2011). These 
findings suggest a role fbr altered GABAg receptor function in schizophrenia.
Chronic administration of monoamine oxidase inhibitors (phenelzine and 
tranylcypromine), tricyclic (desipramine) and selective serotonin re-uptake inhibitor 
antidepressants (fluoxetine) anti-depressants in preclinical studies increased expression 
o f the GABAgia subunit and function o f the GABAg receptors in the hippocampus 
(Sands gZ aZ., 2004). However, pharmacological intervention with the GABAg receptor 
agonist, baclofen, in depressed patients has been suggested to worsen symptoms (Post 
gZ aZ., 1991). Therefbre, this up-regulation of GABAg receptor expression and function
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by antidepressants may result from a down-regulation o f GABAergic tone (Sands aZ 
a/., 2004) and has been suggested to indicate increased GABAergic activity in 
depression (Ghose gZ a/., 2011). In agreement, GABAg antagonists have been 
demonstrated to have antidepressant effects in the forced swim model of depression 
(Slattery gZ a/., 2005; Nowak gZ a/., 2006). Fitting with this role of enhanced 
GABAergic systems in depression, mice lacking the GABAgi receptor have shown 
improved responses in the forced swim test, behavioural characteristics associated with 
antidepressant administration (Mombereau gZ a/., 2004). Studies o f post-mortem 
samples from patients with major depression have linked increased GABAg] 
expression in cortical regions (Sequeira gZ a/., 2009) and the dentate gyrus, however 
GABAgia expression was also shown to be decreased in the dentate gyrus (Ghose gZ 
a/., 2011). As trafficking and function o f the GABAg receptor is dependent on the 
GABAg] receptor subunit Ghose gZ a/. (2011) proposed that these finding demonstrate 
an overstimulation of the GABAg receptors in depression, however, GABAgi y 
expression was not included in this investigation. These findings suggest that the 
GABAg receptor function is increased in depression, possibly involving GABAg ly- 
containing receptors, and that blocking GABAg receptor function may be a potential 
novel therapeutic target fbr depression.
1.2.3 Epilepsy
Seizures are reversible alterations in neuronal electrical activity producing 
synchronised high-6equency activity and epilepsy is the pathological condition 
associated with the recurrence of seizures. Seizures can invoke a diverse spectrum of 
behaviours depending on the location of activity and thus produce numerous epileptic 
syndromes. Epidemiological studies have indicated that 7.1 in 1000 people develop 
epilepsy (Hirtz gZ arZ., 2007) with the majority having onset during childhood 
(Lothman, 1992).
7.2 d. 7 CZa.y.9Z/zgaZZoM q/'EpZZgp.yZg.9 üfW ^ gZzwrg.y
Epilepsies and seizures are categorised depending on whether the seizures are 
generalised or partial, using the classification system proposed by the Commission on 
Classification and Terminology of the International League Against Epilepsy (1989). 
Generalised seizures are defined as those which initially involve both cerebral
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hemispheres, whereas partial seizures originate from an initially localised region (focal 
region). Epilepsies with partial seizure make up approximately 60% of all epilepsy 
cases (Gastaut gZ a/., 1975; Hauser gZ a/., 1996), with temporal lobe epilepsy thought to 
be the most prevalent (Engel, 1996). Due to the participation of both hemispheres 
generalised epilepsies and seizures are associated with the loss o f consciousness. In 
contrast, partial seizures can be either simple, with no loss o f consciousness, or 
complex, with impairment or loss o f consciousness (ILAE, 1989). Partial seizures can 
manifest into generalised seizures if  the region o f hyperactivity spreads to include both 
hemispheres, this is a phenomenon termed a secondary generalised seizure (ILAE, 
1989). However, the differentiation between a generalised seizure and a partial seizure 
with a secondary generalised seizure can be difficult to define as the delay before the 
onset of the secondary seizure can be short in duration (Stefan, 1996). Generalised 
seizures can induce seizures with different clinical manifestations such as clonic, myo- 
clonic, tonic and tonic-clonic seizures. Myo-clonic seizures are observed as the sudden 
brief twitch o f limbs, whereas clonic seizures produce rhythmic movement o f seizures 
(ILAE, 1981). Tonic-type seizures are associated with contraction o f muscles causing 
the outstretching o f limbs (ILAE, 1981). These seizure types can combine to produce 
generalised tonic-clonic seizures causing bilateral tonic sustained contraction o f 
muscle followed by the clonic rhythmic movement (ILAE, 1981). Febrile seizures are 
common childhood generalised seizures typically invoked by fevers seen in 
approximately 2-5% of the population, most febrile seizures are brief and have a fast 
recovery (Scantlebury and Heida, 2010). In contrast, atypical febrile seizures are 
prolonged, lasting over 15 minutes, and can recur multiple times during the fever 
(Scantlebury and Heida, 2010).
7.2.5.2 Bür/aMgg ExczZaZioM & 7M/zz6zZzoM m Egzzwrgj^
Seizures have been suggested to result from the imbalance o f inhibition and excitation 
within key regions in the central nervous system (Sloviter, 1987). For generalised 
seizures in this model abnormal electric activity spreads to other brain regions due to 
the lack o f inhibition and/or excessive excitation. This concept relies on disinhibition, 
the reduced negative-feedback mechanism of the inhibitory system, being promoted in 
high activity states thereby decreasing inhibition. This excitation-inhibition balance 
model has since been fbund to be an over simplification of more complex mechanisms.
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In contrast to this model, absence seizures are due to excessive inhibitory activity 
resulting from synchronised firing of inhibitory intemeurons (Manning gZ a/., 2003).
7.25.5 v46.ygMggEpzZgp.$}^ '
Absence epilepsy is the recurrence of generalised seizures during childhood between 4 
and 8 years of age which is observed as a brief period o f loss o f consciousness (Chang 
and Lowenstein, 2003). During typical absence seizures the patient will cease normal 
activity and stare fbr a few seconds then continue normal activity without knowledge 
of the seizures occurring (Chang and Lowenstein, 2003). Typical absence seizures are 
a generalised seizure characterised by bilateral 3 Hz spike-wave discharges, these 
seizures are idiopathic and are not induced by stimuli (Crunelli and Leresche, 2002). 
Spontaneous seizures generally show remission around adolescence in around 70% of 
patients (Crunelli and Leresche, 2002). Generalised tonic-clonic seizures are observed 
in some cases and are observed in 90% of patients who display seizures past 
adolescence (Crunelli and Leresche, 2002). Seizures have been shown to originate 
from a 'fbcus' in the somatosensory cortex which quickly propagate to other cortical 
regions and relay through thalamic nuclei via the corticothalamic circuit (Figure 1.7) 
(Meeren gZ a/., 2002; Polack gZ a/., 2007). The cortical pyramidal neurons project to 
the thalamus and stimulate the thalamic reticular neurons and the thalamoctical relay 
neurons o f the ventrobasal nuclei. The thalamic reticular neurons are inhibitory 
intemeurons which project to the ventrobasal nuclei, whereas the thalamocortical relay 
neurons are glutamatergic neurons that project to the cortex. Under physiological 
conditions the thalamocortical circuit is involved in rhythm generation in the cortex 
during sleep (Steriade gZ a/., 1993). The GABAg receptor agonist baclofen has been 
shown to exacerbate absence seizures, whereas GABAg receptor antagonists have been 
shown to suppress the spike-wave discharges (Snead, 1996; Vergnes gZ aZ., 1997). 
Direct application of GABAg antagonist to the thalamic reticular neurons or the 
somatosensory cortex abolished absence seizures therefbre indicating that GABAg 
receptors in both regions were involved (Richards gZ a/., 2003). Increasing GABAgia 
expression in the fbrebrain results in atypical type absence epilepsy (Wu gZ a7, 2007) 
which utilises circuits between the medial preffontal cortex, C A l, thalamic reticular 
nucleus and nucleus reuniens o f the thalamus (Wang gZ a/., 2009). Atypical absence 
seizures are associated with major cognitive impairment (Chan gZ a/., 2004), partial
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consciousness and voluntary movement during seizures (Cortez et a l, 2001). 
Interestingly GABAgi'' rnice also displayed atypical absence seizures (Schuler et al., 
2001) and suggest the role of the GABAg receptor in these seizures is complex. 
Activation of T-type calcium channels allow for low-threshold burst firing of the 
thalamocortical relay neurons (Suzuki and Rogawski, 1989). Transgenic mice lacking 
functional T-type channels were resistant to absence epilepsy produced by baclofen 
(Kim et a l, 2001). Genetic linkage studies found no evidence of mutations in the 
GABAgi gene in idiopathic generalised seizures (Peters et a l, 1998; Sander et a l,
1999) and childhood absence epilepsy (Robinson et a l, 2002) suggesting that while 
GABAg receptors have an important role in absence seizures, they are unlikely to be 
the underlying cause.
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Figure 1.7 -  Location of GABAg receptors on the thalam ocortical circuits 
involved in typical absence seizures.
Glutamatergic projections of the pyramidal neurons of the cortex project to the 
thalamus innervating thalamocortical relay neurons (TC) and thalamic reticular 
neurons (nucleus reticularis neurons; NRT). NRT neurons are GABAergic 
intemeurons and form local inhibitory circuits within the thalamus. Thalamocortical 
relay neurons release glutamate and project to the cortex. GABAgia containing 
receptor subtypes are present at presynaptic site on glutamatergic terminals, whereas, 
both GABAgia and GABAgib subtypes are functional as autoreceptors and 
postsynaptic receptors in the thalamus. GABAg autoreeeptors and postsynaptic 
receptors in the cortex are exclusively formed by the GABAgib containing subtype.
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7 .2 j .^
Temporal lobe epilepsy is an umbrella term use fbr seizures arising in the temporal 
lobe and is associated with simple and complex partial seizures, which can develop 
into secondary generalised seizures (ILAE, 1989). Temporal lobe simple partial 
seizures last several seconds and mimic sensory (olfactory and gustatory) 
hallucinations and 'psychic' symptoms ((/ÿà vw andya/Mazj vw) (ILAE, 1989). These 
seizures can occur in isolation, as sensory seizures, or immediately prior to complex 
partial seizures (ILAE, 1989). In some cases, simple partial seizures can act as an aura 
alerting the patient to the onset of complex partial seizures or generalised seizures 
(Engel, 2001). Complex partial seizures in the temporal lobe are typified with 
cessation of motor activity, staring, oroalimentary automatisms, manual automatisms 
and unilateral limbic movements ipsilateral to the hemisphere with seizure activity 
(Engel, 2001). These complex partial seizures usually last a couple o f minutes and are 
followed by amnesia o f seizure onset and confusion, which gradually subsides over 
several minutes (Engel, 2001). Patients with temporal lobe epilepsy usually have 
similar medical histories such as febrile seizure and cerebral insults as a consequence 
of penetrating head wounds (Engel, 2001; Pitkanen and Sutula, 2002). Seizures 
observed in mesial temporal lobe epilepsy (mTLE) patients have initial activity 
localised ^vithin the limbic system, this has been identified to involve the amygdala, 
the hippocampal formation and the parahippocampal regions (including the entorhinal 
cortex) (Spencer and Spencer, 1994; Wennberg a/., 2002). Surgical resection of the 
anterior temporal lobe with the amygdala and hippocampus has been shown to abolish 
or reduce seizure Aequency (Wiebe gf a/., 2001). The most common pathology 
observed in mTLE is hippocampal sclerosis, which is seen in 70 % of hippocampi 
from surgical resection (Cavanagh and Meyer, 1956; Sharma gr a/., 2007). While most 
o f the seizure activity in mTLE has onset in the hippocampus the majority o f this 
activity remained sub-clinical and failed to recruit additional limbic structures, 
whereas, activity initialising in the amygdala and parahippocampal regions was fbund 
to spread to other regions and produce clinical symptoms (Wennberg gr (z/., 2002). 
These findings suggest that inhibition within the hippocampal fbrmation prevent the 
spread o f seizure activity (Wennberg gf" ürZ., 2002).
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7 . 2 .  j .  j  T^gcwrz-gM r ,5gzzM7"g.y
Hippocampal sclerosis is classically described as the atrophy and loss o f pyramidal 
cells and gliosis observed in the CAl and CA3 subfields and is normally observed 
unilaterally (Sloviter, 1994). This neuropathology is also reported in tissue from 
patient without a history of seizures (Sylvester, 1984) and therefbre it remains unclear 
whether hippocampal sclerosis is the cause of seizures or a result o f seizure activity. 
Animal models of cell loss in the hippocampal subfields have been investigated to 
identify the role of CAl and CA3 pyramidal neurons in recurrent seizures (Milward g/ 
a/., 1999; Mellanby and Milward, 2001). These investigations have suggested that 
pyramidal cell loss in the CAl impede seizure onset and severity of limbic seizures 
(Milward gr 6z/., 1999). In contrast, neuronal loss in the CA3 and dentate gyrus hilar 
region increased the susceptibility to, but not severity of  ^ recurrent limbic seizures 
(Mellanby and Milward, 2001). Findings from these investigations suggest that 
hippocampal sclerosis may be responsible fbr recurrent seizures. Prolonged febrile 
seizures have been suggested to be responsible fbr the development o f hippocampal 
sclerosis (Cavanagh and Meyer, 1956; Sagar and Oxbury, 1987; Merkenschlager g/ a/.,
2009) with between 30 and 60% of mTLE patients having a history o f prolonged 
febrile seizures (Scantlebury and Heida, 2010). In addition, hippocampal sclerosis has 
also been shown to develop in animal models o f head trauma (Lowenstein gr aZ., 1992) 
and chemoconvulsants (Liu g/ a/., 1994). However, neuropathological changes in 
mTLE are not limited to the hippocampus, investigations have also shown changes in 
the amygdala (Hudson gr a/., 1993), entorhinal cortex (Du gr a/., 1993) and the 
thalamic dorsomedial nucleus (Juhasz gZ ûfZ., 1999 357; Natsume gZ aZ., 2003).
7 . 2 . 3 . 6  7MvoZvg<7 B m Z /z  7 (g g Z o » .y  ZM zZzg 5]prg6zz7 q /5 " g z z z z rg  v4gZzvzZy z »  f  a rZ zaZ  5'gzzzzrg.s^
Seizures involve a network of neurons to initiate seizure activity. The spread o f seizure 
activity depends on the regions included within the network. Generalised absence 
seizures produce bilateral activity from the outset o f the seizure. On the other hand 
partial seizures are localised in specific regions, but can produce additional secondary 
generalised seizures. In the case o f mTLE initial activity is contained within the limbic 
system, mainly the amygdala, hippocampus, and entrohinal cortex. Secondary 
generalisation o f these seizures has been shown to involve the midline thalamic nuclei 
especially the mediodorsal nucleus (Cassidy and Gale, 1998; Bertram gZ aZ., 2001;
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Bertram gZ a/., 2008). In addition, patients with mTLE have decreased mediodorsal 
nucleus volumes ipsilateral to the seizure focus in contrast to other epilepsies and 
neurological normal individuals (Juhasz gZ a/., 1999; Natsume gZ a/., 2003). Direct 
pharmacological modulation of the mediodorsal nucleus can suppress the secondary 
generalisation of partial seizures with either a GABAA agonist or a glutamate 
antagonist (Cassidy and Gale, 1998). These findings suggest that the role of the 
mediodorsal nucleus is critical in the generalisation of partial seizures.
7.23.7 77zgong.y EpzZ^ZoggMgjz.y zzz Z/zg DgzzZürZg
The mechanisms underlying the development of recurrent seizures, epileptogenesis, in 
hippocampal sclerosis remains unclear. Two main hypotheses have been suggested 
derived from the cellular changes observed in this neuropathology; the dormant basket 
cell hypothesis and the recurrent excitation hypothesis. The dormant basket cell 
hypothesis was proposed by Sloviter (1987, 1991) and is based around the 
observations that basket cells are relatively seizure resistant whereas the mossy cells, 
excitatory intemeurons innervating the basket cells, are prone to seizure induced cell 
loss. This leads to the loss of excitatory synaptic input to the basket cells and therefbre 
silences the inhibition provided by these inhibitory basket cells. These findings are 
observed during the acute period fbllowing seizures, but befbre recurrent seizure onset 
(Dudek and Sutula, 2007). Contrasting evidence has been reported which suggests that 
the intemeurons are not exclusively seizure-resistant and the mossy cells are not 
always lost in mTLE (Esclapez gZ a/., 1997; Bemard gZ a/., 1998). The recurrent 
excitation hypothesis was suggested based on the observation of mossy fibre sprouting, 
an increase in mossy fibre terminals in the dentate gyrus molecular layer, in the rats 
treated with kainic acid (Tauck and Nadler, 1985). These back-projecting axons were 
shown to fbrm recurrent excitatory circuits with the dentate gyms granule cells (Tauck 
and Nadler, 1985). However, these axons are also reported to stimulate the inhibitory 
basket cells (Ribak and Peterson, 1991; Kneisler and Dingledine, 1995) and have been 
suggested to have a net inhibitory effect (Sloviter, 1992). Under normal physiological 
conditions the dentate gyms demonstrates neurogenesis with approximate 6 % of the 
granule cell population made up o f recently differentiated cells (Parent, 2007). Models 
o f mTLE have been shown to accelerate neurogensis in the dentate gyms granular 
layer leading to reorganisation o f the mossy fibre terminals in the dentate gyms
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molecular layer and the hippocampal CA3 (Parent eZ 1997). In addition, some of 
the newly differentiated cells demonstrating granule cell like morphology migrate from 
the dentate gyrus granular layer to the hilar and molecular layers (Parent gZ (zZ., 1997; 
Scharhnan gZ arZ., 2000). These hilar-ectopic cells demonstrate hyperexcitability and 
burst fire in synchronisation to activity in the CA3 pyramidal cells (Scharfman gZ aZ.,
2000). The number o f animals developing recurring spontaneous seizures decreased 
with blockade o f cell division prior to the induction of mTLE (Jung gZ aZ., 2004). 
These findings suggest that the neurogenesis of neurons in the dentate gyrus is in part 
responsible fbr the recurrence of seizures, and may act in combination wdth the loss of 
synaptic drive to the inhibitory neurons. The entorhinal cortex is also reported to show 
neuronal loss within layer 111 o f the medial region in mTLE (Du gZ aZ., 1993; Du gZ 6zZ., 
1995). This region is associated with the projection of the perfbrant pathway to the 
dentate gyrus and hippocampus (Witter et a l, 2000) and suggests that other regions 
within the limbic system are likely to contribute to epileptogenesis.
7 . 2 3 . AZgüZZcaZ 7ZzZgrvgMZZoM.yFÿZZ^jy
Medical interventions in epilepsy aim to abolish seizures or reduce the frequency to a 
manageable level. At present it remains unclear whether uncontrolled seizures are 
directly implicated in disease progression (Mellanby and Milward, 2001). However, 
the risks and quality o f life associated with uncontrolled seizures and loss of 
consciousness remains. Death and injury can result from asphyxia (during prolonged 
tonic-clonic seizures), drowning, falling and other accidents during seizures (Hitiris gZ 
aZ., 2007). Numerous drugs are available fbr the treatment of temporal lobe epilepsy 
and are often used in combination fbr optimisation o f seizure control. Classic frontline 
anti-epileptic drugs fbr temporal lobe epilepsy include phenobarbitone, phenytoin, 
primidone, carbamazepine and valproic acid. Newer anti-epileptic drugs have similar 
mechanisms of action but with fewer side effects, such as, lacosamide and rufmamide. 
The main anti-epileptic action o f carbamazepine, phenytoin and rufinamide is the 
blocking of the fast sodium channels, or slow sodium channels in the case of 
lacosamide, thereby impeding the spread o f seizure activity (Rogawski and Loscher, 
2004; Lason gZ aZ., 2011). Mechanisms of action fbr phenobarbitone and primidone 
(phenobarbitone is the major active metabolite) is via the positive modulation of the 
GTkBAA receptor increasing the probability of chloride channel being open (Rogawski
-29-
Chapter 1 - General Introduction
and Loscher, 2004). Other recently marketed anti-epileptic drugs have novel 
mechanisms of action, fbr example, tiagatine which is a GABA reuptake inhibitor and 
pregabalin which interacts with calcium channels, but has additional mechanisms 
(Lason gZ a/., 2011). Lamotrigine and valproic acid are effective in treating both partial 
and absence seizures due to their mixed mechanisms of action blocking sodium and T- 
type calcium channels, respectively (Rogawski and Loscher, 2004; Lason gZ arZ., 2011). 
Additional pharmacological treatments for absence seizures include the T-type calcium 
channel blocker ethosuximide and the benzodiazepine clonazepam (Rogawski and 
Loscher, 2004). The T-type channel blocking prevents the burst-firing pattern seen in 
the thalamocortical relay neurons due to enhanced inhibition in absence seizures 
(Rogawski and Loscher, 2004). Whereas, benzodiazepines act to desynchronise the 
spike-and-wake activity in absence seizures by enhancing inhibition o f the GABAergic 
neurons of the thalamic reticular neurons thus reducing inhibitory input to the 
thalamorocortical relay neurons (Rogawski and Loscher, 2004).
Estimations suggest that 60% of epilepsy patients display drug refractory seizures 
(Kwan and Brodie, 2000). Polypharmacy is often used to overcome the drug resistant 
seizures, however, it has been suggested that it would take the patient's life time to 
attempt all possible drugs and drug combinations for optimal seizure control (Engel,
2001). In addition, many o f the anti-epilepsy drugs have compliancy-limiting side 
effects such as sedation and cognitive impairment. Depression is a common co­
morbidity associated with temporal lobe epilepsy and periods without seizure-control 
have been suggested to worsen the depressive state (Harden, 2002). In epilepsies with 
a well defined single fbcus radical temporal lobectomy to remove the seizure fbcus has 
been presented as a suitable alternative to drug refractory seizures and trial-and-error 
drug treatment optimisation (Engel, 2001).
7.2 3. P j  wZzZz g ^ goMz.yZ aW  v^ MZagOMZjZ
Systemic administration of GABAg receptor antagonists has been shown to suppress 
absence seizures in rats susceptible to absence-type generalised seizures (Vergnes gZ 
aZ., 1997). At high doses, however, GvABAg receptor antagonists were observed to 
induce tonic-clonic seizures in both rats genetically susceptible to absence seizures and 
non-epileptic rats (Badran gZ aZ., 1997; Vergnes eZ aZ., 1997). In addition, mice were
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found to display myo-clonic seizures with high doses o f GABAg antagonists (Badran 
er a/., 1997). Interestingly, GABAs antagonists were also shown to decrease the 
latency time between an audio stimuli and seizures in audiogenic seizure susceptible 
rats, and increased the susceptibility o f control animals to audiogenic seizures 
(Vergnes gr a/., 1997) and other sensorimotor stimuli (Leung g/ 6z/., 2005). Further 
investigation with GABAs receptor antagonists demonstrated that they induced partial 
seizures in the hippocampus when injected intracerebroventricularly in the rat (Leung 
gr a/., 2005). This has been suggested to result due to lowering of the after-discharge 
threshold and therefore the increasing likelihood o f activity spreading (Leung gr a/.,
2005). Seizures invoked by GABAg blockade can be suggested to be in response to the 
loss o f the inhibitory effect of GABA on GABAs hetroreceptors at glutamate terminals 
or by loss of GABAg postsynaptic inhibition. Conversely the GABAg receptor agonist 
baclofen has been associated with seizures in patient with traumatic brain injuries 
(Kofler gf^  a/., 1994) and with baclofen overdoses (Ghose g/ a/., 1980), suggesting that 
GABAg activation may also increase excitation by disinhibition highlighting the 
complex role of GABAg receptors in the balance of excitation and inhibition. In 
addition, baclofen had been shown to have no effect on seizures in a model o f mTLE 
(Sato g/a/., 1990).
7.2. j. 70 7(gggpmr Exprg.y.yzoM ZM faOgM^j aW  ExpgnrngMW Mb<7g/.y
Expression o f GABAgib mRNA was found to be up-regulated 4 hours after an 
electroshock induced seizure in the rat, this may indicate that this isofbrm has greater 
importance in the control of seizures compared to GAB Agi a '' (Billinton g^  a7, 2000). 
Systemic ii^ection and focal injections of kainic acid into the hippocampus initialises 
seizures and invokes cell loss in the CAI,  CA3 and hilar subfields o f the hippocampus, 
similar to those observed in hippocampal sclerosis (Bouilleret gr a7, 1999). GABAgi 
and GABAg2 receptor subunits show a reduction in immunohistochemical staining 
intensity (Straessle g/ a/., 2003) and decreased mRNA levels (Furtinger gr a/., 2003) in 
the CAI and CA3 24-hours following kainic acid treatment, however the principal 
neurons remained intact. Loss of GABAg expression was found to be persistent in the 
pyramidal cells and remained in the CAI at 1 and 3 months after the kainic acid 
treatment, however analysis in the CA3 was confounded by high levels o f neuronal 
loss (Straessle g/ a7, 2003). In contrast, findings from m jz/w hybridisation
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investigations suggest that the GABAg receptors are up-regulated in the surviving CA3 
pyramidal neurons (Furtinger gr a/., 2003). In addition, the staining intensity for 
GABAg 1 and GABAg2 was increased in the dentate gyrus granular layer, but not the 
molecular layer, at both I and 3 months post-kainic acid administration (Straessle gr 
6f/., 2003). These investigations suggest that decreased expression of the GABAg 
receptor in the CAI and CA3 appears to precede the neuronal loss seen in this model 
(Furtinger g^a/., 2003; Straessle gr a/., 2003).
GABAg receptor binding (Billinton gf a/., 2001b; Princivalle g/ a/., 2002) and 
GABAgi mRNAs (Billinton gr a/., 2001a; Princivalle g/ a/., 2003) were reduced in the 
CAI, CA3 and dentate gyrus hilar region in tissue surgically resected from patients 
with hippocampal sclerosis compared to post-mortem controls. However, when 
corrected for the neuronal loss, the binding per intact neuron was increased in the CAI 
(Billinton g/ a/., 2001b), CA3 and the hilar region (Princivalle g/ a/., 2002). 
Additionally, the GABAgi isofbrms mRNA were increased in the CAI,  dentate gyrus 
and the hilar regions (Billinton gr a/., 2001a; Princivalle gr üf/., 2003). These findings 
suggest an upregulation o f the GABAg receptor in surviving hippocampal neurons in 
mTLE with hippocampal sclerosis. Direct comparison between human and animal 
findings, however, is complex as there are additional factors to be considered. For 
example, epileptic patients receive anti-epileptic drugs to control seizure activity. 
Exposure to these drugs may alter GABAg receptor expression within the brain. 
Findings using human tissues are in agreement with those seen in the animal models 
and suggest that the GABAg receptor may act as a compensatory mechanism in mTLE 
to increase inhibition via up-regulation o f the GABAg heteroreceptors at glutamatergic 
terminals. Interestingly, depression is a common co-morbidity associated with patients 
with temporal lobe epilepsy (Harden, 2002). Up-regulation o f the GABAg receptors in 
epilepsy is in agreement with the concept that overstimulation of GABAg receptors is 
involved in depression (Sequeira gr a/., 2009; Ghose g/ a/., 2011).
The study by Gambardella et al. (2003) reported that patients from an Italian 
population with a polymorphism in the GABAgi gene had a significantly increased 
risk of developing temporal lobe epilepsy in comparison to those without the
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polymorphism. However, this correlation was not repeatable in populations &om 
America (Ma gr a/., 2005), Australia (Tan gf^  a/., 2005), Austria (Stogmann g/ a/.,
2006), China (Ren gf a/., 2005), France (Salzmann gr a/., 2005) and England (Cavalleri 
g/ a/., 2005). This strongly suggests that the results from the first study may be due to 
false positive due to population stratification (Tan gr a/., 2005). However, the study by 
Kauffman et al. (2008) also reported a correlation between the GABAgi gene and 
temporal lobe epilepsy in a population from Argentina. This is proposed to be due to 
hereditary similarity between the populations from Italy and Argentina, as Italian 
immigrants are known to have settled in Argentina (Kauffman g^  a/., 2008). The recent 
investigation by Xi gr a/. (2011) suggested that the sample sizes used for the previous 
investigations were insufficient for a satisfactory statistical power given the rare 
occurrence o f GABAgi polymorphisms. A meta-analysis was performed using pooled 
data from previous investigations and showed that the polymorphisms of GABAgi 
were associated with increased risk o f developing temporal lobe epilepsy (Xi gr a/., 
2011). These investigations therefore suggest that there is a connection between this 
polymorphism and temporal lobe epilepsy.
7.2.3.72 w^^ozTMTMWMg Dfj^ ga.yg
Recent studies have described a type of autoimmune encephalitis presenting with 
convulsive seizures which were associated with antibodies against the GABAgi 
receptor subunit (Lancaster gr a/., 2009; Boronat gf <3/., 2011). This antibody 
production is a result o f paraneoplastic syndrome due to small cell lung cancer 
(Lancaster g/ a/., 2009; Boronat gr (%/., 2011). Interestingly, while the study by Boronat 
gr a/. (2011) mainly identified antibodies for the GABAgi receptor subunit they also 
found antibodies raised to glutamate decarboxylase, an enzyme that catalyses the 
convention of glutamate to GABA, in a small subset of patients without GvABAgi 
antibodies. Seizures in patients with antibodies for the GABAg receptor were likely to 
be as a consequence o f reduced GABAg receptor expression. These findings suggest 
that both loss o f the GABAg-mediated inhibition (Lancaster gr a/., 2009; Boronat g/ 
a/., 2011) and increased GABAg receptor stimulation can produce seizures in humans 
(Ghose gr a/., 1980), demonstrating that GvABAg receptors play a critical role in the 
balance o f excitation and inhibition to maintain the thresholds to seizure activity.
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1.3 GABAg Receptors in the Brain Regions Relevant to Seizures
1.3.1 Generalised Seizures
7.3.7.7 f
The chemoconvulsant pentylenetetrazol (PTZ) invokes characteristic convulsive- 
seizures; partial clonus, generalised clonus and tonic-clonic seizures. Bilateral injection 
o f baclofen into the globus pallidus have been shown to suppress PTZ induced tonic- 
clonic seizures, however the other convulsive-seizures remained unaltered (Chen gt zz/., 
2004). The globus pallidus forms part o f the basal ganglia which provide an inhibitory 
input to the motor systems. Unilateral focal iiijection of baclofen results in an 
ipsilateral turning behaviour (Chen g/ a7, 2002), demonstrating that the GABAg 
receptors play an important role in the regulation of motor activity within the region. 
GABAg heteroreceptors were found to reduce glutamate release from excitatory 
terminals within the globus pallidus (Chen gr a/., 2002) and hyperpolarise globus 
pallidus neurons (Chen et a l, 2004). Baclofen is therefore likely to cause an increased 
inhibitory effect to the motor systems to prevent the convulsive muscle movements of 
the tonic-clonic seizures, but may not suppress the electrical seizure activity. GABAg- 
mediated suppression o f tonic-clonic seizures may be via pre- or postsynaptic 
inhibition, or a combination o f both. GABAgi isofbrms have equal expression within 
the globus pallidus (BischofFgf^ a/., 1999; Charles g/ a/., 2001), as such it is unclear as 
to what are the roles o f each isofbrm in control of seizure activity in this region.
7.3.7.2
Injections o f baclofen into the thalamic laterodorsal nucleus promoted PTZ-induced 
clonic-type seizures (Miller g^  a/., 1991), whereas injection in the midline thalamus 
enhanced clonic-type and tonic-tonic seizures (Miller and Ferrendelli, 1990). Enhanced 
generalised seizures were also promoted with a GABAA agonist, muscimol, within the 
midline thalamus (Miller g/ a7, 1989). In addition, local application o f baclofen or 
muscimol into the midline thalamic nuclei increased locomotor activity (Churchill g7 
a/., 1996). However, muscimol injection into the nearby mediodorsal nucleus 
suppressed the generalisation o f partial seizures (Cassidy and Gale, 1998; Bertram gr 
a/., 2008). These findings suggest that the role of GABA within the thalamic nuclei is
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dependent on the types of seizure activity involved.
Systemic administered baclofen has been shovm to reduce tonic-clonic seizures in 
juvenile rat pups (Veliskova g/ a/., 1996), however the effect was absent in older 
animals (Holland gr a/., 1992). These findings may indicate that systemic baclofen 
administration may produce both pro- and anti- convulsant effects. Pharmacological 
blocking of the T-type calcium receptors was found to impede seizure onset in the PTZ 
model (Mandhane g/ a/., 2007), suggesting a role for T-type channels in PTZ-induced 
seizures. As baclofen is known to enhance seizures using a mechanism involving the 
T-type calcium channels (Kim g/ a/., 2001), PTZ-invoked seizures may be enhanced in 
combination with systemic baclofen.
1.3.2 Limbic System Partial Seizures 
7.3.27 EMfor/zzMaZ Cor^gx
The entrohinal cortex provides glutamatergic innervations to the dentate gyrus and 
directly to the hippocampal formation, via the perforant pathway (Witter g^  a/., 2000). 
GABAg receptors are present at both glutamatergic and GABAergic terminals within 
the entorhinal cortex and function as heteroreceptors and autoreceptors, respectively 
(Bailey gr a/., 2004). Electrophysiological recordings in slices indicated that inhibition 
within the entrohinal cortex differs across the layers of the entrohinal cortex, with the 
superficial layer displaying greater spontaneous inhibition compared to the deeper 
layers (Woodhall g/ a/., 2005). In addition, GABAg autorecptors in deeper layers 
displayed a tonic activation which was absent in the superficial layers (Bailey gr a/., 
2004). GABAg autoreceptor and heteroreceptor functions in brain slices from epileptic 
animals, using the pilocarpine model, were reduced and suggest that increased 
glutamate and GABA may be involved in epileptogenesis within the entrohinal cortex 
(Thompson gf a/., 2006). Increased GABA release within the entrohinal cortex may 
result from a compensatory mechanism in epilepsy as a result o f decreased GABAg 
heteroreceptor-mediated inhibition. In the somatosensory cortex, another neocortical 
region, the GABAgi a containing receptors have been shown to be responsible for the 
heteroreceptor-mediated inihibition, whereas, the GABAgib subtype acted as 
autoreceptors and were present at postsynaptic sites (Perez-Garci g/ a/., 2006).
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Therefore these findings suggest a reduction o f the GABAgi a subtype and an increase 
in the GABAgib within the entrohinal cortex during mTLE.
7.3.22
The entorhinal perforant pathway projects to the dentate gyrus and releases glutamate 
to stimulate the dentate gyrus granule cells (Witter gr a7, 2000). The glutamatergic 
granule cell project, via the mossy fibre, into the hippocampus and innervate the CA3 
pyramidal neurons. In addition to the pyramidal cells, the mossy fibre also synapses 
with GABAergic and glutamatergic intemeurons within the dentate gyrus hilar region 
(Amaral gr a/., 2007). These cells project back to the dentate gyrus granule cells and 
release GABA and glutamate producing recurrent inhibition and excitation, 
respectively. In addition, the excitatory intemeurons also innervate inhibitory 
intemeurons to produce an inhibitory circuit. Within the dentate gyrus GABAg 
receptors have been reported to be functional as heteroreceptors and as autoreceptors 
(Lanthom and Cotman, 1981; Mott g/ a7, 1999). However, inhibition mediated by the 
GABAg heteroreceptor on the prefbrant pathway is weaker in comparison to the 
glutamatergic terminals ^vithin the hippocampus (Lanthom and Cotman, 1981; Ault 
and Nadler, 1983a). In electrophysiological recordings of dentate gyms slices, 
application of baclofen produced LTP from stimulation o f the perforant pathway and 
epileptiform activity (Mott et a l, 1989; Burgard and Sarvey, 1991; Mott and Lewis, 
1991). These findings suggest that under normal physiological conditions the net 
action o f GABAg activation within the dentate gyrus is disinhibition, rather than 
inhibitory, and therefbre will lead to an increased excitation. GABAergic inhibition 
within the dentate gyms has been shown to be enhanced in the kainic acid model of 
epilepsy (Haas gr a/., 1996). This increased inhibition involved changes in GABAg 
receptor function on the recurrent inhibitory pathway and was suggested to result from 
a reduction o f GABAg autoreceptor function (Haas g/ ar/., 1996). This down-regulation 
would therefbre decrease the disinhibitory effect and enhanced inhibition. On the other 
hand, GABAg receptor loss on excitatory terminals in the recurrent inhibition circuit 
may also produce these changes. In agreement with enhanced inhibition in the dentate 
gyrus, administration of baclofen to kainic acid treated rats reduced spontaneous 
activity recorded in the dentate gyms (Sokal and Large, 2001). Conversely, this 
G7\BAg-mediated inhibition was absent 24 hour following partial seizures (Chandler
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gr a/., 2003) in agreement with the short-term decrease of GABAg expression in the 
denate gyrus (Straessle gr a/., 2003). This decrease in GABAg receptor function and 
expression may contribute to greater susceptibility to spontaneous seizure activity, 
however, this effect is likely to be transient as GABAg expression (Straessle gr a/., 
2003) and function (Sokal and Large, 2001) is increased in the long-term following 
partial seizures. On the other hand, as baclofen was administered systemically these 
effects are likely to involve inhibition within other regions in the temporal lobe and not 
just an inhibitory effect of GABAg receptor in the dentate gyrus.
7.3.2.3 77z^ogaTMp
The hippocampal formation receives glutamatergic input for the dentate gyrus granule 
cells via the mossy fibre and the entrohinal cortex. The GABAg receptor expression 
and function within the hippcampus has been introduced in section 1.1.3.15. In this 
region activation of the GABAg la containing heteroreceptors mediates a strong 
synaptic inhibition (Vigot gr a7, 2006). Both GABAg receptor agonist and antagonist 
enhance m vz/ro epileptiform activity invoked by potassium channel blocker, 4- 
aminopyridine, in the hippocampal CA3 region (Motalli gr a7, 1999; Motalli g^  a7,
2002). Blockade of the GABAg receptor with intact GABAa inhibition will not induce 
ZM vz/ro epileptiform activity (Scanziani gr a7, 1991; Sutor and Luhmann, 1998). 
Although during the developmental stage when GABAA receptors are excitatory, 
desensitisation o f the GABAg receptor produces epileptiform activity in the 
hippocampus (Tosetti g/ a/., 2004) and this is also seen in adults with antagonism of 
the GvABAg receptor during GABAA receptor blockade (Scanziani gr a/., 1991; Sutor 
and Luhmann, 1998). However, zzz vzvo investigations have demonstrated that G7\BAg 
antagonist invokes partial seizures originating from the hippocampal formation which 
spread to the entrohinal cortex and amygdala (Vergnes g/ a/., 1997), see section 
7.2.3. P. These findings suggest that GABAg-mediated inhibition within the 
hippocampus is important for the control of seizure activity and are in agreement with 
the suggestion that inhibition in the hippocampus prevents the spread o f the seizure 
activity in mTLE (Wennberg gr a7, 2002), see section 1.2.3.4. Therefbre containment 
of epileptiform activity within the hippocampus may depend on GABAg receptor 
function within this region.
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7.3.24
In the lateral amygdala, the GABAgi a isolfom containing receptor mediates the 
heteroreceptor mediated inhibition at the glutamatergic terminals of the cortical and 
thalamic afférents, whereas, both GABAg la and GABAgib can function as 
autoreceptors (Shaban a/ a/., 2006). Using the pilocarpine model o f mTLE, GABAg 
autoreceptors were found to have reduced function and the GABAA receptors had a 
more depolarised reversal potential in the lateral amygdala (Benini and Avoli, 2006). 
Decreased autoreceptor function can enhance GABA release which will promote 
inhibition within the amygdala. However, sustained activation o f the GABAA receptor 
during high h-equency activity will shift the action from hyperpolarising to 
depolarising due to the transmembrane shift in ion gradients (Lamsa and Taira, 2003). 
Therefbre, this increased inhibition within the amygdala may drive synchronisation of 
cell firing.
7.3.23
As already mentioned, the midline nuclei o f the thalamus appears to play a critical role 
in the secondary generalisation of the partial seizures (see section 7.23.6). At present 
the role o f GABAg receptor in the generalisation o f partial seizure remains unclear. 
However, activation of the GABAA receptor within the midline nuclei suppressed the 
secondary generalisation of partial seizures (Cassidy and Gale, 1998; Bertram a/., 
2008) and reduced activity within the limbic system (Sloan gr a/., 2011). The 
expression o f both GABAgi a and GABAgib isofbrm has been shown to increase 
fbllowing electric shock induced seizure activity (Billinton gf^  a/., 2000). Therefbre, 
GABAg-mediated inhibition within the thalamus is likely to play a key role in the 
suppression of seizure activity.
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1.4 Aims of Thesis and Hypothesis
While numerous genetic deletions in transgenic mice have been shown to result in 
epilepsy the discovery that the loss of functional GABAg receptors induces seizures is 
not a surprise as inhibition is essential for the control of neuronal activity. 
Interestingly, mutations in the genes coding for the GABAg receptors have been 
proposed to increase the risk o f epilepsy and autoimmunity to the GABAg receptors 
has been shown to be associated with seizures in humans. The current body of research 
indicates that the GABAg receptor is strongly involved in seizures. Further 
investigations are needed to show the distribution o f the GABAg isoforms in the brain 
and the roles of GABAg receptor subtypes in seizure activity.
It was hypothesised that the GABAgi a isoform would be present at sites associated 
with presynaptic terminals, whereas the GABAgib isoform would be the main GABAgi 
isoform present at postsynaptic sites. Therefore, the aim was to investigate 
immunohistochemical locations o f the GABAgi and GABAgi receptor subunits in the 
GABAg la'' and GABAgib'' mice allowing for selective labelling of the GABAgib and 
GABAg la containing receptor subtypes, respectively. Also, as the dentate gyrus is 
known to have an important role in temporal lobe epilepsy, the aim was to investigate 
the GABAg-mediated modulation o f synaptic inhibition in this region with 
electrophysiological recordings in tissue from GABAgla'^' and GABAgib'^' mice.
In addition, spontaneous seizures have been reported in the GABAg la'^ ' mice, these 
seizures can be suggested to result from the loss o f the GABAgla-containing 
presynaptic heteroreceptors thereby increasing excitation. Thus this thesis aimed to 
investigate the regional expression o f the GABAg receptor subtypes within the 
fbrebrain nuclei. It was hypothesised that the GABAgia containing receptors would be 
present in locations implicated in the spread of seizure activity.
Finally, this thesis aimed to investigate the net effect of the GABAg receptor subtypes 
on network excitation using acute seizure models. It was hypothesised that the 
GABAgia'^' animals would have higher seizure activity, due to greater spread of seizure 
activity resulting from the loss of GABAg heteroreceptor mediated inhibition.
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2 Immunohistochemical Localisation of the GABAg Subtypes
2.1 Introduction
GABAgi and GABAg] subunits are reported to be widely expressed within the brain, 
with the cerebellum, hippocampus and thalamus demonstrating the highest levels of 
expression (Bischoff gt a/., 1999; Fritschy et a/., 1999; Margeta-Mitrovic et 6z/., 1999; 
Liang gt a/., 2000). Studies with selective GABAgi isofbrm knockout mice 
(GABAgia'^' and GABAgib'^') have found GABAgia to be the exclusive GABAg 
receptor expressed presynaptically at mossy fibre terminals of the hippocampal CA3 
(Vigot gt a/., 2006; Guetg et a/., 2009). The function o f these heterosynaptic GABAgia 
isofbrms have been demonstrated at glutamatergic terminals of the hippocampal CAI 
(Vigot gr a/., 2006), neocortex (Perez-Garci g/ a/., 2006) and thalamus (Ulrich gr a/., 
2007). The GABAgib isofbrm, on the other hand, is mainly expressed at postsynaptic 
sites opposite glutamatergic terminals (Vigot g^  a/., 2006). It has been demonstrated 
that GABAg autoreceptors consist o f both GABAgi isofbrms (Vigot g/ a/., 2006; 
Ulrich gf a/., 2007). There is a growing body o f evidence to suggest that the 
GABAg(ia, 2) has a universal role in the inhibition of excitatory transmission, where it is 
located presynaptically at glutamatergic terminals, whereas, GABAg(ib, 2) has a 
postsynaptic modulatory role mainly at postsynaptic sites. Autoreceptors on 
GABAergic intemeurons have been shown to consist o f both GABAgi isofbrms in the 
hippocampus CAI (Vigot g^  a/., 2006) and thalamus (Ulrich g/ a/., 2007), however in 
the neocortex this was exclusive to the GABAgib isofbrm (Perez-Garci gr a/., 2006).
The dentate gyms granule cells are innervated by glutamatergic projections of the 
perforant pathway originating in the entorhinal cortex (Witter gr a/., 2000). The 
entorhinal cortex can be divided into lateral and medial entorhinal cortex with their 
afferents forming the lateral and medial perforant pathway respectively (Witter gr a/., 
2000; van Groen gr a/., 2002). Terminals of the lateral perforant pathway are located 
within the outer third o f the dentate gyms molecular layer, whereas terminals of the 
medial perforant pathway are located within the middle third (Witter gf a/., 2000; van 
Groen gf a/., 2002). Additionally, both divisions of the perforant pathway are found 
within the CAI lacunosum-moleculare to innervate the CA3 and CAI (van Groen gr 
a/., 2002). Dentate gyms granule cells project to the CA3 pyramidal cells via the
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mossy fibres, which also stimulate the mossy cells within the hilus region (Amaral g/ 
ar/., 2007). Mossy cells can project, via the associational/commissural projection, to the 
inner third o f ipsilateral and contralateral dentate gyrus molecular layer to release 
glutamate -  stimulating granule cells and basket cells (Amaral gr a/., 2007). MOPP 
(molecular layer perforant path cell), basket and HIPP (hilar commissural-associational 
pathway related cell) cells are GABAergic intemeurons which project to the perforant 
path in the outer two thirds of the molecular layer, these originate in the molecular 
layer, the granular layer and the hilar region respectively (Amaral gr a/., 2007). In 
addition, HICAP (hilar commissural-associational pathway related cell) cells are also 
intemeurons, but project to the associational/commissural pathway from the hilar 
region (Amaral gr a/., 2007). Electrophysiological investigations have shown little to 
no effect on perforant pathway mediated responses in the dentate gyms granule cells 
by the GABAg receptor agonist baclofen (Ault and Nadler, 1982, 1983a; Mott gr a/., 
1989). These results may suggest the absence, or low expression, of presynaptic 
GABAg(ia, 2) receptors on terminals o f the perforant pathway, however they may also 
reflect postsynaptic effects either directly on the granule cell, or the network of mossy 
cells and intemeurons.
In the cerebellum Purkinje cells are stimulated by the glutamatergic parallel fibres of 
the granule cells, which are innervated by mossy fibres of the precerebellar nuclei 
(Apps and Garwicz, 2005). Purkinje cells project to the deep cerebellar nuclei to 
release GABA and their activity is modulated by intemeurons. Cerebellar granule cells 
have been shown to express the GABAgia isofbrm, whereas Purkiige cells express the 
GABAgib isofbrm (Billinton gz^ a/., 1999; Bischoff gr a/., 1999; Fritschy gr a/., 1999; 
Liang gr ar/., 2000). GABAg receptors, within the molecular layer, are located on the 
presynaptic terminals of the parallel fibres and at postsynaptic sites on the Purkinje 
cells (Kulik gr a/., 2002). Regional alteration in GABAg, expression within the 
cerebellum, has been demonstrated, and is seen as zebrin-like stripes of high-and-low 
expression across the cerebellar molecular layer, conferring differential functional 
characteristics (Fritschy g/ a/., 1999; Chung g^  a/., 2008). These findings suggest that 
GABAg(ia, 2) and GABAg(%b, 2) are localised presynapticaly and postsynapticaly 
respectively, but it remains unclear whether both receptor subtypes could demonstrate 
a zebrin-like expression pattem.
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This chapter aimed to investigate the locations o f the GABAg receptor subtypes within 
the fbrebrain and at the excitatory synaptic junctions in the dentate gyrus and 
cerebellum. In addition, the GABAg receptor subtypes expressed by the intemeurons 
of the dentate gyms were identified. Finally this chapter aimed to investigate the 
GABAg receptor subtype forming the zebrin-like expression pattem in the cerebellum.
For this investigation immunohistochemistry was preformed using a non-isoform 
selective antibody for the GABAgi subunit in GABAgia and GABAgib isofbrm 
knockout mice to reveal the expression pattem of GABAgib GABAgia isofbrms, 
respectively, within the brain. As coupling o f the receptor subunits is obligatory for 
functional receptors immunolabelling using an antibody for the GABAg] subunit was 
also incorporated for heterodimer identification. Immunohistochemistry weis used in 
combination with semi-quantitative densitometry, in a novel methodology, to 
determine the relative expression o f GABAg subunits in multiple brain regions.
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2.2 M ethods
2.2.1 Animal Husbandry
GABAgia knockout (GABAgia'^'), GABAgib knockout (GABAgib'^') and wild-type 
mice were maintained on a BALB/c background (Vigot gt a/., 2006) and homozygous 
animals were bred from heterozygous pairs for no more than 3 generations. The 
original breeding couples were a gift from Prof. B. Bettler (University of Basel, Basel, 
Switzerland) and were back-crossed with BALB/c /Bkl mice (B & K Universal, Hull, 
Yorkshire, United Kingdom) every 3 generations. Animals were group-housed with a 
12 hour light/dark cycle with food and water available The housing and use
of animals in this investigation was in accordance with the United Kingdom Animals 
in Scientific Procedures Act, 1986.
2.2.2 Materials
All reagents used were of analytical grade and purchased from either Sigma-Aldrich 
(Poole, Dorset, United Kingdom) or Fisher Scientific (Loughborough, Leicestershire, 
United Kingdom), unless otherwise stated.
2.2.3 Genotyping (Qualitative PCR)
The genotype o f the animals was determined by qualitative polymerase chain reaction 
(PCR) on deoxyribonucleic acid (DNA) extracted from tail biopsies taken at 
approximately 5 weeks of age. DNA was extracted from tail biopsy with either 
DNeasy Blood and Tissue Kit (Qiagen Ltd., Crawley, West Sussex), or using 
proteinase K (300 U/ml [10 mg/ml]; Promega, Madison, Wisconsin, USA) with Direct 
PCR Tail solution (Viagen Biotech Inc., Los Angeles, California, USA) fbllowing the 
manufacturers protocols. Sequences fbr the primers used in genotyping were provided 
by Prof. B. Bettler (GABAgia fbrward primer 5'-GGT CCT TGT TCA GTG GGT 
TTG-3% GABAgia reverse primer 5'-TTA GGG CTA AAG CTG GTG CGA-3% 
GABAgib forward primer 5'-AGG ATC CCA GAT CTC TCC TTC-3% GABAgib 
reverse primer 5'-GAA AGG GTC TAG AGA GGA TGC-3') and the oligonucleotides 
were synthesised by Invitrogen Ltd. (Paisley, Glasgow, United Kingdom). 
Amplification o f target DNA was achieved with puRe Taq Ready-To-Go PCR beads 
(GE Healthcare UK, Chalfbnt St Giles, Buckinghamshire, UK) on a thermal cycler
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(GeneAmp PCR System 2700, Applied Biosystems, Foster City, California, USA). 
The amplified DNA was separated using gel electrophoresis using precast 2 % agarose 
gel with ethidium bromide (E-Gel, Invitrogen Ltd.) and run for 20 minutes at 60 V and 
40 mA (Electrophoresis Power Supply 301, GE Healthcare UK [formally Amersham 
Pharmacia Biotech]). Gels were run with a DNA ladder (FastRuler Low Range DNA 
Ladder, Fermentas UK Ltd., York, Yorkshire) to aid identification of bands. Bands for 
wild-type animals are expected at 155 base pairs (bp) and 148 bp for the GABAgia and 
the GABAgib PCR products, respectively. For the mutation of GABAgia a band is 
expected at 299 bp with the GABAgia PCR product and for the mutation of GABAgib 
a band is expected at 292 bp. An example gel is shown in Figure 2.1 below.
Wild-Type GABAgi GABA
Figure 2.1 -  Genotyping of the GABAgi isoform silenced mice.
Image shown is an example gel for genotyping of wild-type, GABAgia’^ ’ and 
GABAgib'^’ mice. DNA was extracted from tail biopsies and underwent PCR 
amplifieation with either (a) GABAgia primers or (b) GABAgib primers. PCR products 
were run on a 2 % agarose gel DNA for 20 minutes. DNA ladder (‘Lad’) shows bands 
at 1500, 850, 400, 200 and 50 base pairs for shortest to furthest distance travelled from 
the well.
2.2.4 Comparison o f GABA b Receptor Subunits and Antibodies
The amino acid sequences of the GABAgia, GABAgib, GABAg] proteins from mouse 
(Q9WV18-1; Q9WV18-2; Q80T41-I), rat (Q9Z0U4-2; Q9Z0U4-3; 088871-1) and
human (Q9UBS5-1; Q9UBS5-2; 075899-1) were retrieved from the UniProt database 
on 20^  ^ January 2010. These sequences and the sequences used as antigens for the 
antibody for the GABAgi receptor subunit (anti-GABAgi [sc-14006]; amino acids 
661-991 from the rat GABAgle [Q9Z0U4-1]; Santa Cruz Biotechnology Inc.,
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Heidelberg, Germany) and the GABAg] receptor subunit antibody (anti-GABAg] 
[AB5394]; amino acids 921-941 from the human GABAg] [075899-1]; Millipore Ltd., 
Watford, Hertfordshire, United Kingdom) were aligned and their percentage sequence 
identity was calculated with ClustalW2 running on the European Bioinfbrmatics 
Institute Server (Larkin gr a/., 2007). A ‘B last?’ search o f the National Centre fbr 
Biotechnology Infbrmation (NCBI) mouse protein database with the antigen sequences 
was perfbrmed to identify similar sequences within the anti-GABAg i and anti- 
GABAg] antibodies. An additional two antibodies directed against the N ’-terminus of 
GABAgi receptor subunit were used in this investigation manufactured by Millipore 
(anti-GABAg 1-Millipore [AB9167]; Millipore Ltd.) and Sigma-Aldrich (anti- 
GABAgi-Sigma [G1295]; Sigma-Aldrich Company Ltd.). The immunogen sequences 
of these antibodies were withheld as proprietary infbrmation so were unable to be 
included in the comparison. The immunogen sequence for antibodies directed against 
GABAgia and GABAgib isofbrms, reported in previous investigations (Poorkhalkali g/ 
2000; Charles g/ a/., 2001; Princivalle g/ a/., 2001), were aligned using ClustalW2 
(Figure 2.2). These antibodies were fbund to be non-specific fbr their selected isofbrm 
in the mouse, with the exception of anti-GABAgib reported by Princivalle et al. (2001) 
and Charles gz^  a/. (2001), and were rejected fbr use in the immunohistochemistry 
protocol.
10 20  30 40 50 60 70
I I I I I I I
M u s - O l a  M-LLLLLVPLFLRPLGAGGAQTPNVTSEGCQIIHPPWEGGIRYRGLTRDQVKAINFLPVDYEIEYVCRGE
Rat-GBla M-LLLLLVPLFLRPLGAGGAQTPNATSEGCQIIHPPWEGGIRYRGLTRDQVKAINFLPVDYEIEYVCRGE
Hom-GBla MLLLLLLAPLFLRPPGAGGAQTPNATSEGCQIIHPPWEGGIRYRGLTRDQVKAINFLPVDYEIEYVCRGE
A n t i - G B l a -------------------- GGAQTPNATSEGCQIIHPPW----------------------------------------
A n t i - G B l a B  -------------------------------------------------------------------- HPPWEGGIRY-GLTRDQVK-------------------------------------
• k ' k - k - k ' k - k ' k i f ' k - k ^ - k - k - k - k - k - k ' k ' k
Anti-GBla_C ----------------------------------- C HPPWEGGIRYRGLTRDQVK----------------------
*  * * * * * * * * * * * * * * * * * * *
10 20  30 40 50 60 70
I I I I I I I
M u s - Œ l b  MGPGGPCTPVGWPLPLLLVMAAGVAPVWASHSPHLPRPHPRVPPHPSSERRAVYIGALFPMSGGWPGGQA
Rat-GBlb MGPGGPCTPVGWPLPLLLVMAAGVAPVWASHSPHLPRPHPRVPPHPSSERRAVYIGALFPMSGGWPGGQA
Hom-GBlb MGPGAPFARVGWPLPLLWMAAGVAPVWASHSPHLPRPHSRVPPHPSSERRAVYIGALFPMSGGWPGGQA
Anti-GBlb_A ------------------------------------ HSPHLPRPHSRVPPHPS----------------------------
A n t i “ GBlb__B ----------- ------------------ - ----------- - ------- - -------SHSPHLPRPHPRVPPHPS  ---------------------------------------
■ k - k - k ' k ' k ' k - k - ^ - k ' k ' k ' k ' k - k - k ' k ' k - k
A n ti - G B lb _ C  --------------------------------------------------------------HSPHLPRPHPRVPPHPS  -----------------------------------------
* * * * * * * * * * * * * * * * *
Figure 2.2 -  Alignment of immunogic sequences fo r GABAgia and GABAgib 
antibodies.
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Residues 1 to 70 of the GABAgia (GBla) and GABAgib (GBlb) proteins from human 
(TTb/MO .yqpfgMj; Hom), mouse (Mwj Mus), rat Rat) and
the immunogen sequences used to raise antibodies to GABAgia (Anti-GBIa) or 
GABAgib (Anti-GBlb) were aligned using ClustalW2. Antibodies sequences were 
from (A) Poorkhalkali gf a/. (2000), (B) Princivalle g/ a/. (2001) and (C) Charles gr ür/. 
(2001).Comparisons were made between mouse GABAgi proteins and the isofbrm 
antibodies (‘*’ identical amino acid, missing, replaced).
2.2.5 Tissue Processing
Adult male GABAgia'^', GABAgib'^' or wild-type mice (aged 21.6 ± 2.6 weeks; weight
35.6 ± 1.4 grams) were killed by cervical dislocation and the brains quickly dissected 
out and immersed in ice-cold 4 % (w/v) parafbrmaldehyde in 0.1 M phosphate buffer 
(PB) fbr 4 hours. Brains were washed in 3 changes o f 0.0 IM phosphate buffered saline 
(PBS) fbr 15 minutes and incubated fbr 24 hours in sodium citrate buffer (0.1 M citric 
acid and 0.2 M sodium phosphate dibasic, adjusted to pH 4.5) at room temperature. 
Tissues were then immersed in fiesh sodium citrate buffer and exposed to microwave 
radiation for antigen retrieval (130 sec in a 750 W microwave oven), as previously 
described by Fritschy g^  a/. (1998). Brains were incubated fbr a further 24 hours in a 
buffered sucrose solution (30% [w/v] sucrose in 0.1 M PB) at 4 °C for cryoprotection 
prior to freezing in isopentane cooled between -30 and -20 °C with dry-ice. Coronal 
brain sections were cut in a cryostat (Model OTF Cryostat, Bright Instruments, 
Cambridgeshire, UK) maintained at -21 °C. Sections were cut at a thickness of 30 pm 
and were transferred to netwells (Coming Inc., Coming, New York, USA), with a 
maximum of 8 sections per well, kept in a 12-well tissue culture dish containing PBS. 
Sections were kept at 4 °C fbr a maximum of 24 hour befbre being processed fbr 
staining. Brain regions o f interest were identified with the aid of a brain atlas (Paxinos 
and Franklin, 2001).
2.2.6 Preparation for Gelatine Subbed Microscope Slides
Slides were immersed in a warm dilute detergent solution ovemight and then washed 
with hot running water fbr 15 minutes followed by rinsing with reverse osmosis (RO) 
water fbr a further 15 minutes. Slides were then soaked fbr 20 minutes in a [96 %] 
ethanol and [37 %] hydrochloric acid (9:1) mix. Finally slides were immersed in a 
warm filtered solution containing 1% gelatine (w/v) and 0.07% chromium potassium
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sulphate fbr 2 minutes, and dried ovemight at room temperature. Slides were stored in 
a dust free environment befbre use.
2.2.7 Immunohistochemical Staining
GABAg subunits were stained using free-floating immunoperoxidase labelling and 
visualised with 3, 3’-diaminobenzidine (DAB), as described previously (Gassmann g/ 
a/., 2004). Endogenous peroxidase activity was quenched using a 0.3 % hydrogen 
peroxide (v/v) in methanol, followed by a wash in 3 changes of PBS fbr 15 minutes 
per wash. Blocking o f background staining was achieved by incubation with 5 % 
Normal Goat Serum (v/v) with 0.5 % Triton X-100 (v/v) in PBS (blocking solution) 
fbr 30 minutes. Brain sections were then incubated ovemight (approximately 15 hours) 
at 4 °C with primary antibodies raised against either the GABAgi subunit in rabbit 
(anti-GABAgi; 2 pg/ml; sc-14006; Santa Cruz Biotechnology Inc.) or the GABAg] 
subunit in guinea pig (anti-GABAg]; 1:6000 dilution; AB5394; Millipore Ltd.), or 
altematively without primary antibodies to serve as negative control sections. The 
additional GABAgi antibodies anti-GABAgi-Millipore (0.5 ug/ml) and anti-GABAg i- 
Sigma (2 ug/ml) were raised in rabbit. Primary antibodies were diluted in blocking 
solution and the blocking solution alone was used fbr the negative control sections. 
Sections were washed in 3 changes of PBS fbr 15 minutes each. Primary antibodies 
were labelled by incubating the sections with biotinylated secondary antibodies. 
Sections were incubated fbr 2 hours with either anti-rabbit (6 pg/ml; 111-065-003; 
Jackson Immuno Research Laboratories Inc, West Grove, Pennsylvania, USA) fbr 
anti-GABAgi or anti-guinea pig (5.5 pg/ml; 106-065-003; Jackson Immuno Research 
Laboratories Inc, West Grove, Pennsylvania, USA) fbr anti-GABAg], both antibodies 
were raised in goat and diluted in blocking solution. Sections were washed in 3 
changes o f PBS fbr 15 minutes each. The biotin molecules o f the secondary antibodies 
were then labelled with a peroxidase-avidin complex by incubation with Vectastain 
ABC Kit (Standard; Vector Laboratories Ltd., Peterborough, Cambridgeshire, United 
Kingdom) in PBS with 0.5 % Triton X-100 (v/v) fbr 30 minutes. Sections were then 
washed in three changes of 0.05 M tris buffered saline adjusted to pH 7.6 fbr 15 
minutes each. Sections were stained using DAB (ImmPACT DAB Substrate; Vector 
Laboratories Ltd.) under visual guidance fbllowed by a final set o f three washes in tris- 
buffered saline fbr 15 minutes each. Peroxidase enzymes catalysed the reaction of
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DAB to an alcohol insoluble golden-brown coloured precipitate with minimal 
dispersion from the site o f its formation. Stained sections were mounted onto gelatine 
subbed slides using a PBS solution with 0.01 % Triton X-100 (v/v) and allowed to dry 
ovemight. Sections were dehydrated in rising concentrations of ethanol (50 % to 100 
% [^M ), cleared in xylene and mounted with a glass cover slip. Brains were dissected, 
fixed, frozen, sectioned and stained in batches containing all three genotypes (wild- 
type, GABAgia'^' and GABAgib'^') to minimise variability in staining intensity between 
the genotypes. Sections lacking the primary antibody were used as negative control fbr 
staining.
2.2.8 Visualisation and Semi-Quantitative Analysis
Whole section images were digitally captured using a digital densitometry system 
(MCID Elite version 7.0, InterFocus Imaging Ltd, Linton, Cambridge, UK) from a 
cooled digital camera (CoolSNAP cf  ^ Photometries, Tucson, Arizona, USA) and 
illuminated by a temperature controlled light box (Northem Light Illuminator, Model 
B95, GE Healthcare UK [formally Imaging Research Inc.]). All images fbr each 
antibody were captured under identical conditions on the same day. The density o f 
staining in selected brain regions was measured as relative optical density (ROD). 
ROD was converted to an inverted 12-bit greyscale values (O-to-4096; white-to-black) 
and used fbr the quantification of staining intensity. High magnification images were 
capture using a Nikon digital microscope camera (DS-2Mvm, Nikon Instruments 
Europe, Kingston, Surrey, United Kingdom) attached to a Nikon light microscope 
(Potiphot, Nikon Instruments Europe) under identical settings. Images were converted 
to 8-bit monochromatic images using ImageJ (version 1.38x) (Abramoff gr a/., 2004) 
and the ROD measure fbr selection subfields using the MCID software and converted 
to an inverted 8-bit greyscale values (O-to-256; white-to-black). Intensity values in 
matched control sections (those stained without the primary antibody and captured 
using identical conditions and equipment) were used as the background staining and 
subtracted from all other sections from the same animal using the same antibody. Data 
fbr whole brain sections are expressed as the ratio o f the region o f interest to the wild- 
type whole brain section in same staining batch. For the region of interest in the 
microscopic images data are the mean inverted greyscale. Whole section densitometry 
data were analysed fbr differences using a two-way analysis of variance (ANOVA;
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genotype and brain region as factors) fbllowed by a Bonferroni post-hoc test. 
Brightness and contrast of the photomicrographs were adjusted to enhance image 
clarity using GNU Image Manipulation Program (GIMP version 2.6.10). Identical 
changes were made to the all images presented fbr each region across all the genotypes 
and control sections. Images presented were representative fbr all animals o f the same 
genotype and stained with the same antibody.
2.2.9 NissI Staining
Neuronal cell bodies o f the wild-type and GABAgi isofbrm knockout mice were 
stained using Nissl stain, using a method similar to that used in Young a/. (2009). 
Previously unstained frozen sections, processed and cut as befbre, were mounted onto 
gelatine subbed slides using a PBS solution with 0.01 % Triton X-100 (v/v) and 
allowed to dry ovemight. Tissue was fixed in Camoy’s fixative (ethanol, chlorofbrm 
and acetic acid; 6:3:1) fbr 20 minutes, to further fix the tissue and remove lipid, 
fbllowed by rehydration in lowering concentration of ethanol (100%, 70%, 50% [v/v]) 
and RO water fbr 3 minutes each (Carleton gr a/., 1967). Sections stained with Nissl 
stain, containing cresyl violet acetate 0.1 % (w/v), sodium acetate 0.01 % (w/v), acetic 
acid 1.2 % (v/v) adjusted to pH 3.5 with acetic acid or sodium acetate, fbr 5 minutes 
and the slides rinsed in RO water. This resulted in an over-staining of the brain 
sections. Differentiation was achieved using cresyl violet differentiator (ethanol, 
chlorofbrm, acetic acid; 90:10:1) under visual guidance until only staining of the nuclei 
was achieved. Slides were then dehydrated in 95% and 100% ethanol fbr 1 minute 
each and then cleared in two changes of xylene fbr 3 minutes each and mounted with a 
glass coverslip.
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2.3 Results
2.3.1 Receptor Subunits and Antigen Sequence Identities
The immunogen sequence used in manufacturing of the anti-GABAgi and anti- 
GABAg] antibodies used in this study were aligned and compared with the amino acid 
sequence o f the GABAgia, GABAgib and GABAg] receptor subunits from mouse, rat 
and human, and the percentage sequence identity calculated (Figure 2.3, Figure 2.4 and 
Table 2.1). The sequence used fbr the creation of the GABAgi antibody was larger, 
331 amino acid sequence, compared to the 20 amino acid sequence used fbr the 
GABAg] antibody. The immunogen sequence used fbr the anti-GABAgi was 
sequenced from the rat GABAgie isofbrm and when aligned with the mouse GABAgia 
and GABAgib isofbrms had a 31 amino acids region which was not present in the 
mouse (Figure 2.3). Therefbre, the low percentage sequence identity observed between 
the anti-GABAgi and both GABAgia and GABAgib isofbrms of GABAgi subunit 
(Table 2.1) was due to this missing region. The anti-GABAgi antibody was targeted 
towards the intra-cellular C’ terminus o f the receptor subunit, it was identical in both 
isofbrms (Figure 2.3) and should give matching affinities fbr both isofbrms. The 
immunising amino acid sequence used for the anti-GABAg] was taken from the 
published sequence fbr the human GABAg] receptor subunit. The region taken fbr the 
creation of this antibody was identical in all the species examined (Figure 2.4), 
therefbre the anti-GABAg] was hypothesised to have identical affinity in human, 
mouse and rat, whereas the GABAgi possibly had variability of affinity fbr GABAgi 
receptor subunit in human, mouse and rat. A ‘BlastP’ search o f the GABAgi 
immunising peptide sequence in the NCBI mouse protein database produced no results 
above 34% sequence identity and search resulted in no hits fbr GABAg]. This 
suggested that the antibodies are selective fbr their target proteins.
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Table 2 .1- Percentage sequence identity between hum an, mouse and ra t GABAb 
receptor subunits and the antibodies used for im munohistochemistry.
Horn Rat Horn Mus R #  Aaü- Horn Mus R #  Aad-
B la  B la  B la  B ib  B ib  B ib  B1 B2 B2 B2 B2
Hom B la  
(961) 100
Mus B la  
(960) 98 100
Rat B la  
(960) 98 99 100
Hom B ib 
(844) 95 94 94 100
Mus B ib  
(844) 94 95 94 98 100
Rat B ib  
(844) 94 94 95 98 99 100
Anti-Bl
0 3 1 ) 89 89 90 89 89 90 100
Hom B2 
(941) 29 28 28 31 32 32 30 100
Mus B2 
(940) 28 27 28 32 32 32 30 98 100
RatB2
(940) 29 27 28 32 33 33 30 97 99 1 100
Anti-B2
(20) 30 25 25 30 25 25 25 100 100 1 100 100
GABAs receptor subunits amino acid sequences for human denoted
above as Hom), mouse denoted above as Mus) and rat
denoted above as Rat) were retrieved from the UniProt database. 
Sequences, including the immunising sequences for the anti-GABAsi and anti- 
GABAg], were aligned and the percentage sequence identity calculated. Amino acid 
sequence length is shown in parenthesis. Shaded cells highlight the percentage identity 
between the antibodies and the mouse sequences expected in this investigation.
2.3.2 Forebrain Regions
The GABAs antibodies stained neurons widely distributed in the wild-type mouse 
brain and displayed an absence of staining in the primary antibody negative controls 
(images D, E and F in Figure 2.5 and Figure 2.6). Brain sections from transgenic mice 
stained with anti-GABAgi showed a reduction in staining intensity (Figure 2.5 and 
Figure 2.6) compared to wild-type animals (23.4 ± 2.6 % reduction in GABAgia^ mice 
and 33.1 ± 3.5 % reduction in GABAgib  ^ mice), which was also true for anti-GABAg] 
staining (35.7 ± 6.3 % reduction in GABAgia^ mice and 16.5 ± 12.5 % reduction in 
GABAgib  ^ mice). Brains from all genotypes were processed and stained in parallel, 
and the staining intensities were normalised as a ratio of the mean densitometry
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measured in the wild-type whole brain sections for each wild-type, GAB Agi a'" and 
GABAgib  ^ staining batch (Table 2.2 and Table 2.3). This transformation gave the data 
a Gaussian distribution and allowed for a more direct comparison o f the expression 
between the genotypes.
Using the anti-GABAgi antibody in GABAgia^ and GABAgib^ mice allowed for 
selective staining and regional visualisation of the GABAgib and GABAgia isofbrms 
respectively (Figure 2.1). Semi-quantitative densitometry was preformed on sections 
stained with anti-GABAgi and a significant effect was found for both genotype (F  [2, 
191] = 337 ,^  <0.001) and brain region (F  [15, 191] = 68,/? <0.001 ***) using a two- 
way ANOVA. Anti-GABAgi staining showed a significant reduction of staining 
compared to the wild-type brains (two-way ANOVA with Bonferroni post-hoc test) in 
12 o f the 15 fbre-brain regions measured in GABAgia'' mice, whereas staining in 14 of 
the 15 fbre-brain regions was reduced in the GABAgib'^ mice (Table 2.2). This 
widespread decrease was expected as staining intensity in the wild-type animals 
showed both GABAgia and GABAgib isoffoms, whereas the transgenic mice show 
selective staining fbr one of the isofbrms. Staining was fbund to be significantly 
reduced (two-way ANOVA with Bonferroni post-hoc test) in GABAgib'' mice 
compared to GABAbla'^ ’ mice in the hippocampal CAl and CA3 subfields, the dentate 
gyrus molecular layer, the thalamic habenular and laterodorsal nuclei, the amygdala, 
and the hypothalamus, revealing a predominant expression of the GABAgib protein 
within these regions. The thalamic reticular nucleus o f the GABAsib'' animals 
exhibited a significantly increased staining intensity compared to GAB Asia"' mice, 
suggesting that GABAsia is the main GABAsi expressed in this location.
The functional GAB As receptor is a heterodimer comprised o f GAB Agi and GAB Agi 
subunits (Prosser gt a/., 2001; Schuler gt a/., 2001; Gassmann gt ür/., 2004). This study 
also investigated the expression pattern o f the GABAg: subunit to identify the location 
o f functional receptors. Analysis o f the anti-GABAgi staining revealed a significant 
effect fbr both genotype (F  [2, 335] = 42, /? <0.001 ***) and brain region (F  [15, 335] 
= 11, /? <0.001). Staining with anti-GABAg2 identified fewer regions showing 
significant reduction in the transgenic animals compared to the wild-type animals, than 
was observed with the anti-GABAgi staining (Table 2.3; anti-GABAg]). GABAgia'^' 
mice had a reduction in 4 o f the 15 brain regions and GABAgib' ' had a reduction in 2
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of the 15 brain regions (Table 2.3; anti-GABAg]), both compared to wild-type animals. 
The GABAg2 receptor subunit, unlike the overall decrease observed with the GAB Agi 
subunit, showed a reduction in selective areas in the transgenic mice. GABAgib'^' mice 
were fbund to have reduced staining intensity in the thalamus compared to wild-type 
and GAB Agi a'" mice. The staining intensity of the caudate putamen, globus pallidus 
and the amygdala, including the amygdala central nucleus, was decreased in the 
GABAgia'^' mice in comparison to wild-type and GABAgib'^' mice.
Reduction of both GAB Ag receptor subunits was seen in the amygdala, including the 
amygdala central nucleus, the caudate putamen and the globus pallidus in GABAgia'^' 
mice, whereas the GABAgib'" mice showed a reduced expression fbr both subunits in 
the thalamus, excluding the thalamic reticular nucleus. This combined reduction with 
both GAB Agi and GABAg2 may suggest exclusivity in expression of GABAgia and 
GABAgib isofbrm in these regions.
-5 9
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Figure 2.5 -  Localisation of the GABAbi subunit in the fore-brain of wild-type,
GABAbih’’ and GABAbi b’ ’ mice.
Whole brain sections from wild-type (WT; A), GABAbi a knockout (GABAb la  ^; B) or 
GABAb lb knockout mice (GABAb ib'^ ’; C) were labelled with anti-GABABi and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABABi antibody and show minimal 
staining compared to the anti-GABABi stained sections (A, B and C). Abbreviations: 
AM, amygdala; C A l, Cornu Ammonis Region 1; CA3, Cornu Ammonis Region 3; 
CE, amygdala central nucleus; CP, caudate putamen; DG, dentate gyrus; GP, globus 
pallidus; HB, thalamic habenula nucleus; HIP, hippocampus; HY, hypothalamus; LD 
thalamic laterodorsal nucleus; RS, retrosplenial cortex; RT, thalamic reticular nucleus; 
SC, sensory cortex, TH, thalamus. The scale bar represents 2 mm. IGS bar shows the 
inverted gray scale.
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Anti-GABAg2 Anti-GABAg2 Control
IGS
4090
3600
3090
B
/ I  .
2570
2040
1570
#
1060
530
Figure 2.6 -  Localisation of the GABAb2 receptor subunit in the fore brain  of
wild-type, G A B A b i  a  ^ and G A B A b i  b ’ mice.
Whole brain sections from wild-type (WT; A), GABABia knockout (GABAbih’^ '; B) or 
GABAb lb knockout mice (GABAb ib'^ ’; C) were labelled with anti-GABABi and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
staining with blocking solution in place of anti-GABABi antibody and show minimal 
staining compared to the anti-GABABi stained sections (A, B and C). Abbreviations: 
AM, amygdala; C A l, Cornu Ammonis Region 1; CA3, Cornu Ammonis Region 3; 
CE, amygdala central nucleus; CP, caudate putamen; DG, dentate gyrus; GP, globus 
pallidus; HB, thalamic habenula nucleus; HIP, hippocampus; HY, hypothalamus; LD 
thalamic laterodorsal nucleus; RS, retrosplenial cortex; RT, thalamic reticular nucleus; 
SC, sensory cortex, TH, thalamus. The scale bar represents 2 mm. IGS bar shows the 
inverted gray scale.
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2.3.3 Hippocampal Formation and Dentate Gyrus
Ih e  hippocampal formation has a very characteristic tri-synaptic circuit and 
differential expression of GABAg receptor subunits has been reported previously in 
CA3 of the GABAgi isofbrm knockout mice (Vigot gt a/., 2006). The hippocampal 
formation and the dentate gyrus were studied in further detail. The hippocampus 
showed good immuno-positive staining with anti-GABAgi and anti-GABAgi 
compared to absence of staining in the white matter o f the corpus callosum in 
antibody-positive sections and the antibody-negative control sections (Figure 2.7 and 
Figure 2.8). This demonstrated that the methodology used in this investigation showed 
good positive to negative staining fbr the primary antibodies and low background 
staining fbr the secondary antibody. The cytoarchitecture of the dentate gyrus and 
hippocampal fbrmation was unaltered between genotypes (Figure 2.9).
To date, there have been no reported immunohistochemical investigations using the 
specific anti-GABAgi antibody employed in the current study. The pattern of staining 
seen with this antibody was similar to the immunohistchemistry reported for other 
GABAgi antibodies in rats (Fritschy gt a/., 1999; Margeta-Mitrovic gt a/., 1999; 
Sloviter gt <2/., 1999; Kulik g/ a/., 2003) and mice (Gassmann gt a/., 2004; Vigot gt a/., 
2006). Immunohistochemical staining o f the hippocampus using the anti-GABAgi 
antibody has been reported previously in the rat (Lopez-Bendito g/ a/., 2004) and 
mouse (Gassmann gt a/., 2004; Vigot g/ a/., 2006).
The cell bodies o f the dentate gyrus granule cells, identified with the Nissl staining 
(Figure 2.9), were not positively stained with anti-GABAgi (Figure 2.10) in contrast to 
the pyramidal cells o f the hippocampal CAl subfield (Figure 2.12). Staining fbr 
GABAgi in the outer two thirds o f the dentate gyrus molecular showed a visibly 
similar staining intensity in wild-type and GABAgia'' mice, but was decreased in 
GABAgib'^' mice (Figure 2.10) as shown by densitometry analysis of this region (Table 
2.2). Staining fbr GABAg2 of the outer two thirds of the dentate gyrus molecular layer 
was unchanged in all genotypes (Figure 2.11 and Table 2.3). These finding suggest 
that mainly GABAgib were present in the molecular layer, however the GABAgib'^' 
mice may not have a functional reduction as the GABAg] protein was unchanged in 
the outer two-thirds of dentate gyrus molecular layer.
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The inner third of the dentate gyrus molecular layer showed an inversion o f the trend 
seen with staining of the outer two-thirds where wild-type and GABAg animals 
have a similar intensity but it was decreased in the GABAgia'^' mice (Figure 2.10; see 
white arrow). This observation was more striking with anti-GABAg] staning, where a 
narrow band of GABAg] immuno-positive staining was seen in the molecular layer 
proximal to the granular layer of wild-type and GABAgib'^' mice, but was absent in 
GABAgia'^' animals (Figure 2.11; see white arrow). These findings indicate that 
GABAgia is exclusively expressed in the proximal region of the molecular layer 
associated with the terminals of the associational/commissural pathway with a 
complete loss o f GABAg receptors in GABAgia'^' mice.
The neurons o f hilar region (HICAP, HIPP and mossy cells) and basket cells (Figure 
2.10; denoted by the black arrow) demonstrated strong GABAgi staining in the cell 
bodies and the cellular processes were visible. Basket cells were identifiable from their 
location within the granular layer. The number of GABAgi positively stained basket 
cells in a section demonstrating staining o f the cellular processes (wild-type 3.37 ± 
1.48 [« = 4], GABAbi/  2.61 ± 1.18 [n = 4], GABABib"'' 2.62 ± 1.35 [n = 4]) was 
found to be decreased in both G A B A g i/ and GABAg ib"'" mice compared to wild-type 
(one-way ANOVA with a Bonferroni post-hoc test; F  [2, 164] = 6.1,/? < 0.01 **), no 
difference was fbund between GABAgia'^' and GABAgib'^' mice. This finding suggests 
that basket cells express both GABAgi isofbrms, however as staining was not visible 
with anti-GABAg] these receptors may not be functional. GABAgi staining o f hilar 
neuron somata was not visible in all sections, but was fbund to be present in all o f the 
genotypes. However, it was not possible to distinguish between GABAergic 
intemeurons (HICAP and HIPP) and glutamatergic mossy cells. The cell bodies 
present in the dentate gyrus molecular layer o f Nissl stained sections most likely 
belonged to MOPP cells (images D, E and F in Figure 2.9). There were very few cells 
stained with anti-GABAgi (Figure 2.10) and anti-GABAg] (Figure 2.11) in the 
molecular layer.
Staining with the anti-GABAgi antibody showed intense staining in pyramidal cell 
layers of the hippocampus proper (CAl, CA2 and CA3 subfields) in the wild-type and 
GABAgia'^' mice (Figure 2.7 and Figure 2.12), and was fbund to be fainter in the
-65
Chapter 2 -  Immunohistochemical Localisation of the GABAg Subtypes
GABAgib'^' animals. The overall staining in the hippocampus was reduced in the 
GABAgib"^' mice compared to the wild-type and GABAgia'^' mice (Table 2.2). Cell 
bodies immuno-positively stained with anti-GABAgi outside of the pyramidal cell 
layer are likely to be intemeurons, as reported before with GABAgi antibodies in the 
hippocampus (Fritschy gt a/., 1999). Intemeurons of the hippocampal fbrmation 
showed a similar staining pattem as seen with the intemeurons of the dentate gyms. 
Staining of the intemeuron cellular processes with anti-GABAgi was not visible in all 
sections, however, it was observed in all genotypes. Anti-GABAg] staining within the 
hippocampus and dentate gyms showed a more diffuse and widespread staining pattem 
with an absence o f staining in any of the cell-body layers or intemeurons (Figure 2.8), 
in contrast to the staining observed with the anti-GABAgi (Figure 2.7). Locations of 
the cell body staining in the hippocampus proper with anti-GABAgi matched with 
those locations of the neuronal nuclei fbr the pyramidal cell layer seen in the Nissl 
stained sections (Figure 2.9).
Anti-GABAgi showed intense staining of the CA3 and CAl stratum lacunosum- 
moleculare in wild-type and GABAgia'^' mice, but had lower stain intensity in the 
GABAgib'^' (Figure 2.14 and Figure 2.12). Staining o f the CAl lacunosum-moleculare 
with anti-GABAg] was present in all the genotypes, but was visibly more intense in the 
GABAgia'^' animals compared to the wild-type and GABAgib'^' mice (Figure 2.8 and 
Figure 2.13). Nevertheless, staining in the CA3 lacunosum-moleculare was similar in 
all genotypes (Figure 2.15). The lacunosum-moleculare contains terminals of the 
perfbrant pathway that innervate the CA3 and CAl (van Groen gt a/., 2002). The anti- 
GABAgi staining suggested that both GABAgi isofbrms may be present on the 
perfbrant pathway, but GABAgib was the predominate isofbrm. Interestingly, staining 
fbr GABAg] may indicate a possible up-regulation of GABAg receptor function in 
GABAb, / .
Staining of the CAl stratum oriens, stratum pyramidale and stratum radium showed 
similar staining between the genotypes (Figure 2.13). However, staining fbr GABAgi 
and GABAg] m the CA3 region showed a decrease in the staining intensity o f the 
stratum lucidum in GABAgia'' compared to that seen in wild-type mice, whereas in the 
GABAgib'^' animals the stratum lucidum had similar intensity as the stratum radium 
(Figure 2.14 and Figure 2.15; see arrows). Stratum lucidum has a dense population o f
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the large terminal boutons of mossy fibre with the CA3 pyramidal cells (Amaral g/ a/., 
2007). This finding demonstrates labelling o f the GABAgiaat presynaptic sites and are 
in agreement with those reported by Vigot gt a/. (2006) using the same animals, but 
stained with a different GABAgi antibody.
Staining in the hippocampus of wild-type mice was attempted with the GABAgi 
antibodies produced by Millipore (AB9167) and Sigma-Aldrich (G1295) (Figure 
2.16). However these antibodies produced a low intensity stain with a more 
generalised and less differentiated staining pattem compared to the Santa Cruz anti- 
GABAgi (Figure 2.7). Staining within the dentate gyms molecular layer and CAl 
stratum lacunosum-moleculare was visible with Millipore and Sigma-Aldrich 
antibodies (Figure 2.16), with an absence of cell body staining in contrast with that 
seen with the Santa Cruz anti-GABAgi antibody. Therefore the Santa Cruz anti- 
GABAgi was used in preference to these additional antibodies, shown in Figure 2.16, 
as it produced greater stain intensity and with better differentiation of cell populations.
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Anti-GABAgi Anti-GABAgi Control
Figure 2.7 -  Localisation of the GABAgi subunit in the hippocam pus and dentate
gyrus of wild-type, GABAgia and GABAgib mice.
Brain sections from wild-type (WT; A), GABAgia knockout (GABAgia'^*; B) or 
GABAgib knockout mice (GABAgib' '; C) were labelled with anti-GABAgi and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABAgi antibody and show little 
staining compared to the anti-GABAg] stained sections (A, B and C). Different pattem 
of staining is visible across the regions shown. Abbreviations: C A l, Cornu Ammonis 
Region 1; CA3, Comu Ammonis Region 1; cc, corpus callosum; DG, dentate gyms. 
The scale bar represents 400 pm.
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Anti-GABAg2 Anti-GABAg2 Control
Figure 2.8 - Localisation of the GABAgi subunit in the hippocam pus and dentate 
gyrus of wild-type, GABAgia and GABAgib mice.
Brain sections from wild-type (WT; A), GABAgia knockout (GABAgia'^'; B) or 
GABAgib knockout mice (GABAgib'^'; C) were labelled with anti-GABAg] and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABAg] antibody and show little 
staining compared to the anti-GABAg] stained sections (A, B and C). Different pattem 
of staining is visible across the regions shown. Abbreviations: C A l, Comu Ammonis 
Region 1; CA3, Comu Ammonis Region 1; cc, corpus callosum; DG, dentate gyms. 
The scale bar represents 400 pm.
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Anti-GABAgi Anti-GABAgi Control
Figure 2.10 -  GABAgi subunit location w ithin the dentate gyrus of wild-type,
GABAgia and GABAgiL mice.
Brain sections from wild-type (WT; A), GABAgia knockout (GABAgia’^ '; B) or 
GABAgib knockout mice (GABAgiL^'; C) were labelled with anti-GABAgi and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABAgi antibody (A, B and C). White 
arrows denote the location of associational/commissural pathway, which has an 
absence of staining in GABAgia mice. Black arrows indicate the location of a basket 
cell, showing staining in all genotypes. Abbreviations: DGMOL, dentate gyrus 
molecular layer; GCL, granule cell layer; HI, hilar region. The scale bar represents 200 
pm.
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Anti-GABAg2 Anti-GABAg2 Control
Figure 2.11 -  G A B A g z  subunit location w ithin the dentate gyrus of wild-type, 
G A B A g i a  and G A B A g i  y  mice.
Brain sections from wild-type (WT; A), GABAgia knockout (GABAgia’^ '; B) or 
GABAgib knockout mice (GABAgib'^'; C) were labelled with anti-GABAg] and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place o f anti-GABAg] antibody (A, B and C). White 
arrows denote the location of associational/commissural pathway, which has an 
absence of staining in GABAgia mice. Abbreviations: DGMOL, dentate gyrus 
molecular layer; GCL, granule cell layer; HI, hilar region. The scale bar represents 200 
pm.
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Anti-GABAgi Anti-GABAgi Control
Figure 2.12 -  Localisation of the GABAgi subunit in the hippocam pal C A l 
subfield of wild-type, GABAgia and GABAgi y mice.
Brain sections from wild-type (WT; A), GABAgia knockout (GABAgia'^'; B) or 
GABAgib knockout mice (GABAgib'^’; C) were labelled with anti-GABAgi and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABAgi antibody (A, B and C). The 
white arrow indicates lower staining intensity of the stratum lacunosum-moleculare in 
GABAgib'^' mice. Abbreviations: LMOL, stratum lacunosum-moleculare; OR, stratum 
oriens; PY, pyramidal cell layer; RA, stratum radiatum. The scale bar represents 200 
pm.
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Anti-GABAg2 Anti-GABAg2 Control
W . :
Figure 2.13 -  Localisation of the GABAg: subunit in the hippocam pal C A l
subfield of wild-type, GABAgia and GABAgib mice.
Brain sections from wild-type (WT; A), GABAgia knockout (GABAgia'^’; B) or 
GABAgib knockout mice (GABAgib'^'; C) were labelled with anti-GABAg] and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABAg] antibody (A, B and C). The 
white arrow indicates higher staining intensity of the stratum lacunosum-moleculare in 
GABAgia'^’ mice. Abbreviations: LMOL, stratum lacunosum-moleculare; OR, stratum 
oriens; PY, pyramidal cell layer; RA, stratum radiatum. The scale bar represents 200 
pm.
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Anti-GABAgi Anti-GABAgi Control
LMOh
PY OR
Figure 2.14 -  GABAgi subunit location within the hippocam pal CA3 subfield of
wild-type, GABAgia and GABAgib mice.
Brain sections from wild-type (WT; A), GABAgia knockout (GABAgia'^’; B) or 
GABAgib knockout mice (GABAgib’^ ’; C) were labelled with anti-GABAgi and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABAgi antibody (A, B and C). The 
white and black arrows indicate loss and presences of ant-GABAgi staining in the 
stratum lucidum (LU) of GABAgia'^’ and GABAgib'^’ mice, respectively.
Abbreviations: LMOL, stratum lacunosum-moleculare; OR, stratum oriens; 
pyramidal cell layer; RA, stratum radiatum. The scale bar represents 200 pm.
PY,
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Antl-GABAg2 Anti-GABAg2 Control
Figure 2.15 -  GABAg: subunit location within the hippocam pal CA3 subfield of 
wild-type, GABAgia and GABAgiL mice.
Brain sections from wild-type (WT; A), GABAgia knockout (GABAgia'^'; B) or 
GABAgib knockout mice (GABAgib'^'; C) were labelled with anti-GABAg] and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABAg] antibody (A, B and C). The 
white and black arrows indicate loss and presences of ant-GABAg] staining in the 
stratum lucidum (LU) of GABAgia"' and GABAgib’^ ' mice, respectively. 
Abbreviations: LMOL, stratum lacunosum-moleculare; OR, stratum oriens; PY, 
pyramidal cell layer; RA, stratum radiatum. The scale bar represents 200 pm.
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Anti-GABAgi Anti-GABAgi Control
Figure 2.16 -  Staining of hippocam pal sections with alternative anti-GABgi 
antibodies in wild-type mice.
Brain sections from wild-type mice were labelled with alternative antibodies for 
GABAgi from Millipore (AB9167) and Sigma-Aldrich (Sigma; G 1295). Staining 
protocol was identical to anti-GABABi using free-floating immunoperoxidase and 
DAB. Control sections (B and C) were stained with blocking solution in place of the 
antibodies (A and D) and match to sections from the same animal. Both antibodies 
demonstrated a lack of cell body staining. Abbreviations: CA l, Comu Ammonis 
Region 1; CA3, Comu Ammonis Region 1; cc, corpus callosum; DG, dentate gyms. 
The scale bar represents 400 pm.
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2.3.4 Cerebellum
Staining with anti-GABAgi showed differentiation across the cell body layers within 
the cerebellum (Figure 2.17 and Figure 2.18), however, the staining intensity was 
lower than that seen in the fbre-brain regions. GABAg] staining had a lower level of 
staining compared to that seen in the fbre-brain regions. While the staining showed 
differentiation over regions in the cerebellum, the intensities were not sufficient fbr a 
robust quantification, and an alternative semi-quantification was perfbrmed without 
statistical comparison. Anti-GABAgi staining intensities, mean inverted grey scale 
levels, were grouped into a narrow range o f intensities and given labels (high, 
moderate, and low; Table 2.4). Semi-quantification, however, was not possible fbr 
anti-GABAg] staining. Instead, staining fbr anti-GABAgi in the cerebellum was scored 
high, medium or low by an experienced observer (Table 2.5).
GABAgi immuno-positive staining was seen in the cell bodies of the Purkinje cell 
layer (Figure 2.17). Staining in the wild-type animals showed a ‘high’ intensity in both 
the molecular and granular layers. In contrast, staining in the GABAgia'^' mice showed 
a decrease in staining intensity to ‘moderate’ fbr the granular layer and GABAgib' " 
animals showed a decrease of both the molecular and granular layers staining to low 
and moderate respectively (Table 2.4). Staining fbr GABAg] was fbund to be present 
in the molecular layer o f wild-type and GABAgia'^' mice but absent in GABAgib'^' 
mice (Figure 2.18 and Table 2.5), which is in agreement with that seen with anti- 
GABAgi (Figure 2.18). Both anti-GABAgi and anti-GABAg] demonstrated zebrin-like 
stripes in wild-type and GABAgia'^' (Figure 2.17 and Figure 2.18). These finding 
suggest that both GABAgi isofbrm were present in the granular layer, whereas, 
GABAgib was predominantly fbund in the molecular layer and was responsible fbr the 
zebrin-like stripes.
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Anti-GABAgi Anti-GABAgi Control
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Figure 2.17 -  GABAgi subunit location w ithin the cerebellum of wild-type,
GABAgia and GABAgib mice.
Brain sections from wild-type (WT; A), GABAgia knockout (GABAgia'^'; B) or 
GABAgib knockout mice (GABAgib'^’; C) were labelled with anti-GABAgi and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABAgi antibody (A, B and C). The 
arrows indicate zebrin-like stripes in WT and GABAgiL^' animals. Abbreviations: 
CMOL, cerebellar molecular layer; GL, granular layer; PCL, Purkinje cell layer; WM, 
white matter. The scale bar represents 400 pm.
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Anti-GABAgg Anti-GABAe2 Control
A
CMOL PCL GL WM
i
B %
CÛ
I
CO
<
o
Figure 2.18 -  GABAb2 subunit location w ithin the cerebellum of wild-type, 
GAB Agi a and GABAgib mice.
Brain sections from wild-type (WT; A), GABAb ia knockout (GABAb la'^ ’; B) or 
GABAb lb knockout mice (GABAb ib^’; C) were labelled with anti-GABABi and stained 
using free-floating immunoperoxidase and DAB. Control sections (E, F and G) were 
stained with blocking solution in place of anti-GABABi antibody (A, B and C). The 
arrow indicates zebrin-like stripes in WT and GABABib^’ animals. Abbreviations: 
CMOL, cerebellar molecular layer; GL, granular layer; PCL, Purkinje cell layer; WM, 
white matter. The scale bar represents 400 pm.
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2.4 Discussion
Staining of the fbre-brain regions with GAB Agi and GAB Agi in conjunction with 
GAB Agi isofbrm deficient mice demonstrated that GABAg(ia, 2) subtype was 
predominant in the amygdala whereas GABAg(ib^ 2) is favoured in the thalamus. 
GABAgib was found to be the main isofbrm located at sites associated with the 
perforant pathway terminals. Basket cells in the dentate gyrus were shown to express 
both GAB Agi isofbrms. The presence of GABAgia was confirmed at the presynaptic 
sites fbr the mossy fibre-CA3 interface. In the cerebellum, the GABAg(ib, 2) subtype 
was fbund to be responsible fbr the zebrin-like stripes in the molecular layer.
2,4,1 Comparison o f Methodology with that Used in Previous Investigations
Previous studies have synthesised antibodies selective fbr GABAgia and GABAgib 
isofbrms, however, antibodies targeting the GABAgia isofbrm are unsuited fbr fixed 
tissue used in immunohistochemistry (Fritschy et a/., 1999; Vigot gt a/., 2006). A few 
investigations have used antibodies directed towards the GABAgia isofbrm in 
immunohistochemistry, however, they lacked additional labelling o f the GABAg2 
subunit (Poorkhalkali et a l,  2000) or were limited in the scope of regions studied 
(Princivalle et al,  2001). In addition, alignment o f the immunogen sequences for 
these antibodies (Figure 2.2; antibody alignment) fbund missing amino acids (Charles 
gt a/., 2001; Princivalle gt a/., 2001) and species variation (Poorkhalkali g/ a/., 2000) in 
the sequences, questioning their suitability in immunohistochemistry.
Receptor binding studies, in comparison to immunohistochmistry, allows fbr the 
quantification and localisation o f the GABAg receptors (Bischoff gf a/., 1999), 
however a higher resolution was achieved in the current investigation enabling a more 
detailed mapping o f the GABAg receptors locations. The study by Bischoff gt ar/. 
(1999) used GABAg 1 isofbrm m .yztw hybirdization in combination with GABAg 
receptor location. It is, at present, unclear whether receptor binding demonstrates 
location fbr heterodimeric GABAg(i, 2) receptor or all GABAg] proteins, both singular 
and dimerised, due to the presence of the ligand binding domain (Kaupmann gt a/., 
1998b; Malitschek g/ a/., 1999a). Studies of GABAg receptor expression within the 
brain have also used western blotting and histobloting with antibodies selective fbr 
each isofbrm (Benke gt a/., 1999; Ciruela g^  a/., 2010). This methodology allows for
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semi-quantitative densitometric and crude histological analysis o f protein expression, 
however, they lack a detailed neuroanatomical expression pattern.
Utilisation o f the GABAg i isofbrm knockout mice has enabled selective labelling of 
GABAgia and GABAgib using a general GABAgi antibody as isofbrm selective 
antibodies are not available. While this experimental design has been used previously 
by Vigot gt a/. (2006) fbr the hippocampal CA3, other brain regions were not included 
in their investigation. The methodology used in this investigation presents a novel 
approach fbr semi-quantification of the immunohistochemical staining intensity, using 
a CCD video capturing system with a temperature controlled light source, to 
demonstrate regional expression o f GABAgia and GABAgib isofbrms.
2.4.2 Antibody Screening and Selection
Both anti-GABAgi and anti-GABAg2 were fbund to produce strong labelling of the 
GABAg receptor subunits with little background staining hom  the secondary 
antibodies alone. The anti-GABAg] antibody has confirmed specificity for its target 
due to the lack o f positive-staining in GABAg2 knockout mice (Gassmann gt a/., 
2004). The specificity of the anti-GABAg] could be confirmed, in a similar manner, by 
an absence o f positive staining with brains from GABAgi knockout mice. However, 
using the immunogen sequences in a search of the NCBl mouse protein library did not 
reveal any similar sequences, other than the target protein, and suggested that the 
antibody is specific fbr the GAB Agi subunit alone. The missing residues o f GABAg i 
primary sequence from the anti-GABAg i antibody are unlikely to detract from the 
staining affinity fbr each isofbrm as (i) the antibody is polyclonal so will have 
numerous epitopes from the sequence and (ii) the missing region is absent in both 
isofbrms.
2.4.3 Comparison o f  the Finding with those in the Literature
Staining seen with anti-GABAgi had a similar pattern reported with other antibodies 
raised against GABAgi (Fritschy g/ a/., 1999; Margeta-Mitrovic gt <3/., 1999; Sloviter 
g/ a/., 1999; Kulik g^  a/., 2003; Gassmann gt ü:/., 2004). Cell bodies of the hippocampal 
pyramidal cells demonstrated intense stain within the cell bodies, a finding that is 
consistent with the cell body Nissl staining observed. This is consistent with staining
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o f endoplasmic reticulum and suggests that staining within the cell body is a result o f 
the GABAgi subunit being retained within the endoplasmic reticulum (Kulik gt a/., 
2003). Non-heterodimerised GABAg] receptor subunits are retained in the 
endoplasmic reticulum and require heterodimerisation with GABAg2 to be trafficked to 
the plasma membrane (Margeta-Mitrovic gt a/., 2000; Pagano gt 2001). Therefore, 
staining with anti-GABAg] labels both the functional (heterodimerised) and non­
functional (non-heterodimerised) receptors. While the GABAg2 subunit is not retained 
it is not expressed at high levels without being heterodimersed (Prosser gt a/., 2001; 
Schuler gt <2/., 2001), therefore GABAg2 expression within the brain gives a more 
functional representation of the GABAg receptor. In agreement, the staining pattern 
seen with anti-GABAg2 fits well with GABAg receptor binding (Bischoff gf a/., 1999).
In the amygdala o f GABAg]a" ' mice both GABAg] and GABAg2 were fbund to be 
decreased. In addition, it was fbund that GABAgia expression was lower than 
GABAg ]b expression in the amygdala, although GABAg2 expression was decreased 
only in GABAgia'^' mice. This may indicate a predominance of the GABAg(]a, 2) 
receptor subtype as the functional GABAg receptor in the amygdala and indicates that 
GABAg activity is mainly acting at pre-synaptic sites. This finding is in agreement 
with the loss of long term potentiation in the amygdala and the generalisation of 
conditioned fear behavioural effect in GABAgia'^' mice (Shaban gr a/., 2006). 
Alternatively, the decreased expression of GABAg2 may result from a compensatory 
down-regulation o f GABAg(ib, 2) to reduce excess postsynaptic inhibition in the 
GABAgia'^' mice. Previous investigations have suggested an equal expression of both 
GABAg] isofbrms (Bischoff gt a/., 1999; Fritschy g^  a/., 1999), although a higher 
expression o f GABAgia has been reported (Charles g/ <2/., 2001) suggesting that this 
may not be a compensatory mechanism.
In the thalamus, expression of GABAgi and GABAg2 were fbund to be decreased in 
GABAgib'^' mice compared to GABAgia'' mice suggesting the thalamus predominately 
expresses GABAg(ib, 2)- These findings are in agreement with previously reported 
findings showing a greater expression of GABAgib in the thalamus (Bischoff gf n/., 
1999; Fritschy gt a/., 1999). GABAgia was also fbund to be expressed, but data 
suggests that GABAgib may be more densely expressed in this region. However, the 
study by Ulrich (2007) demonstrated a loss of presynaptic responses in the thalamus of
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GABAgia'^" mice demonstrating the presence o f GABAg(ia, 2) function in the thalamus. 
Therefore, the decrease in GABAgia expression without a decrease in GABAg2, in this 
study, will demonstrate a loss o f function without a corresponding decrease in 
GABAg2 expression. This finding suggests that decreased labelling o f the GABAg 
receptor with anti-GABAgi can also demonstrate a loss of functional receptors.
The caudate putamen and globus pallidus were fbund to have decreased expression of 
GABAgi isofbrms. This finding of equal expression of GABAgi is in agreement with 
those reported previously (Bischoff g/ a/., 1999; Charles gt a/., 2001). Expression of 
GABAg2 was shown to be decreased in GABAgia" ' and suggests that GABAgia is the 
predominant isofbrm in those regions. The caudate putman innervates the globus 
pallidus to fbrm part o f the motor system in the central nervous system, functional 
alterations in these regions are likely to result in abnormal motor control. In agreement 
with these findings GABAgia"' mice demonstrated reduction of hypolocomotion 
induced by GABAg receptor agonist GHB, not seen in wild-type or GABAgib"^" mice 
(Jacobson gt a/., 2006a). However, it remains unclear whether changes in expression of 
GABAg2 subunit is due to lack of GABAgi isofbrm to fbrm the dimer or is a knockout- 
induced compensation mechanism.
2.4.4 GABAb and the Cerebellum
This study fbund both GABAgi isofbrms to be expressed within the granular layer of 
the cerebellum. While this finding is in contrast to those fbund with .yztw 
hybirdization (Billinton gt a/., 1999; Bischoff gt a/., 1999; Liang gt a/., 2000), they are 
in agreement with other immunohistochemical investigations (Charles gr a/., 2001; 
Kulik gt a/., 2002). Staining fbr the GABAgia isofbrm is likely to demonstrate a 
presynaptic location o f the GABAg receptor on mossy fibre terminals within the 
cerebellar granular layer, whereas staining fbr the GABAgib receptor can be be located 
on the postsynaptic site on granule cells.
The cell bodies of Purkinje cell and the cerebellar molecular layer were shown to 
express GABAg(ib, 2) only, suggesting an exclusively postsynaptic role fbr GABAg 
receptors in the cerebellar molecular layer, which is in agreement with previous 
findings (Billinton gt a/., 1999; Bischoff gt a:/., 1999; Fritschy gt a/., 1999). Previous
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immunohistochemical investigations have shown zebrin-like staining with GABAgi 
(Fritschy gr a/., 1999) and GABAg] (Chung gt <3/., 2008), however have not been able 
to confirm its exclusivity with either GABAgi isofbrms. The current investigation 
demonstrated that GABAg zebrin-like stripes were associated ^vith postsynaptic 
GABAg(ib, 2) subtype only. This finding suggests zebrin-like local expression in the 
cerebellar molecular layer is a phenomenon of postsynaptic proteins allowing fbr the 
Purkinje cells to actively modulate activity.
2.4.5 GAB A  b and the Perforant Path way
This investigation fbund both GABAgi isofbrms to have reduced expression within the 
molecular layer o f the denate gyms, with the GABAgib isofbrm showing the greatest 
reduction, and indicates the presence of both receptor subtypes in this region. 
However, these reductions in GABAgi isofbrm expression may not demonstrate a loss 
o f function as expression of GABAg2 remained unchanged. Therefbre these finding 
may suggest that GABAgia and GABAgib can compensate fbr the loss of either isofbrm 
within the molecular layer.
A small presynaptic inhibitory effect o f baclofen on the medial perforant pathway has 
been reported (Ault and Nadler, 1983a; Mott gt a/., 1989; Mott and Le^vis, 1994), but 
no effects fbund on the lateral pathway (Ault and Nadler, 1982, 1983a). As this effect 
was reported to be presynaptic it is hypothesised that GABAgia is greater at the medial 
terminals o f the perforant path compared to the lateral terminals. However, no 
difference in the expression of GABAg receptor subtypes on the medial and lateral 
perforant path was observed. Inputs into the dentate gyms molecular layer are strictly 
organised, it would therefore be expected to find banding within the molecular layer. 
GABAgi and GABAg2 staining of the lacunosum-moleculare was fbund to be less 
visible in GABAgib'^' suggesting the predominant presence o f the GABAg(ib, 2) 
receptors. In agreement, positive staining fbr the GABAgib receptor isofbrm and an 
absence of the GABAgia staining in the stratum lacunosum-moleculare is shown by 
Vigot gt nZ. (2006), but was not reported as a finding. An increase in GABAg] 
expression was seen in the CAl stratum lacunosum-moleculare in GABAgia'^', 
possibly indicating an up-regulation of GABAg(ib, 2) receptor function and raises the 
possibility o f a compensation mechanism fbr the loss o f the presynaptic GABAgia. The
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expression o f GABAgia was also shown to be reduced in the molecular layer, which 
may suggest the presence at presynaptic terminals. It, however, also fbund both 
isofbrm to be expressed in intemeurons.
The experimental protocol used in this investigation did not allow fbr further 
dissection o f receptor expression than f-om that shown by anatomical locations. 
Therefbre, these findings may represent (i) low GABAg(ia, 2) expression at the 
perfbrant pathway presynaptic sites, (ii) expression at postsynaptic sites, or (iii) 
expression by intemeurons. Low expression on the perfbrant pathway is in accordance 
Avith the relatively small effect seen in the previous electrophysiology studies (Ault and 
Nadler, 1983a; Mott and Le^vis, 1994; Wang and Wojtowicz, 1997). Although, the 
reported differences in the lateral and medial perfbrant path may be due to 
contamination with postsynaptic effects or a recurrent network effect, rather than a 
presynaptic GABAg effect. This study revealed a lack o f GABAg receptors at 
presynaptic sites on the perfbrant path terminals and suggests that the postsynaptic 
GABAg(ib, 2) is the main GABAg receptor subtype at the perfbrant pathway synapses in 
the dentate gyms and hippocampus. This could indicate that specific activation of 
presynaptic GABAg receptors by GABA spill-over activation may not be 
physiologically relevant at terminals o f the perfbrant pathway, in contrast to those 
fbund at other glutamatergic terminals vsdthin the hippocampus (Ault and Nadler, 
1983a; Lei and McBain, 2003; Vigot gZ a/., 2006; Guetg gZ a/., 2009).
2.4.6 GABA g Receptor and the Associational/Commissural Path way
Expression o f GABAg(ia, 2) was prominent in the inner molecular layer o f the dentate 
gyms. Glutamate terminals in this location are characteristic fbr the associational 
/commissural pathway projections o f the mossy cells (Witter gZ aZ., 2000). Therefbre 
these data suggest a predominant expression o f the GABAg(ia, 2) subtype on mossy cell 
terminals.
In addition the molecular layer proximal to the granular layer is also the characteristic 
location fbr mossy fibre sprouting (Tauck and Nadler, 1985). Epilepsy is a 
characteristic outcome as a result o f pathophysiological changes to the dentate gyms. 
Staining shown in this investigation is unlikely to be due to mossy fibre sprouting.
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however it can be suggested that GABAgia'' mice would experience greater excitation 
as a result o f mossy fibre sprouting. This indicates that GABAgia'^' Avill demonstrate 
greater susceptibility to epilepsy or enhance seizure onset.
2.4.7 GABA g Receptor and the Dentate Gyrus Hilus
This investigation fbund cell-body staining in the dentate gyrus basket cells fbr both 
GABAgia and GABAgib isofbrms, suggesting the intemeurons can express either 
receptor subtype. In addition, staining o f the cellular processes confirmed that this is 
heterodimerised GABAg receptor, as trafficking to the cell surface would not have 
taken place if interaction Avith GABAg] was abscent (Margeta-Mitrovic gZ , 2000; 
Pagano gZ a/., 2001). This demonstrates that the dentate gyms basket cells fbrm 
functional receptors with both GABAgi isofbrm.
The GABAgi positive cells found within the hilar region have been suggested to be 
GABAergic intemeurons (Fritschy gZ aZ., 1999; Kulik gZ aZ., 2003). This study 
demonstrated GABAgia to be expressed on mossy cell terminals, therefbre it is 
possible that these cells will express GABAgi in their cell-bodies and would fbrm part 
of the GABAgi positive population. Mossy cells form a large population within the 
hilus regions, however, only a small population of GABAgi positive cells were shown 
not to co-express glutamate decarboxylase (GAD) (Kulik gZ aZ., 2003), a marker fbr 
GABAergic neurons. Therefbre it is unlikely that GABAg is present in the soma of the 
mossy cells. Many GAD positive cells were reported not to express GABAgi 
suggesting a sub-population o f GABAergic intemeurons within the hilar region which 
lack the GABAg autoreceptors (Kulik gZ aZ., 2003). In this study, it was not possible to 
attribute the GABAgi-positive staining exclusively to either HIPP or HICAP cells.
2.4.8 Co-localisation o f  GABAb Receptors with Other Receptors
Recently GABAg receptors have been shown to co-localise and cross-talk with 
receptors fbr acetylcholine muscarinic M] (Boyer gZ aZ., 2009), ionotropic glutamate 
NMDA (Chalifbux and Carter, 2010; Guetg gZ ürZ., 2010), metabotropic glutamate 
m G lula (Rives gZ aZ., 2009), IGF-1 (Tu gZ ûrZ., 2010) and the extracellular calcium 
sensing receptor (Chang gZ ü:Z., 2007).
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Overlapping of expression is seen within the inner molecular layer of the dentate gyrus 
fbr M] (Levey gZ a/., 1995) and NMDA (Thompson gZ aZ., 2002) with GABAg]. In 
addition, binding fbr mGlul is especially strong in the molecular layers of the dentate 
gyrus (Mutel gZ aZ., 2000). This strengthens the finding o f interaction between these 
receptors and GABAg] (Boyer gZ aZ., 2009; Chalifbux and Carter; Guetg gZ aZ., 2010). 
It can be suggested that M], mGlu and NMDA localises exclusively with the 
GABAg(ia, 2) subtype, as this GABAg complex is present at glutamatergic terminals of 
the perfbrant and associational/commissural pathways. To add to this, binding fbr the 
mGlul was also prominent at GABAg(ib, 2) locations in the cerebellar molecular layer 
(Mutel gZ 6zZ., 2000) indicating that it is unlikely to be selective fbr GABAg receptor 
subtypes. This raises the possibility that GABAgia'^' mice may exhibit altered M2, 
mGlu and NMDA receptor function within the dentate gyrus molecular layer, due to 
lack of GABAg2 subunit expression. Therefbre the GABAg-deficient seizure 
phenotype reported fbr both GABAgi (Prosser gZ aZ., 2001; Schuler gZ üfZ., 2001) and 
GABAg2 (Gassmann gZ aZ., 2004) knockout mice could be in part due to altered 
functions of additional receptors other than GABAg.
2.4.9 Model o f  GABAb Locations within the Dentate Gyrus
Overall the findings from this investigation suggest that the perfbrant pathway lacks 
GABAg receptors. Mossy cells exclusively express GABAgia at synapses Avith dentate 
granule cells as part o f the associational/commissural pathway. Intemeurons were 
fbund to express both GABAgi isofbrms. The findings are in agreement Avith the 
current idea that GABAgia are expressed presynaptically at glutamatergic terminals 
and GABAgib at postsynaptic site. This investigation has demonstrated that the 
perfbrant pathway is an exception to this mle as it lacks GABAg receptors. Figure 2.19 
illustrates a simple schematic o f the dentate gyms connections and locations of 
GABAg receptors subtypes identified by this investigation.
While GABAg2 expression appears to alter ^vith GABAgi expression, its function may 
not be mutually exclusive to GABAgi, suggesting GABAg involvement in numerous 
disease states. Currently no pharmacological agents have been shown to be selective 
fbr either GABAg receptor subtype. However, modulation of GABAgia containing 
heteroreceptors has been demonstrated using modified GABAg receptor proteins (Tiao
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gZ 2008). Using drugs targeted fbr these receptors may effectively decrease 
inhibition in the amygdala, caudate putamen and globus pallidus, suggesting possible 
therapeutic targets fbr cognitive and locomotor disorders.
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3 GABAb Receptors in the Dentate Gyrus
3.1 Introduction
Within the dentate gyrus and hippocampus GABAg receptors have functional roles at 
both glutamatergic and GABAergic terminals (Lei and McBain, 2003). The principal 
network in the hippocampal formation is the tri-synaptic circuit, with the first synapse 
being formed by the glutamatergic projections of the entorhinal cortex to the dentate 
gyrus via the perfbrant pathway (Witter gr a/., 2000). The second synapse in the circuit 
is formed by the dentate gyrus granule cells projecting to the CA3 via the mossy fibre 
and the final synapse consists of the pyramidal cells of the CA3 projecting to the CAl 
via the Schaffer collaterals (Witter g/ a/., 2000). GABAg heteroreceptors have been 
shown to be present at the presynaptic terminals of the tri-synaptic circuit (Lanthom 
and Cotman, 1981; Ault and Nadler, 1983a; Scanziani gr a/., 1992; Isaacson g/ a/., 
1993). Activation of GABAg receptors at both dentate gyrus mossy fibre and Schaffer 
collateral terminals produces a strong and almost complete inhibition of glutamate 
release (Lanthom and Cotman, 1981; Ault and Nadler, 1983a). In contrast, GABAg 
receptors at the terminals of the perfbrant pathway invoke a modest and partial 
inhibition (Lanthom and Cotman, 1981; Ault and Nadler, 1982, 1983a). GABAg- 
mediated presynaptic inhibition o f the mossy fibre (Guetg g/ a/., 2009) and Schaffer 
collateral has been attributed exclusively to the GABAgia isofbrm (Vigot g/ a/., 2006). 
In addition, the GABAgia isofbrm is solely responsible fbr inhibition at glutamatergic 
terminals vidthin the amygdala (Shaban g/^  a/., 2006), neocortex (Perez-Garci g^  a/., 
2006) and thalamus (Ulrich gr 2007). In contrast the GABAgib isofbrm is fbund 
exclusively at postsynaptic sites at glutamatergic terminals (Perez-Garci g/ a/., 2006; 
Vigot g^  a/., 2006). These finding have lead to the idea of GABAgia arid GABAgiy 
being universally present at presynaptic and postsynaptic sites, respectively, at 
glutamatergic terminals.
The perfbrant pathway is divided into two projections, lateral and medial, originating 
from the lateral and medial entorhinal cortex, respectively (Witter g/ a/., 2000; van 
Groen gf a/., 2002). Afferents of the lateral perforant path are exclusive to the outer 
third o f the dentate gyrus molecular layer, whereas, the medial afferents are present in 
the middle third (Witter g/ a/., 2000; van Groen g/ uf/., 2002). Pharmacological
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responses differ between the branches o f the perfbrant pathway. The medial pathway 
has greater inhibition mediated by the GABAg (Lanthom and Cotman, 1981; Ault and 
Nadler, 1983a) and muscarinic receptors (Kahle and Cotman, 1989; Rouse g/ a/., 
1998). Conversely, the metabotropic glutamate receptors mediate greater inhibition in 
the lateral pathway (Macek gr üf/., 1996).
The dentate gyms molecular layer also receives glutamate and GABA signals h-om 
populations o f neurons within the hilar region resulting in recurrent excitation and 
recurrent inhibition, respectively. Projections of the glutamatergic mossy cells o f the 
dentate gyms hilus region fbrm the associational/commissural pathway and terminate 
within the inner third o f the dente gyms molecular layer (Witter g/ (?/., 2000; van 
Groen gf a/., 2002). GABAergic intemeurons of the hilar region innervated by granule 
cells, project to both the outer two thirds (HIPP) and the inner third o f the molecular 
layer (HICAP) (Amaral et a l, 2007). In addition, GABAergic intemeurons are also 
located within the molecular layer (MOPP) and granular layer (basket cells) (Amaral g/ 
a/., 2007). This network of recurrent excitation and inhibition has been shown to be 
modulated by activation of GABAg receptors, resulting in an increased excitation 
(Mott gr a/., 1989) and long term potentiation (LTP) (Burgard and Sarvey, 1991; Mott 
and Lewis, 1991). These effects were attributed to the activation of GABAg 
autoreceptors, causing a reduction of inhibition known as disinhibition. These findings 
demonstrated that the net effect o f GABAg receptor activation in the dentate gyms is 
disinhibitory rather than inhibitory (Mott g/ a/., 1989). Both GABAgia and GABAgib 
isofbrms have been fbund to act as autoreceptors in the CAl (Vigot gr 2006) and 
the thalamus (Ulrich gr a/., 2007), however, GABAgib was fbund to be exclusively 
responsible as the autoreceptor in the cortex (Perez-Garci gr a/., 2006).
This investigation aimed to identify whether the GABAgia isofbrm is responsible fbr 
GABAg-mediated presynaptic inhibition of the medial perfbrant pathway in the 
dentate gyms. In addition, this chapter aimed to identify roles o f the GABAg receptor 
isofbrms in network inhibition within the dentate gyms.
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3.2 M ethod
3.2.1 Animal Husbandry
GABAgia knockout (GABAgia'^'), GABAgib knockout (GABAgib'^') and wild-type 
mice were maintained on a BALB/c background (Vigot gt a/., 2006). The housing and 
use o f animals in this investigation was in accordance with the United Kingdom 
Animals in Scientific Procedures Act, 1986. See section 2.2.7 fbr further details.
3.2.2 Materials
All reagents used were o f analytical grade and purchased from either Sigma-Aldrich 
Company Ltd. (Poole, Dorset, United Kingdom) or Fisher Scientific UK Ltd. 
(Loughborough, Leicestershire, United Kingdom). GABAg receptor agonist (±)- 
baclofen (referred to hence forward as baclofen) was purchased from Sigma-Aldrich. 
GABAA receptor antagonist (-)-bicuculline methochloride (referred to hence forward 
as bicuculline) and GABAg receptor antagonist CGP55845 was purchased from Tocris 
Bioscience (Bristol, United Kingdom).
3.2.3 Genotyping (Qualitative PCR)
Genotyping was preformed as described in the previous results chapter (section 2.2.3).
3.2.4 Preparation o f  Brain Slices
Adult animals (aged 12.0 ± 0.5 weeks) were killed by cervical dislocation, in 
accordance with Schedule 1 Killing o f the Animals in Scientific Procedures Act 1987. 
Brains were quickly removed and immersed in an ice-cold oxygenated (5% CO2 / 95% 
O2) solution containing (in mM) sucrose (200), HEPES (10), NaHCO] (25), glucose 
(10), MgS0 4  (7.1), KCl (2.5), NaH2P0 4  (1.4) and CaCl2 (0.5). Brain hemispheres 
were bisected and mounted on a vibratome cutting stage (either a Series 1000 
Vibratome [Vibratome, St. Louis, Missouri, USA] or a Leica VT1200 [Leica 
Microsystems GmbH, Wetzlar, Germany]) using cyanoacrylate glue (Loctite 401, 
Henkle Ltd., Düsseldorf, Germany). Parasagittal sections were cut at a thickness o f 
300 pm and trimmed to contain the dentate gyrus and hippocampus. Harvested 
sections were submerged in oxygenated (5% CO2 / 95% O2) artificial cerebral spinal 
fluid (ACSF) maintained at 31 °C fbr 1 hour prior to use in electrophysiological
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experiments. ACSF contained (in mM) NaCl (123), NaCOg (25), glucose (10), KCl 
(3.7), CaCl2 (2.5), NaH2P0 4  (1.4) and MgS0 4  (1.2).
3.2.5 Orientation o f  Brain Slices on Multi Electrode Array
Brain slices were transferred to the recording chamber o f a multi-electrode recording 
system (MED64; Alpha MED Sciences, Osaka, Japan). The multi-electrode probe 
(MED-P210A; Alpha MED Sciences, Osaka, Japan) consisted o f 64 indium tin oxide 
and platinum black electrodes arranged in an 8 by 8 grid with an inter-electrode 
distance of 100 pm and an impedance below 30 kO fbr each electrode. Slices were 
orientated with a row of electrodes in line with the granular layer and 2 rows in the 
inner and outer halves o f the molecular layer (Figure 3.1). Sections were held in place 
using a nylon mesh and weighted down with a platinum ring. Images were captured fbr 
reference to electrode locations using an inverted digital microscope (MIC-D; 
Olympus, Tokyo, Japan). During recording slices were continuously perfused with 
oxygenated (5% CO2 / 95% O2) ACSF with a flow rate o f 1-2 ml/minute using a 
peristaltic pump (Minipulse 3, Gilson, Middleton, Wisconsin, USA) and heated to
31.5 °C using an in-line heater (heater, SH-27B; temperature controller, TC-324B, 
Warner Instruments, Hamden, Connecticut, USA).
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Figure 3.1 -  Positioning of a dentate gyrus slice on multi-electrode array  and the 
location of recordings.
Slices were placed on the multi-electrode array (A) and were orientated with electrodes 
within the outer molecular layer (OML), the inner molecular layer (IML) and the 
granule cell layer (GCL), as shown in the simple outline of the array (B). Field 
excitatory postsynaptic potentials (fEPSP) were recorded in the OML and IML, and 
population spikes in the GCL from stimulation within the IML. Two electrodes were 
selected for alternating stimulation in the experimental protocol, however, for clarity 
the electrodes observed with responses from one single electrode is shown in the 
diagram above (B).
3.2.6 Stimulation and Input-Output Relationship
Two stimulation electrodes within the inner half of molecular layer, in the blade 
proximal to the hippocampus sulcus, were chosen per slice to evoke field excitatory 
postsynaptic potentials (fEPSP) or population spikes. The medial perforant pathway 
was stimulated with electrodes within the inner half of the molecular layer. Using this 
stimulation a current sink was seen in both inner and outer halves of the molecular 
layer. Field EPSPs and population spikes were recorded within the molecular layer and
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granular layers, respectively. Input-output relationships were created by alternating 
stimulation of the two electrodes every 30 seconds using escalating stimulation 
intensities in steps o f 10 pA from -10 to -150 pA with a 0.2 ms pulse duration. Field 
EPSP fiom either the inner or outer molecular layer, or population spikes recorded 
from single electrodes were used to assess the input-output relationship. Field EPSP 
slope or population spike slope were analysed as input and population spike amplitude 
as the output. Stimulation intensities that evoked 60 - 80% maximum were used fbr 
further single and paired pulse studies. Field EPSPs with amplitudes > 200 pV and 
population spikes amplitudes > 200 pV were used fbr analysis in this investigation. 
EPSP-population spike (E-S) relationships were investigated using either fEPSP or 
population spike slope with population spike amplitude. E-S curves were normalised 
using percent maximum slope versus percent maximum amplitude, in 10% bins, from 
each input-output recording.
3.2.7 Paired Pulse Stimulation
Paired pulses were delivered at inter-pulse intervals o f 10, 20, 30, 50, 70, 100, 150 and 
200 ms to a single electrode every 30 seconds. Paired pulse ratio was calculated using 
the ratio of the population spike amplitude o f the second pulse divided by the first 
pulse. Each data point is generated from averages o f several consecutive recordings at 
each inter-pulse interval on two electrodes.
3.2.8 Pharmacological Modulations o f  Evoked Responses
Baclofen and bicuculline were dissolved in RO water and CGP55845 was dissolved in 
dimethyl sulfbxide (DMSO). Drugs were stored in aliquots at -20 °C at a concentration 
1000-fbld higher than the concentration required in the ACSF. Drugs were diluted to 
working concentrations in oxygenated ACSF. The final concentration o f DMSO in 
ACSF was thus no more than 0.01%. A baseline period fbr at least 30 minutes prior to 
the first drug application and a wash-out period fbr 60 minutes fbllovGng the final drug 
application were recorded.
3.2.9 Data Capture and Analysis
Stimulation and offline analysis o f fEPSP and population spike was performed using 
Mobius software (version 0.3.7; Alpha MED Sciences, Osaka, Japan). Evoked activity 
was captured at 20 kHz with a 1 Hz high-pass filter in a 100 ms recording (5 ms pre­
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stimulation and 95 ms post-stimulation). Presynaptic glutamate release was assessed 
using the slope function fbr both fEPSP and population spikes, which were measured 
using 10 -  90% slope function (Figure 3.2). Postsynaptic responses were investigated 
using amplitude of the fEPSP and population spike. The population spike amplitude is 
proportional to the number of neurons reaching the threshold fbr action potential 
(Andersen er a/., 1971). Field EPSP amplitude was measured using the minimum 
amplitude and population spike amplitude was measured as the peak-to-peak 
amplitudes of the population spike (Figure 3.2). Half-decay times were measured from 
the minimum amplitude to the half minimum fbr fEPSP, and from the maximum 
amplitude to the half^maximum for population spike (Figure 3.2). Post-synaptic 
excitability was measured as area under the curve, both above and below baseline, fbr 
fEPSP and populations spike recordings. Multiple recording electrodes showing the 
population spikes or fEPSP were grouped together. The use o f the averaged effects 
was fbund to enhance repeatability of drug effects between slices (Chen gr a/., 2006).
Field EPSPs recorded in the inner and outer halves of the molecular layer were found 
not to differ fbr the measured parameters (Students' t-test) and were therefbre grouped 
together. Time course plots were normalised to the 30 minute baseline period (control) 
and expressed as a percentage control. Summary plots were created from the mean of 
the last 5 minutes fbr baseline and wash-out and the peak mean 5 minutes o f the drug 
phases. Values were normalised to the baseline values or, where present, the 
bicuculline values for each recording using percentage control. Data were compared 
using a two-way repeated measure ANOVA with treatment and genotype as factors. 
Pair-wise comparisons were made using a Bonferroni post-hoc test to compare 
between genotype and either a paired t-test (fbr two groups) or a Dunnett's post-hoc 
test (fbr more than 2 groups) to compare treatment groups to baseline levels. The linear 
relationships between the measured parameters were compared using a linear best fit 
forced through the origin. The Pearson's correlation coefficient (R^) values were 
calculated fbr each linear relationship (adjusted R^ using the linear regression function; 
SPSS version 15.0; SPSS Inc., Chicago, Illinois, USA) and values greater than 0.75 in 
Avild-type animals were accepted as showing a relationship.
The latencies to the peaks of the population spike were measured from the time of 
stimulation (Figure 3.2) from 1 recording electrode per stimulation pathway. Genotype
TOO-
Chapter 3 -  GABAg Receptors in the Dentate Gyrus
pooled baseline values were compared by a one-way ANOVA. Normalised data and 
population spike timing data were compared between the treatment groups and 
genotype using a two-way repeated measure ANOVA. Curves were fitted with a four- 
parameter dose-response curve using GraphPad Prism (version 5.04, GraphPad 
Software Inc., La Jolla, California, USA). The probabilities of population spike firing, 
from single recording electrodes, were calculated fbr each stimulation level and were 
compared between the genotypes using multiple Kolmogorov-Smimov tests. Each 
simulation pathway was used as one data point (/?) and up to two pathways were 
evoked alternatively in each slice. Slices prepared from the same animal were used fbr 
different experimental protocols. Data are expressed as mean ± standard error o f the 
mean (SEM).
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Figure 3.2 -  Param eters m easured from  fEPSPs and population spikes.
Parameters o f the field excitatory postsynaptic potentials (fEPSP) (A) and population 
spike (B and C) were investigated as shown in the diagram above. Field EPSP 
amplitude was measured from baseline to peak negativity and population spike 
amplitude was measured as peak-to-peak amplitude, denoted by AMP arrows. The 
absolute area was measured as the area under the curve both above and below baseline, 
denoted by the shaded areas. Half-decay was measured as the time taken from peak 
minimum to half minimum for fEPSP recordings and peak maximum of the second 
positive peak to half maximum for population spikes, denoted by the HD arrows. The 
slope function was measured at the 10-90% slope for both fEPSPs and population 
spikes, denoted by the SL line. Latencies to the first (LI), second (L2) and third (L3) 
peaks o f the population spike (C) were measured from the stimulus, denoted by arrow 
STIM.
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3.3 Results
3.3.1 Synaptic Transmission at the Perforant Path-Dentate Gyrus Granule Cells 
Synaptic transmission at the medial perfbrant pathway-dentate gyms granule cell 
synapse was investigated using input-output relationships. Input-output relationships 
fbr fEPSP slope (Figure 3.3 A) evoked from perfbrant pathway stimulation were fbund 
to increase in a stimulation intensity dependant manner (F  [14, 350] = 38, /? < 0.001 
***). Field EPSP slopes evoked with stimulation intensities above 10 pA were 
significantly greater than those recorded with the threshold 10 pA stimulation 
(Bonferroni post-hoc test), however no difference between the genotypes was fbund (F  
[2, 350] = 0.60,/) > 0.05). This finding suggests that baseline synaptic transmission at 
the medial perfbrant pathway was unaltered by deletion of either GABAgi isofbrms.
The input-output relationships of the population spikes were also examined. 
Population spikes were not present at all stimulation intensities, however, the 
probabilities o f population spike firing were fbund to increase with higher simulation 
currents (Figure 3.3 D). No significant differences were identified between the 
population spike firing probabilities from the different genotypes (Kolmogorov- 
Smimov tests, all tests /? > 0.5). Population spike slope (Figure 3.3 B) and amplitude 
(Figure 3.3 C) were compared at stimulation intensities above 70 pA. Population 
spikes were present in most recordings at 70 pA or greater intensities. Both population 
spike slope and amplitude increased in a stimulation intensity dependent manner 
(slope, F  [8, 240] = 3 6 ,p  < 0.001 ***; amplitude, F  [8, 240] = 9.5,/) <0.001 ***), but 
no differences between the genotypes were fbund (slope, F  [8, 240] = 2.5, /) >0.05; 
amplitude, F  [2, 240] = 0.89, /) > 0.05). These findings suggest that the excitability of 
granule cells evoked by stimulation of the medial perfbrant pathway was similar in all 
genotypes.
Coupling of input and output within the dentate gyms was investigated using E-S 
relationships using fEPSP slope (inner molecular layer. Figure 3.4 A, and outer 
molecular layer. Figure 3.4 B) and population spike amplitude, or population spike 
slope and amplitude (Figure 3.4 C). E-S relationships were compared between the 
genotypes by analysing the population spike amplitude evoked with 50% maximum 
slope. E-S relationships did not differ significantly between the genotypes fbr inner (F
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[2, 224] = 0.917,/) > 0.05), outer molecular layer fEPSP slope (F  [2, 314] = 0.097,/) > 
0.05) and population spike slope recordings (F  [2, 494] = 0.3862, /) > 0.05). These 
findings suggest that the coupling of input and output within granule cells of the 
dentate gyrus was unaltered by genotype.
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3.3.2 Presynaptic Effect o f  G A B A b Receptors on the Medial Perforant Pathway 
Slope, amplitude, half-decay time and area were measured from fEPSPs recorded in
both the inner and outer halves o f the dentate gyrus molecular layer. All measured
parameters in both the inner and outer molecular layer of all genotypes displayed
similar baseline values (Students' T-test, all tests y? > 0.05). Values from the inner and
outer molecular layer were grouped together with an average o f 6 recording electrodes
per stimulation pathway. Field EPSP slope and amplitude demonstrated a similar linear
relationship in all the genotypes (wild-type R^ = 0.92, GABAgia^ R^ = 0.89 and
GABAsib  ^ R^ = 0.90; Figure 3.5 A). Any recording electrodes not fitting this linear
relationship were removed from further analysis (wild-type 3 electrodes; GABAsia  ^ 3
electrodes; GABAgib  ^ 5 electrodes). Field EPSP absolute areas demonstrated linear
correlation with both fEPSP slope and amplitude in all genotypes (Figure 3.5 B and C).
However, the half-decay time did not to correlate with slope, amplitude or absolute
area (R^ values <0.75; Figure 3.5 D, E and F). Field EPSP traces from similar locations
in the dentate gyrus were observed to have similar rise and decay phases (Figure 3.6
A). These findings suggesting that the same population o f neurons were sampled in the
recordings from all genotypes.
The potential presence o f presynaptic GABAg receptors on the medial perforant 
pathway was investigated by examining changes in fEPSPs in the presence o f the 
GABAg receptor agonist baclofen (Figure 3.7). Baclofen (10 pM) was applied for 35 
minutes and was followed by the GABAg receptor antagonist CGP55845 (1 pM) for 
20 minutes. Changes seen in the wash-out phase were small (<20%) and were not 
included in the analysis. Field EPSP slope and amplitude showed no changes during 
baclofen application (Figure 3.8 and Figure 3.10; slope F  [1, 21] = 2.8, > 0.05;
amplitude F  [1, 21] = 9.8, < 0.01 **, no significance in post-hoc tests). In addition,
neither fEPSP slope nor amplitude revealed genotype differences (slope F  [2, 21] = 
0.2, > 0.05; amplitude F  [2, 21] = 0.3,/? > 0.05). These findings show that baclofen
had no effect on fEPSP slope and amplitude, which indicate that GABAg receptors 
may not be present at the presynaptic site of medial perforant pathway o f wild-type, 
GABAg la'^ ' and GABAg ib'^ ' mice.
However, fEPSP half-decay time (Figure 3.9 and Figure 3.10) was increased from 
baseline in GABAgia"' mice during baclofen application, but no effect was seen in
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either wild-type or GABAgiy'^' mice (F  [1, 21] = 8.3,;? < 0.01 **). No genotype effect 
was found for decay-time (F  [2, 21] = 2.1, /? > 0.05) suggesting that the genotypes 
have similar changes in decay-time. Absolute area o f the fEPSP (Figure 3.9 and Figure 
3.10) was increased &om baseline during the baclofen phase (F  [1, 21] = 18.4, /? > 
0.001 ***) and did not differ between the genotypes (F  [2, 21] = 0 .1 ,^  > 0.05). These 
findings suggest that both GABAgia and GABAgib isofbrms are responsible for this 
baclofen-mediated disinhibitory effect.
108.
Chapter 3 -  GABAb Receptors in the Dentate Gyrus
(siu .A rt) B9JV 9 » n |o sq v
o00
CD ±1
I
o■o3
o
(sui,Ari) eaiV 3in|osqv
(O 00 00
o  o  o
o
u_
(stu,Ari) B3JV 9»n|0sqv
a
a=m
X
o00
o) 00 
o  o  o
(siu ) 9U1Ü AeoaQ-jjBH
T f CM
I
I
(/)
a.
V)
Q.
CÛ
a> o(D <0 00
o  o  o
ill
5  ^
a.
üi
(Arl) a p n ) ! | d u i v  d S d 31
(S U l) 9U 1I1 Ab 0 9 Q -) |B H
o
CL
Cs|
& & &
CM
I(/>
Q .(/>
CL
IÜ
1 1 1
O) (U <u
s l l
M S S'I il
G ^
I I
13 CL ^
F i t
(U <
Sil  
l ï
i î
C LO
B *
• 3 2
I  "
’.S
IKs
o
£ 'c«
tu
1
a
2
'W%C01■o
-aI
c.
S«
f i
03
Va
IK
0HC/2
Pk
W
"O
E
1
•T)
2 
S  dX)
T3
<L)
'S
8
£
<m
A
Ph03Ph
CZJ
1
i
I
g
s
c3
1
I
I
m
<ucxo
W .
l i  ' C3
II
a  "g  13it
P VO
I*
ii
I!
g ,11
II
g - o  
S S
c  II
O _
P h CQÏ?
tlo p
I
I
"OI_o
"o
U
<s
g  II
Ilf.
«
IIP,
 IK
II"!la
^  oxH^  p Æ 
« 1 1
pP,_o
1a
8  CQ
CÜ O
-109-
Chapter 3 -  GABAg Receptors in the Dentate Gyrus
5ms
5ms
W i l d - T y p e  GABAb.,/
Figure 3.6 -  Scaled and superimposed fEPSP and population spike traces.
Evoked field excitatory postsynaptic potentials (fEPSP, A) and population spikes (B) 
were recorded from stimulation of the medial perforant pathway in dentate gyrus slices 
prepared from wild-type and GABAgi isoform knockout mice (GABAgia'^’ and 
GABAgib’^ ’). Traces shown represent the average of five consecutive traces scaled and 
superimposed with traces from all genotypes. Rise and decay phases were found to be 
similar in all genotypes.
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3.3.3 Disinhibitory Effect o f GABAg Receptor in the Dentate Gyrus
Population spikes were recorded from the granular layer o f the dentate gyrus evoked
by stimulation o f the medial perforant pathway (Figure 3.3). Recordings from an
average of 4 electrodes were used per stimulation pathway. Population spike slope and
amplitude demonstrated a linear relationship in all genotypes (R^ >0.75; Figure 3.11).
Any recordings not fitting this relationship were removed from further analysis.
Population spike amplitude has been reported to increase with the number of neurons
recruited (Andersen g/ <2/., 1971). These findings suggest that the greater the slope the
larger the population of neurons firing, in agreement with the E-S curves (Figure 3.4).
Linear relationships were also found between slope and area (R^ >0.75; Figure 3.11),
amplitude and area (R^ >0.75; Figure 3.12), and half-decay and area (R^ >0.75; Figure
3.13). These findings demonstrate that area represents net excitation o f the population
spike. No linear relationship was found between slope and amplitude with half-decay
(R^ <0.75; .slope vs. half-decay. Figure 3.12; amplitude vs. half-decay), indicating that
the half-decay may be independent Aom the input. Differences in the latencies from
peak 1 to peak 2 (F  [2, 66] = 1.5, /? > 0.05) and from peak 1 to peak 3 (F  [2, 65] = 1.3,
> 0.05; Figure 3.14) did not differ between the genotypes during baseline recordings,
further confirming that the population spikes have similar shape (Figure 3.6). These
findings show that all the responses had similar trends and thus were grouped together
for each genotype. Therefore it can be suggested that the deletion of GABAg receptor
subtypes had no effect on action potential time course.
Baclofen can induce multiple population spikes from perforant pathway stimulation 
within the dentate gyrus. A concentration-response curve was produced using baclofen 
(0.1 pM -  100 pM) applied using cumulative dosing with each concentration applied 
for 10 minutes in wild-type mice. Multiple-spiking was observed at 10 pM baclofen 
and greater in those animals (Figure 3.15). However, prolonged application of either 1 
pM or 10 pM showed no multiple-spiking in wild-type or GABAg 1 isofbrm knockout 
mice (Figure 3.16). The effects of baclofen were reversed using application of the 
GABAg receptor antagonist CGP55845 (1 pM) confirming that this was a GABAg 
receptor mediated effect.
The effect of baclofen on the population spikes was investigated using single
concentrations of baclofen (1 pM or 10 pM) for 35 minutes, followed by a 20 minute
-1 1 5 .
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CGP55845 (1 pM) and 60 minute wash-out period. For control experiments slices 
were incubated with CGP55845 (1 pM) for 20 minutes and had CGP55845 (1 pM) 
simultaneously applied with baclofen (10 pM). The population spike amplitude 
increased compared to the baseline level in GABAgib'' mice with 1 pM baclofen 
(Figure 3.19 and Figure 3.23; F  [1, 15] = 17.0, < 0.001 ***) and in both GABAgi
isofbrm knockouts with 10 pM baclofen (Figure 3.21 and Figure 3.23; F  [1, 19] = 
21.6, < 0.001 ***). A genotype effect was found with 1 pM baclofen with
GABAgib'^' showing a greater increase compared to GABAgia'^' mice (F  [2, 15] = 5.8, 
< 0.05 *), however, no genotype differences were found at 10 pM baclofen (F  [2, 19] 
= 0.0, > 0.05). These findings suggest that GABAgib'^' mice may demonstrate a
greater sensitivity to baclofen-mediated increases in population spike amplitude.
Population spike half-decay times (Figure 3.20, Figure 3.22 and Figure 3.24) increased 
compared to the baseline in the presence of both 1 pM (F  [1, 15] = 42.6, p  < 0.001 
***) and 10 pM baclofen (F  [1, 19] = 50.0,/? < 0.001 ***). In agreement, populations 
spike traces showed a distinct biphasic decay with 10 pM baclofen (Figure 3.16 G, H 
and I). GABAgib'' had an increased half-decay compared to both wild-type and 
GABAgia'^' with 1 pM baclofen (Figure 3.24; F  [2, 15] = 3.9,/? < 0.05 *), however no 
difference between the genotypes were identified with 10 pM (F  [2, 19] = 0.6, /? > 
0.05). Absolute areas o f the population spikes (Figure 3.20, Figure 3.22 and Figure 
3.24) were increased compared to the baseline level with both concentrations of 
baclofen in all genotypes (baclofen 1 pM, F  [1, 15] = 105.4,/? < 0.001 ***; baclofen 
10 pM, F  [1, 19] = 161.5,/? < 0.001 ***). These findings suggest that the increase o f 
population spike area accompanies the increase in amplitude and half^decay time. 
Genotype differences were found with 10 pM baclofen with GABAgib'^'mice having 
increased population spike absolute area compared with both wild-type and 
GABAgia' ' mice (F  [2, 19] = 4.2,/? < 0.05 *). No genotype difference was found at 1 
pM  baclofen (F  [2, 15] = 1.2, /? > 0.05). These findings further confirm the greater 
sensitivity of GABAgib'' mice to baclofen-mediated disinhibition.
The population spike slope was unchanged after baclofen application (Figure 3.17 and 
Figure 3.23; 1 pM baclofen F  [1, 15] = 0.3,/? > 0.05; 10 pM baclofen F  [1, 19] = 2.2, 
/? > 0.05) and no differences were found between the genotypes (1 pM baclofen F  [2, 
15] = 0.1, /? > 0.05; 10 pM baclofen F  [2, 19] = 0.1, /? > 0.05). This finding is in
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agreement with the absence o f baclofen-mediated effect in the fEPSP recordings and 
further suggests that the GABAg receptor is not present at presynaptic sites.
The effect of baclofen was blocked by CGP55845 and were absent in the control 
experiments indicating the effects are mediated by GABAg receptor activation. This 
finding demonstrates that GABAg receptor activation induces an increase in excitation 
that is likely to be due to activation o f both GABAgi isofbrms. Changes seen in the 
wash-out phase for population spike for all experiments were small (<20%) and were 
not included in the analysis.
Latencies from stimulation to the peaks of the populations spike (Figure 3.14) were 
measured in each stimulation pathway and the difference between latency 3 and 
latency 1 (peak-to-peak duration), and latency 2 and latency 1 (population spike onset 
time) were calculated (Figure 3.25). The population spike onset time (latency 2 -  
latency 1) showed no differences between the drug phases (baclofen IpM , F  [1, 15] = 
1.2,/? > 0.05; baclofen lOpM F  [1, 15] = 4.0,/? > 0.05) and genotypes (baclofen IpM , 
F  [2, 15] = 1.3,/? > 0.05; baclofen lOpM, F  [2, 15] = 0.4,/? > 0.05). While the peak-to- 
peak duration of the population spike differed between drug phases (baclofen 1 pM, F  
[1, 15] = 5.3,/? < 0.05 *; baclofen lOpM F  [1, 15] = 1.8,/? > 0.05) no differences were 
found with tlie post-hoc test and no genotype effect was found (baclofen 1 pM, F  [2, 
15] = 0.4, /? > 0.05; baclofen lOpM, F  [3, 15] = 1.6, /? > 0.05). These findings show 
that the timing o f action potentials was unaltered by GABAg receptor activation.
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■■■« T- 2.0-
■5 . ^
g S 1.5- •••••
0.5-
-J 0.0
Wild-Type GABAei/ GAB^Sfeib
••
5 M
Wild-Type GAB/^-
Figure 3.14 -  Latencies to evoked population spikes were sim ilar in all genotypes.
Evoked population spikes were recorded from stimulation of the medial perforant 
pathway in dentate gyrus slices prepared from wild-type and GABAgi isoform 
knockout mice (GABAgia'^ and GABAgib*^’). The difference in latencies from peak 1 
to peak 2 (latency 2 -  latency 1 ; A) and from peak 1 to peak 3 (latency 3 -  latency 1 ;
B) were measured at baseline level and found not to differ between genotypes. Wild- 
type: « = 20 from 15 animals. GABAgia’^ ’: « = 24 from 16 animals. GABAgib'^': « = 23 
from 15 animals.
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20 m s
 BASELINE
BACLOFEN [10 ijM]
S 3.0-,B t
S 2.5-
a  2.0-
1.5-
100
B aclofen (gM)
Figure 3.15 -  Baclofen evoked multiple population spikes in the dentate gyrus of 
wild-type mice.
Evoked population spikes were recorded from stimulation of the medial perforant 
pathway in dentate gyrus slices prepared from wild-type mice (A; n = S, from 5 
animals). A second pulse was delivered at 15 ms, however was not analysed. The 
number of population spikes (negative peaks) evoked from the first pulse were counted 
in the presence of escalating baclofen concentrations. Each baclofen concentration was 
applied for 10 minutes. Multiple population spikes were observed with 10 pM 
baclofen and greater (B). This effect was reversed with application of the GABAg 
receptor antagonist CGP55845 (1 pM, not shown). Traces shown represent the average 
of five consecutive traces.
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3.3.4 GAB As-Mediated Inhibition within the Dentate Gyrus in the Absence o f  
GABAa Inhibition
Iidnbhion vhhhn the cbnüüe gyrus vms invesügakd thrüier i#ing pahed-pihse 
simulation with varying inter-pulse periods. Paired pulse inhibition was seen at inter­
pulse periods shorter than 30 ms and paired pulse facilitation at inter-pulse periods 
greater than 30 ms (Figure 3.26). The paired pulse ratio differed between the inter­
pulse periods (F  [7, 147] = 37.06,;? < 0.001 ***). Both GABAsia'" aiid GABAgib'^' 
mice showed increased paired-pulse inhibition at 10 ms compared to wild-type animals 
(Figure 3.26), however, no statistical significance between genotypes was found (F  [2, 
147] = 0.52, jC) > 0.05). This finding suggests that paired-pulse mediated inhibition is 
therefore unaltered by deletion o f GABAgi isofbrms.
GABAA-mediated inhibition was blocked using bicuculline to elucidate the role o f 
GABAg receptors on population spike in the absence of GABAA-mediated effects. 
Bicuculline (10 pM) was applied for 20 minutes followed by a 20 minute co- 
application with baclofen (10 pM). Finally, bicuculline (10 pM) and CGP55845 (1 
pM) were co-applied for 20 minutes. Application of bicuculline evoked multiple 
population spikes (Figure 3.28) and found to increase population spike absolute area 
from the baseline level (Figure 3.29 and Figure 3.30). A linear relationship was found 
between population spike absolute area in the presence of bicuculline with both 
baseline amplitude and absolute area (R^ >0.75; Figure 3.27). This finding shows that 
the increase in excitation of the population spike in the presence of bicuculline was 
proportional to the baseline excitation. As all recording electrodes showed similar 
trends they were grouped together by genotype. Population spike absolute area and 
slope were normalised to the application of bicuculline to distinguish the effects of 
baclofen compared to bicuculline rather than baseline. DiBerences in population spike 
area were found between both drug treatments (F  [3, 48] = 345.9,;? < 0.001 ***) and 
genotypes (F  [2, 48] = 5.6, ;? < 0.05 *). Baclofen reduced population spike absolute 
area in the presence of bicuculline in v\dld-type and GABAsia'' mice, while a visible 
decrease is seen in the GABAgib  ^ mice this failed to reach statistical significance 
(Figure 3.29 and Figure 3.30). These findings show that GABAg receptor activation 
caused inhibition when GABAA receptors are blocked, this inhibition appears to be 
mediated by the GABAgib isofbrm. Blockade o f the GABAg receptors with CGP55845
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increased population spike area above the bicuculline level in GABAgia^ and 
GABAsib'^' mice (Figure 3.30 and Figure 3.30). This finding may suggest the presence 
o f a tonic GAB As inhibition, not involving GABAA receptors, in the GABAsi isofbrm 
knockout mice but not v^ild-type mice. Recordings of fEPSPs from experiments using 
paired pulse stimulation and bicuculline were reanalysed, however, data were 
insufficient to be presented due to population spike contamination of the fEPSP.
A delayed positive wave followed the multiple spikes in some recordings and was 
observed in all genotypes (Figure 3.28, denoted by arrows; ^vild-type, 2 out o f 6 
recordings; GABAgia'^', 3 out o f 6 recordings; GABAgib'^', 3 out o f 6 recordings). This 
wave was absent in the presence of baclofen but returned during CGP55845 
application (Figure 3.28). The restoration of the positive wave was greater than that 
seen with bicuculline alone in both GABAsia'' and G A B A gib 'how ever, it was not 
different to bicuculline level in wild-type mice. This finding is in agreement with the 
data from the population spike absolute area and may indicate that the delayed positive 
wave is regulated by both GABAeia and GABAeib isoforms.
The population spike slope differed v\dth drug treatment (F  [3, 48] = 19.4, < 0.001
***) and genotype (F  [2, 48] = 16.6, p  < 0.001 ***). Wild-type mice showed a small 
(>20%) inhibition o f slope with baclofen during GABAa receptor blockade (Figure 
3.30 and Figure 3.30). This inhibitory effect was not seen wdth either GABAsi isofbrm 
knockout mice (Figure 3.30 and Figure 3.30). This finding may demonstrate that 
blockade o f the GABAA receptor unmasked a small presynaptic GABAg-mediated 
inhibition on the medial perforant pathway in wild-type mice.
Population spike onset times were reduced compared to baseline in the presence of 
bicuculline (Figure 3.311; F  [2, 28] = 16.0,;? < 0.001 ***) in all genotypes (change 
from baseline to bicuculline: wild-type 0.47 ± 0.13 ms, GABAgia^ 0.25 ± 0.08, 
GABAgib'^' 0.51 ± 0 .12  ms) and no genotype difference was found (F  [2, 28] = 2.5, p  
>0.05). This shift in population spike onset may result from the lack of feed-forward 
inhibitory input into the dentate gyrus. Population spike peak-to-peak duration differed 
with drug phases (F [2, 32] = 6 .1 ,p  < 0.01 **) ^vith GABAgib'^' mice demonstrating a 
reduction in the presence o f bicuculline compared to the baseline. However, no effect 
o f baclofen, CGP55845 or wash-out compared to bicuculline (post-hoc test compared
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to bicuculline) or genotype effects were found (F [2, 32] = 1.4, ;? > 0.05). These 
findings show that blockade of the GABAA receptors can alter the timing of the action 
potentials in the dentate gyrus.
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Figure 3.26 -  Paired-pulse mediated inhibition of population spike was unaltered 
by deletion of the GABAbi isoforms.
Evoked population spikes were recorded from stimulation of the medial perforant 
pathway in dentate gyrus slices prepared from wild-type (A), GABAeia’^ ’ (B) and 
G A B A sib   ^ (C ) isoform knockout mice. Two stimulations were delivered at varying 
inter-pulse periods (10, 20 30, 50, 70, 100, 150 and 200 ms) and the population spike 
amplitude measured for both pulses. Traces shown represent the average of five 
consecutive traces. Data are presented as the paired pulse ratio (pulse 2/pulse 1 ; D). No 
differences were found between the genotypes. Pair-wise comparisons to the 30 ms 
grouped response (only wild-type shown for clarity) showed paired pulse inhibition 
below 30 ms and paired pulse facilitation above 30 ms inter pulse period (# p  < 0.05, 
##/? < 0.01, ### p  < 0.001). Wild-type: n = 6 from 4 animals. GAB Asia 2 n = 9 from 
6 animals. GABAgib 2 n = 9 from 6 animals.
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Figure 3.27 -  Population spike am plitude and population spike area in the 
presence of bicuculline had a linear relationship.
Evoked population spikes were recorded from stimulation of the medial perforant
pathway in dentate gyrus slices prepared from wild-type, GABAeia’^ ’ and GABAeib 
isoform knockout mice. Baseline population spike amplitude (A) and absolute area (B) 
were compared with population spike area in the presence of GABAa receptor 
antagonist bicuculline. A linear relationship was found with both parameters (R^ 
>0.75). Each data point denotes a recording electrode (wild-type = 37, GAB Agi a '' =
30, GABAeib’^ ’ = 29). Wild-type: n = 1 from 5 animals. GABAsia : n = 6 from 4
animals. GABAgib'^': n = 6 from 4 animals.
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Figure 3.30 -  G A B A b  receptor activation evokes inhibition when G A B A a  
receptors are blocked in wild-type and GAB Agi a mice, but is w eaker in
G A B A b i b'^' mice.
Evoked population spikes were recorded from stimulation of the medial perforant 
pathway in dentate gyrus slices prepared from wild-type, GABAb la’^ ’ and GABAb ib’^ ’ 
isoform knockout mice. (A) Population spike absolute area increased compared to 
baseline levels during application of the GABAa receptor antagonist bicuculline. A 
decrease in area from the bicuculline level was observed in wild-type and GABAbi a 
mice in the presence of GABAb receptor agonist baclofen. (B) A decrease in slope 
from the bicuculline level was seen in wild-type animals. Paired comparisons verses 
bicuculline: # p  < 0.05, ## p  < 0.01, ### p  < 0.001. Paired comparison between 
genotypes: * p  < 0.05, * * p <  0.01, ***/>< 0.001. Wild-type: n = 7 from 5 animals.
GABABI a : n = 6 from 4 animals. GABAB l y :  n = 6 from 4 animals.
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Figure 3.31 -  GABAa receptor blockage changes the timing of the population 
spike in the dentate gyrus.
Evoked population spikes were recorded from stimulation of the medial perforant 
pathway in dentate gyrus slices prepared from wild-type and GABAbi isoform 
knockout mice (GABAbla'^' and GABAbib'^’). Differenced in the latencies between 
population spike peak 2 and peak 1 (A), and peak 3 and peak 1 (B) were found in the 
presence of bicuculline compared to the baseline (# p  <0.05, ##, p  <0.01, ### p  
<0.001). No differences between the bicuculline alone and co-application of baclofen 
and bicuculline treatment group were identified using pair-wise comparison. Wild-
type: n = 4-5 from 3-4 animals. G A B A b i  
5-7 from 3-4 animals
n = 5-1 from 3-5 animals. GABAbi y n =
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3.4 Discussion
This investigation examined the roles of individual GAB As i isofbrms in inhibition 
within the dentate gyrus network. In contrast to many other neuronal networks an 
absence o f GABAg heteroreceptor-mediated inhibition o f the medial perforant 
pathway was confirmed. Both GABAgia and GABAsib isofbrms were fbund to 
contribute to disinhibition within the dentate gyrus. However, a direct GABAg- 
mediated inhibition on the excitability of granule cells, during blockade of the GABAA 
receptors, was fbund to be due solely to the GABAsib isofbrm.
3.4.1 Extracellular Recording using the Multi-Electrode Array System
The recording o f extracellular potentials used in this investigation was achieved by the
use o f a multi-electrode array system. This system allowed fbr the simultaneous
recording of activity in multiple sites ^vithin the dentate gyrus. In addition, the use of
this methodology has been fbund to allow the use of several recording sites
simultaneously leading to an increase in the reproducibility of treatment effects
between slices (Chen cr a/., 2006). Electrodes were positioned in the outer and inner
halves of the dentate gyrus molecular layer and the granular layer. Stimulation of the
medial perfbrant pathway was achieved by delivering a stimulus to the inner half of the
molecular layer. Previous studies investigating differences between the lateral and
medial perforant pathways have recorded potentials within the outer and middle thirds
of the molecular layer in the rat (Lanthom and Cotman, 1981; Ault and Nadler, 1982,
1983a). Stimulation o f the medial pathway revealed current source and current sink
within the outer and middle thirds, respectively, and was fbund to switch locations
with stimulation o f the lateral pathway (Dahl and Sarvey, 1989; Wang and Wojtowicz,
1997). This investigation, however, fbund current sink in both the inner and outer
halves of the molecular layer while stimulating the medial perfbrant pathway. This
may indicate that the stimulation sites used in this investigation evoked both pathways
due to the shorter distance between the inner and outer molecular layer in the mouse.
Stimulation sites fbr this investigation were chosen by anatomical location within the 
inner half of the molecular layer to stimulate the terminals o f perfbrant pathway. 
Studies investigating differences between the medial and lateral perfbrant pathways 
have revealed that evoked fEPSP differ in their paired pulse responses (McNaughton,
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1980) and decay phases during GABAA receptor blockade (Hanse and Gustafsson, 
1992). While similar methodologies were used in this investigation fbr population 
spike recordings, they were however, not used to investigate fEPSPs. Stimulation of 
both lateral and medial perfbrant pathways and associational/commissural pathway 
would be expected to produce mixed and variable response (Ault and Nadler, 1982). In 
the current investigation, fEPSP data were robust suggesting that the perfbrant 
pathway was stimulated exclusively.
The dentate gyms molecular layer is smaller in the mouse compared to the rat 
(molecular layer -150 pm in the mouse pm versus -450 pm in the rat) (Blaabjerg and 
Zimmer, 2007). As such the distance between the stimulating electrode within the area 
associated with the medial perforant path and the recording electrode in the outer 
molecular layer may not be sufficient fbr current source to occur. This may therefore 
account for the absence of current source in the outer molecular layer and further 
support the argument that both medial and lateral perfbrant pathways were stimulated.
The role of GABAg receptor in disinhibition from recurrent inhibition has been 
previously investigated in the dentate gyms using a two stimulation paradigm where, 
orthodromic stimulation was preceded with antidromic stimulation, resulting in a 
strong recurrent inhibition that is blocked in the presence o f baclofen (Mott et a l, 
1989). While the methodology unutilised fbr this investigation was not identical it did, 
however, allow fbr the study of disinhibition evoked by baclofen.
3.4.2 Absence o f  GABAb Heteroreceptors on the Perforant Pathway
The current investigation fbund no GABAg-mediated inhibition on the prefbrant
pathway, as shown by the lack o f reduction in fEPSP slope in the presence o f baclofen.
This finding may suggest that (i) mice used in this investigation lacked GABAg
receptors on the perfbrant pathway, or (ii) stimulation of the lateral perfbrant pathway
and the associational/commissural fibre. It is plausible that the stimulation evoked a
mixture o f pathways including the lateral perfbrant pathway and
associational/commissural fibre, both of which have an absence of GABAg
heteroreceptor function (Lanthom and Cotman, 1981; Ault and Nadler, 1982, 1983a).
In the rat, baclofen produces a small inhibition (<25 %) o f the fEPSP slope evoked
6om  perfbrant pathway stimulation (Ault and Nadler, 1983a). Currently it is not
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possible to confirm whether GABAg heteroreceptors are present on the medial 
perfbrant pathway due to the lack of investigations conducted in the mouse. Population 
spike paired-pulse responses have been reported to vary across strains o f mice 
suggesting that inhibition within the dentate gyms may differ between strains 
(Bampton er a/., 1999). The current study indicates a lack of GABAg receptors on the 
perfbrant pathway in the BALB/c background strain of mice used fbr this 
investigation. This finding may be a novel species difference between rat and mouse. 
To add to this, dentate gyms hilar intemeurons demonstrate lower action potential 
thresholds to stimulation from the perfbrant pathway than granule cells, suggesting that 
a feed-fbrward inhibition within the dentate gyms from the perfbrant pathway is 
present (Scharfman, 1991). Feed-fbrward inhibition has been shown to modulate input 
into the CAl giving rise to greater dynamic range (Pouille u:/., 2009). Thus, it is 
possible that feed-fbrward inhibition may mask the presence of presynaptic GABAg 
heteroreceptors on the perfbrant pathway. In the current study it was fbund that the 
population spike slope was unaltered in the presence of baclofen alone, however 
during blockade o f the GABAA receptors the population spike slope showed a small 
reduction in wild-type animals, but was absent in both GABAgi isofbrm knockout 
animals. In addition, timing of the population spike onset decreased in the presence of 
bicuculline suggesting the presence o f a feed-fbrward inhibition. Therefore, it can be 
concluded that GABAg-mediated inhibition on the perforant pathway is masked by 
feed-forward inhibition. If tme this inhibition is likely to be attributed to both the 
GABAg la and the GABAg % y receptor sub-types.
3.4.3 Disinhibition Mediated by the GABAb Receptor
GABAg-evoked multiple spiking was shown in wild-type mice with escalating 
concentrations of the GABAg receptor agonist baclofen. In contrast, this was not 
observed using fixed doses of the agonist, at concentrations that induced spiking with 
the escalating doses. Previous investigations have shown multiple spiking with fixed 
concentrations o f baclofen using a maximal stimulation of the perfbrant pathway and 
inhibition with sub-maximal stimulation (Mott gf a/., 1989). In this investigation 
stimulation strength of 60 - 80% maximal stimulation was used fbr both escalating and 
fixed baclofen concentration. While multiple population spiking was not observed, an 
increase in amplitude and absolute area was fbund in the presence of baclofen. This 
suggests that recurrent inhibitory circuits were activated at the stimulation strength
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used fbr this investigation and demonstrated disinhibition with baclofen. Population 
spike amplitude increase with low concentration baclofen was fbund only in 
GABAg ib'^ ' mice, and in all the genotypes at higher concentration. These findings 
indicate that GABAg ly'^ ' have a greater sensitivity to the disinhibitory effects of 
baclofen and suggest that the GABAgla containing subtype is present at a key location. 
Dentate gyrus basket cells have been reported to show heterogeneity of GABAg 
receptor function and raising the possibility that a sub-population o f baskets cells 
express different GABAg receptor subtypes (Mott er a/., 1999). While other inhibitory 
intemeurons also contribute to recurrent inhibition (HICAP and HIPP cells) exclusive 
expression o f either GABAg i isofbrms in basket cells would be expected to result in a 
reduction of disinhibition. Findings from this investigation demonstrate an increase in 
excitation as a result o f baclofen-mediated disinhibition from activation o f GABAg 
receptors containing both GABAgia and GABAgiy isofbrms. This suggests that both 
subtypes act as autoreceptors. The greater sensitivity of the GABAg la-containing 
subtype may indicate a presynaptic location on the excitatory input to the inhibitory 
intemeurons. Long-term potentiation (LTP) has been fbund previously as a result of 
GABAg-mediated disinhibition (Mott and Lewis, 1991), but was not observed in this 
investigation. This lack of LTP is likely due to the same mechanism that caused the 
lack of multiple spikes induction using the fixed baclofen concentration. It could be 
suggested that the multiple spiking may be dependent on rising concentrations of 
baclofen.
3.4.4 Inhibition Mediated by the GABAb Receptor
When GABAA-mediated inhibition was intact activation of GABAg receptor resulted 
in disinhibition. However, during GABAA receptor blockade GABAg receptors evoked 
inhibition. As the GABAA receptors are blocked this inhibition is unlikely to be due to 
the inhibitory intemeurons. In addition, the previous findings o f this investigation 
fbund no significant heteroreceptor-mediated inhibition in the GABAg i isofbrm 
knockout mice. Therefore, this inhibitory effect is likely to demonstrate inhibition 
mediated by the postsynaptic GABAg receptors (Ault and Nadler, 1983b). As 
postsynaptic inhibition was fbund in wild-type and GABAgia" ' mice this effect can be 
attributed to the GABAgiy isofbrm. This finding is in agreement with the notion of the 
GABAgib isofbrm mediating postsynaptic inhibition (Vigot gr a/., 2006; Ulrich g/ a/., 
2007).
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A  delayed positive deflection followed population spikes in the presence of 
bicuculline, in some recordings, and was inhibited by baclofen. Similar delayed 
responses have been reported with antidromic stimulation of the dentate gyrus granule 
cells and were associated with recurrent excitation from mossy fibres (Okazaki et uZ., 
1999). While in naïve animals few recurrent mossy fibre terminals are present, the 
number is greatly increased in animal models of epilepsy due to mossy fibre sprouting 
(Tauck and Nadler, 1985). The delayed positive deflection seen in this investigation is 
unlikely to be due to direct recurrent mossy fibre connections alone and may include 
mossy cells projections, to generate recurrent excitation. In both GABAgi isofbrm 
knockout animals this delayed response was observed to increase above the bicuculline 
level during application of GABAg receptor antagonist which is in agreement with the 
finding o f increased population spike absolute area in these animals during this period. 
This effect may be due to increased input into the dentate gyrus as demonstrated by the 
enhanced slope in the GABAgia'^' and GABAgiy'^' animals. The findings from this 
investigation suggest that recurrent excitation is inhibited by GABAg receptor 
activation with receptors containing either the GABAgia or the GABAgiy isofbrms.
3.4.5 Model o f  the GABAb Receptors in the Dentate Gyrus
Overall the findings from this investigation demonstrate that GABAg-mediated 
disinhibition in the dentate gyrus can be produced by both GABAgia and GABAgiy 
isofbrms and that postsynaptic inhibition in the dentate gyrus granule cells was 
mediated exclusively by the GABAgiy isofbrm. These findings are in agreement with 
studies showing that both GAB Agi isofbrms act as autoreceptors within the 
hippocampus and that the GABAgiy isofbrm is essential fbr postsynaptic inhibition 
(Vigot a/., 2006). The current investigation has functionally demonstrated that the 
GABAg receptors are not present on the perfbrant pathway in contrast to the currently 
held idea that the GABAgia containing receptor is universally present at glutamatergic 
terminals. Thus, indicating that not all glutamatergic terminals express GABAg 
heteroreceptors. However, the loss o f GABAg heteroreceptors may be due to masking 
by feed-fbrward inhibition. These finding are in agreement with the model discussed in 
the previous chapter (Figure 2.19).
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The findings h"om this investigation have demonstrated that GABAgiy containing 
receptors are exclusively responsible fbr postsynaptic inhibition within the dentate 
gyrus. This may suggest that the GABAgiy isofbrm has an important role in 
hyperexcitable states. The hippocampal fbrmation is reported to be the site o f seizure 
generation fbr medial-temporal lobe epilepsy (Chang and Lowenstein, 2003) and as the 
dentate gyrus fbrms the first synapse of tri-synaptic circuit the GABAgiy isofbrm may 
play a crucial role in control of seizure and epilepsy. Nonetheless, this requires further 
investigation as GABAg receptor activation is predominately associated with net 
excitation due to the disinhibitory role of the GABAg receptor.
1 4 7 .
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4 GABAgia Containing Receptors are Essential for Maintaining 
Seizure Thresholds
4.1 Introduction
Pharmacological antagonism of the GABAg receptors is reported to induce convulsive 
seizures (Badran g/ a/., 1997) and reduce typical absence-type seizures (Vergnes e/ a/.,
1997) in rodents. In agreement, transgenic mice with genetic deletion of either the 
GABAgi (Prosser gr aZ., 2001; Schuler gr aZ., 2001) or the GABAgi (Gassmann g/ aZ., 
2004) receptor subunits developed a spontaneous epileptic phenotype ^vith convulsive 
seizures and atypical absence seizures. Genetic investigations in humans have 
suggested a link between a polymorphism in the GABAgi gene and a greater severity 
o f temporal lobe epilepsy (Gambardella gr aZ., 2003; Kauffman gr aZ., 2008). 
Furthermore, autoimmune encephalitis presenting with convulsive seizures has been 
identified with antibodies against the GABAgi receptor subunit (Lancaster g^  arZ., 2009; 
Boronat gr <3Z., 2011). These pro-seizure effects can be suggested to result from the 
impairment of GABAg-mediated inhibition. Studies using baclofen, a GABAg receptor 
agonist, suggested that it can have an anti-convulsant effect in rat pups (Veliskova g/ 
aZ., 1996), which is however diminished in adults (Mares and Slamberova, 2006). In 
addition, baclofen showed no anticonvulsant effects in several acute seizure models in 
adult mice (Holland gf aZ., 1992). Conversely, baclofen has been shown to exacerbate 
absence seizures (Hosfbrd g/ aZ., 1992) and at high doses it has been linked to 
convulsive seizures in humans (Ghose g^  aZ., 1980). These pro-convulsant effects are 
likely due to the disinhibitory effect o f the GABAg receptor on neuronal networks 
(Mott gr arZ., 1989; Mott and Lewis, 1991).
The GABAgi subunit has two major splice variants, GABAgia and GABAgiy, which 
fbrm two receptor subtypes GABAg(i&, 2) and GABAg(iy, 2). Investigations using 
GABAg isofbrm knockout mice, GABAgia'^' and GABAgiy'^', have shown the 
GABAgia subtype to be present in presynaptic locations at the glutamatergic terminals 
o f the hippocampal CAl (Vigot g/ aZ., 2006) and CA3 fields (Guetg gr aZ., 2009), 
amygdala (Shaban g^  aZ., 2006), thalamus (Ulrich gr aZ., 2007) and neocortex (Perez- 
Garci g/ aZ., 2006). In addition, the GABAgiy subtype was present at postsynaptic sites
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in the CAl (Vigot gf aZ., 2006) and neocortex (Perez-Garci gZ aZ., 2006). GABAg 
autoreceptors are fbrmed by both GABAgia and GABAgiy isofbrms in the CAl (Vigot 
gZ aZ., 2006) and thalamus (Ulrich gZ aZ., 2007), but GABAgiy is the sole receptor 
subtype in the neocortex (Perez-Garci gZ aZ., 2006). Activation o f the GABAg 
autoreceptor is reported to be responsible fbr the disinhibitory effects of baclofen 
(Mott gZ aZ., 1989). These different synaptic locations of the GABAg receptor within 
the brain may account fbr the contrasting inhibitory and disinhibitory actions of the 
GABAg receptor in hyperexcitable states.
This investigation aimed to identify the roles o f GABAg receptor subtypes in acute 
seizure models. For this study seizure phenotypes and latencies to seizures were 
investigated in the GABABgi isofbrm knockout mice, using acute seizure models 
invoked with the chemoconvulsants PTZ or kainic acid. Ligands acting at the GABAg 
receptor, baclofen and CGP7930, were used in the GABAgi isofbrm knockouts to 
modulate seizure activity.
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4.2 M ethods
4.2.1 Animal Husbandry
GABAgia knockout (GABAgia'^'), GABAgiy knockout (GABAgiy'^') and wild-type 
mice were maintained on a BALB/c background (Vigot gZ a/., 2006). The housing and 
use of animals in this investigation was in accordance with the United Kingdom 
Animals in Scientific Procedures Act, 1986. See section 22.7 fbr further details. All 
animals used fbr the chemoconvulsant study had not been previously observed to 
display seizures. Animals selected fbr seizure experiments were handled and singly 
housed 2 days prior to participation in the experimental protocol.
4.2.2 Materials
The GABAg receptor agonist (±)-baclofen (referred to hence fbrward as baclofen) and 
pentylenetetrazole (PTZ), systemic convulsant interacting with the GABAA receptor 
complex (Fisher, 1989; De Deyn gZ aZ., 1992), were purchased from Sigma-Aldrich 
Company Ltd. (Poole, Dorset, United Kingdom). CGP7930, a positive allosteric 
modulator of the GABAg receptor, and kainic acid, a kainate receptor agonist, were 
purchased from Tocris Bioscience (Bristol, United Kingdom). All other reagents used 
were o f analytical grade and purchased 6om  either Sigma-Aldrich (Poole, Dorset, 
United Kingdom) or Fisher Scientific (Loughborough, Leicestershire, United 
Kingdom).
4.2.3 Genotyping (Qualitative PCR)
Genotyping was prefbrmed as described in a previous chapter (section 2.2.2).
4.2.4 PTZ Seizure Induction
Adult wild-type, GABAgia'^' and GABAgia'^' animals (aged 26.7 ± 1 .1  weeks; weight
33.6 ± 0.4 g) were injected subcutaneously with PTZ (40 or 60 mg/kg body weight) 
dissolved in saline or vehicle control (saline) into the scruff of the animals in an 
injection volume of 5 ml/kg. These animals were observed fbr 15 minutes prior to 
injection fbr baseline activity and 45 minutes fbllowing the injection fbr seizure 
activity. Mice surviving the observation period were killed by cervical dislocation.
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PTZ-induced seizure activity was observed as hypoactivity, partial clonus, generalised 
clonus and tonic-clonic seizures, as described previously (Ferraro gZ a/., 1999). 
Hypoactivity was observed as decreased motor activity with the animal in a prone 
position (prostrate position). Partial clonus was seen as clonic seizures involving the 
head and fbre limbs. Generalised clonus was seen as a rearing, loss of righting, clonus 
involving all limbs and wild-running. Tonic-clonic seizures were seen with as 
extension of all limbs normally preceding death. For the intervention studies, animals 
were injected intrapenitoneally with baclofen (6 or 12 mg/kg) dissolved in saline, 
CGP3079 (30 mg/kg) dissolved in 5 % dimethyl sulfbxide (DMSO) with 5 % Tween 
80 in reverse osmosis water (RO) or matched vehicle control (saline or DMSO/Tween) 
in an injection volume of 5 ml/kg 45 minute prior to the injection of PTZ (60 mg/kg).
4.2.5 Kainic Acid Seizure Induction
Kainic acid (25 mg/kg body weight) dissolved in saline or vehicle control (saline) was 
injected subcutaneously into the scruff o f the animal in an iiyection volume o f 5 ml/kg. 
Dose finding studies were prefbrmed in wild-type mice and indentified that 25 mg/kg 
to induce generalised seizures. Kainic acid induced hypoactivity, partial clonus, 
generalised clonus, tonic-clonic seizures and status epilepticus (continuing seizures), as 
described previously (Ferraro gZ a/., 1997). Seizure activity was observed fbr 120 
minutes and the surviving animals were killed by cervical dislocation.
4.2.6 Calculation o f  Seizure Score
Seizure levels were classified as 0 -  no abnormal behaviour, 1 -  hypoactivity, 2 -  
partial clonus, 3 -  generalised clonus, 4 -  tonic-clonic seizures and 5 -  death. 
Latencies, in minutes, to the onset of seizure levels 2 to 5 were recorded by a trained 
observer blinded to the genotypes and vehicle control verses drug treatment 
experiments. A seizure score was calculated using the modified equation (Figure 4.1) 
adapted from Ferraro gZ aZ. (1997; 1999). The original equation used the inverse of the 
latencies to seizure fbr levels 2 to 4. This equation was modified fbr this investigation 
to use time fbllowing onset o f behaviour as a faction of the observation period and 
included level 5 (latency to death). Seizure levels not observed were given the latency 
fbr the full observation time, either 45 or 120 minutes.
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f =2
Figure 4.1 -  Seizure score equation for the calculation of seizure severity.
Seizure scores were calculated fbr each animal using the equation above. Where T is 
the seizure level, T, is the latency in minutes to the seizure level and 7^ is the whole 
length of seizure observation in minutes. Seizure levels were classified as level 2 fbr 
partial clonus, level 3 fbr generalised clonus, level 4 fbr tonic-clonic seizure and level 
5 fbr death. Animals were observed fbr 45 minutes with PTZ and fbr 120 minutes with 
kainic acid.
4.2.7 Data Analysis
The percentage of the observation period to the onset o f each seizure level was 
calculated as the proportion o f the observation period to the first instance of activity at 
that level. Latencies analysed with parametric tests using either a one-way or a two- 
way ANOVA with Bonferroni post-hoc test or a Students' t-test. Maximum seizure 
levels and the calculated seizure scores were non-parametric data and were analysed 
using one-way Kriskal-Wallis test or fbr two-way data using an extension o f the 
Kriskal-Wallis test giving a test statistic with a distribution (Zar, 1984). Pair-wise 
comparisons o f non-parametric data were performed using the Mann-Whitney U test 
with Bonferroni correction. All data are presented as mean ± SEM.
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4.3 Results
4.3.1 Spontaneous Seizures
Spontaneous seizures were observed during cage cleaning in a sub-population of 
GABAgia^ mice older than 4 months, from different parental backgrounds. These 
seizures, however, were not seen during all cage cleaning sessions. In a population of 
12 GABAgia'^' mice allowed to age older than 4 months 4/12 were observed to display 
spontaneous seizures on a small number o f occasions. Seizures were observed as a 
brief period o f rapid fbrelimb movement and head bobbing without loss of righting, 
this progressed on to rapid synchronised jerking o f the fbre and hind limbs with loss of 
righting. Seizures lasted fbr approximately 20 seconds and were fbllowed by a period 
of hypoactivity and grooming. These seizures were not induced by handling or a startle 
by noise in mice either showing previous seizure activity or those without prior 
observed seizures. Age-matched wild-type and GABAgiy'' mice were never observed 
to display spontaneous seizures. The GABAgia'' mice may therefbre be more prone to 
seizure.
4.3.2 Seizure Induction with PTZ
In order to characterise seizure susceptibility in all genotypes a chemoconvulsant was 
used to induce seizures. PTZ was found to induce partial clonus in all mice at doses of 
40 mg/kg (» = 5) and 60 mg/kg (n =7) fbr all genotypes. Few mice injected with the 40 
mg/kg PTZ displayed generalised clonus (wild-type 2/5, GABAgia'^' 1/5 and GABAgiy' 
0/5) without progressing to tonic-clonic seizures and all mice survived to the end of 
the observation period. Generalised clonicity seen in all animals injected with 60 
mg/kg PTZ with 1/7 wild-type, 6/7 GABAgia'^' and 1/7 GABAgiy'^' mice progressing 
to show tonic-clonic seizures. All transgenic mice showing tonic-clonic seizures died 
from the first tonic-clonic seizures, but the wild-type mouse displaying tonic-clonic 
seizure survived. No seizures were observed in any animals injected with the saline 
vehicle control (n = 7 fbr all genotypes), demonstrating that handling and injection of 
these mice did not invoke seizures.
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The maximum seizure level and the calculated seizure score were fbund to increase 
with higher concentrations o f PTZ in GABAgia'^' and GABAgiy'^' mice (Figure 4.2; 
maximum seizure level 77 [1, A = 36] = 16.5, < 0.001 ***; seizure score 77 [1, TV =
36] = 20.0,/) < 0.001 ***) but not in the wild type animals. No difference between the 
genotypes was fbund with maximum seizure level at the 40 mg/kg PTZ concentration 
(77 [2, TV = 15] = 2.3, p  > 0.05), but GABAgiy'^' mice were fbund to have lower seizure 
scores compared to the wild-type and GABAgia" ' animals (pair-wise comparison, p  < 
0.05 *). With 60 mg/kg PTZ both maximum seizure level and seizure score showed 
increases in GABAgia'^' mice compared to wild-type and GABAgiy'^' mice (maximum 
seizure level 77 [2, TV= 21] = 14.2,p < 0.001 ***; seizure score 77 [2, TV= 21] = 13.0,;; 
< 0.01 **). Latencies to partial seizures were decreased with the higher PTZ 
concentration in wild-type and GABAgiy'^' mice (Figure 4.2; 7^  [1, 30] = 18.1, <
0.001 ***), indicating a faster seizure onset. The partial seizure latency was lower in 
GvABAgia' '^ compared to GABAgiy'^' mice (genotype effect, F  [2, 30] = 4.5, < 0.05).
The latency fbr generalised seizures did not differ between the genotypes with 60 
mg/kg PTZ administration (F  [2, 20] = 1.5, /? > 0.05). The largest proportion o f the 
observation period was spent at partial seizures level fbr 40 mg/kg PTZ and shifted to 
higher seizure levels with the 60 mg/kg PTZ dose (Figure 4.3). These findings show a 
PTZ dose-dependent increase in seizure activity in the transgenic animals. The 
GABAgiy'^' mice had a lower seizure activity at the lower PTZ concentration, whereas 
GABAgia'^" mice displayed greater seizure activity at the higher concentration.
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Figure 4.3 -  G reater proportion of time was spent at higher seizure levels with 
high dose PTZ.
Wild-type, GAB Agi a '' and GABAgib  ^ mice were injected with PTZ and observed to 
display hypoactivity (level 1), partial clonus (level 2), generalised clonus (level 3), 
tonic-clonic seizures (level 4) and death (level 5). The proportion of the observation 
period (45 minutes) to the onset of seizure levels was calculated. The majority o f time 
was spent at level 2 with 40 mg/kg PTZ and level 3 or greater with 60 mg/kg PTZ. 40 
mg/kg n = 5 and 60 mg/kg n ^ l .
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4.3.3 Seizure Induction with Kainic Acid
Systemic administration of kainic acid (25 mg/kg) invoked partial seizures in mice 
6om  all genotypes (wild-type 5/5, GABAgia'^' 5/5, GABAgib'^' 4/5) with the m ^ority 
o f these mice progressing to show generalised seizures (wild-type 5/5, GAB Agi a '' 4/5, 
GABAgib'^' 3/5). Tonic-clonic seizures was observed in 1/5 wild-type, 2/5 GABAgia'^' 
and 4/5 GABAgib'' mice, these mice often showed recovery or a reduction in seizure 
level before displaying tonic-clonic seizure again (status epilepticus). However, by the 
end o f the observation period some of these mice eventually died from these seizures 
(wild-type 1/5, GABAgia'^' 1/5, GABAgib'^' 4/5). Maximum seizure level (7T [2, A  = 
15] = 1.3, > 0.05), seizure score ( / /  [2, A =  15] = 1.8,/? > 0.05) and the latencies to
partial (F  [2, 14] = 0.2, > 0.05) and generalised seizures (F  [2, 14] = 0.1, /? > 0.05)
were found not to differ between the genotypes (Figure 4.4). The largest proportion of 
the observation period for wild-type and GABAgia'^' mice was spent at the generalised 
seizure level, whereas, GABAgib'' animals died early on in the observation period 
(12.13 ± 3.08 minutes in a 120 minute observation period) making death the largest 
proportion o f the observation time (Figure 4.4). These findings are more variable 
compared to those seen with PTZ and no difference was identified between the 
genotypes.
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4.3.4 Intervention with GABAb Pharmacological Agents
Baclofen concentrations used in this study were selected based on previous 
investigations o f the effects o f baclofen on motor activity in these GAB Agi isofbrm 
knockout mice. At a dose o f 6 mg/kg baclofen only wild-type mice demonstrated 
ataxia, whereas mice from all genotypes had ataxia with 12 mg/kg (Jacobson gt a/., 
2006a). Baclofen was administered intraperitoneally 45 minutes before the PTZ 
injection, this gave peak analgesic (Balerio and Rubio, 2002a) and motor effect 
(Malcangio gt a/., 1991), suggesting that baclofen may have peak activity just prior to 
the PTZ challenge.
Baclofen pre-treatment (6 or 12 mg/kg) was found to sedate the mice and was 
observed as hypoactivity during the baseline period and lethargy during injection of 
PTZ, whereas, vehicle treated control (saline/PTZ) displayed similar behavioural 
responses to those seen with 60 mg/kg PTZ alone. All mice pre-treated with vehicle 
control (» = 5), 6 mg/kg baclofen (/? = 5) and 12 mg/kg baclofen (w = 4) were observed 
to have partial clonus which progressed to generalised clonus, additionally all 
GAB Agi a '' mice were observed to display tonic-clonic seizures. In contrast, the 
proportion o f wild-type and GABAgiy'^' mice displaying tonic-clonic seizures was 
increased with increasing baclofen concentration (wild-type: saline 1/5, 6 mg/kg 2/5, 
12 mg/kg 4/4; GABABik'^': saline 0/5, 6 mg/kg 1/5, 12 mg 3/4). No wild-type or 
GABAgib ' mice died from the seizures. However, all saline treated (5/5), 2/5 6 mg/kg 
baclofen and 2/4 12 mg/kg baclofen treated GAB A sia'' animals died from seizures 
during the observation period.
Baclofen did not change the maximum seizure level in mice from any genotypes (Ff [2, 
#  = 42] = 3 .0 ^  > 0.05), however a genotype effect was identified (Figure 4.5; Ff [2, A/ 
= 42] = 19.4 jc) < 0.001 ***). With the baclofen vehicle control, the maximum seizure 
levels were higher in GABAgia'' mice compared to both wild-type and GABAsib'' 
animals, as seen with the PTZ alone (Figure 4.2). With 6 mg/kg baclofen treatment 
GAB Agi a'" mice had higher seizure levels than GABAgib"' mice and no differences 
were found with 12 mg/kg balcofbn. The calculated seizure score decreased -  with 
both concentrations o f baclofen -  for GABAgia ^  mice, but increased in GABAsib ^
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with 6 mg/kg (Figure 4.5; / /  [2, #  = 42] = 24.6 < 0.001 ***). This decrease in
seizure score was due to more GAB Agi a'" mice surviving, whereas the increase in 
GABAgib'^ animals was due to mice showing higher seizure levels. No differences 
between the genotypes were identified with seizure score ( / /  [2, #  = 42] = 0.3 /? > 
0.05). Latencies to the onset of partial clonus levels were lower in GABAgia^ mice 
compared to GABAsib ' animals in the baclofen vehicle control group (Figure 4.5; 
genotype, F  [2, 32] = 5.9 /) < 0.01 **; baclofen, F  [2, 32] = 8.2, < 0.01 **), in
contrast to the 60 mg/kg PTZ alone in the previous study (Figure 4.2). Latencies to 
partial clonus were decreased in GABAgib  ^ mice with 12 mg/kg baclofen compared to 
the vehicle control. The findings suggest that the onset o f partial clonus was faster in 
GABABib"' mice with baclofen. No differences were found in the latencies to 
generalised clonus with baclofen and between the genotypes (Figure 4.5; genotype, F  
[2, 32] = 1 .5 ^  > 0.05; baclofen, F  [2, 32] = 8 .2 ,^  > 0.05). Latencies to tonic-clonic 
seizures were analysed with 12 mg/kg baclofen (the only level with sufficient data for 
all genotypes) and showed that the latency to seizure onset was lower in GABABia ^  
mice compared to wild-type animals (Figure 4.5; F  [2, 11]= 4.7,/? < 0.05 *). Latencies 
to tonic-clonic seizure onset were unchanged with baclofen in GABAB la'^ ' mice (F  [2, 
13] = 0.1,/? > 0.05). The largest proportion of the observation period for wild-type and 
GABABib  ^ mice was spent at the partial clonus level with baclofen vehicle control 
group, however, with 12 mg/kg baclofen pre-treatment the largest proportion shifted to 
generalised clonus (Figure 4.6). In contrast, all GABABia^ mice died in the baclofen 
vehicle control group making death the largest proportion of the observation period. 
This was changed for lower seizure levels with injections o f either concentrations o f 
baclofen. Overall, these results demonstrated that wild-type mice showed little change 
in seizure activity with baclofen, whereas GABABib"' had an increase in seizure 
activity and GABABia  ^ showed a decrease in seizure activity.
The positive allosteric modulator o f the GABAB receptor, CGP7930, is a hydrophobic 
compound therefore in previous investigations it has been administered orally as a 
suspension in methyl cellulose (Jacobson and Cryan, 2008) or by parental injections 
dissolved in ethanol (Brusberg gt a/., 2009) or a suspension in methyl cellulose (Smith 
gt 6z/., 2004; Liang gt a/., 2006; Paterson gt a/., 2008). In this investigation ethanol was
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excluded as a vehicle due to its interaction with the GABAA receptor (Sapp and Yeh,
1998). For this investigation, CGP7930 did not form a homogenous suspension in 
methyl cellulose. However, CGP7930 dissolved in DMSO and did not precipitate out 
when mixed with Tween 80 and RO water. Both DMSO and Tween 80 have been 
shown not to alter locomotor activity in mice at the concentration used in this 
experiment (Castro gt a/., 1995). Studies using CGP7930 have used varying times 
prior to experiments hom  15 minutes (Smith gr a/., 2004) to 1 hour (Jacobson and 
Cryan, 2008; Paterson gr a/., 2008). For consistency with the baclofen experiment a 
period of 45 minutes was chosen between administrations o f CGP7930 and PTZ.
Mice treated with CGP7930, the GABAb receptor positive allosteric modulator, did 
not differ from the vehicle control (DMSO/Tween) during the observation period prior 
to PTZ challenge. PTZ induced partial clonus was seen in all CGP7930 vehicle control 
pre-treated animals, with 3/4 and 2/4 animals showing generalised clonus and tonic- 
clonic seizures, respectively, in wild-type animals. All GAB Asia'" (M = 4) and 
GABAgib  ^ (/% = 4) animals treated with the CGP7930 vehicle control displayed 
generalised clonus then tonic-clonic seizures. In both wild-type and GABAgib  ^ 2/4 
mice died from tonic-clonic seizures in the vehicle control group, whereas all (4/4) 
GABAsia'' animals died. GABAgia'' mice pre-treated with CGP7930 showed no 
change in PTZ-induced seizures compared to the vehicle control group with all mice 
showing partial clonus, generalised clonus, tonic-clonic seizures and death (» = 4). In 
addition, no change in PTZ-induced seizure phenotypes was observed in wild-type 
CGP7930 pre-treated animals compared to the vehicle control (partial clonus, 4/4; 
generalised clonus, 2/4; tonic-clonic seizures, 2/4; death, 2/4). In contrast, GABAsib'' 
mice were found to have a reduction in the number of animals reaching tonic-clonic 
seizures (1/4) and all survived the observation period (» = 4).
No differences were found between the CGP7930 treatment and the genotypes for 
maximum seizure level and the latencies for partial and generalised clonus (Figure 4.7; 
seizure level, 77 [1, # =  24] = 0.5,/? > 0.05; partial clonus, F  [1, 18] = 0.03,/? > 0.05; F  
[1, 17] = 0.05,/? > 0.05). The calculated seizure scores were decreased in CGP7930 
pre-treated GABAsib' ' mice compared to vehicle control, however while a genotype
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effect was found no difference was found using post-hoc testing (77 [1, A  = 24] = 6.1, /? 
< 0.01 **). The latency to tonic-clonic seizures in GABAsia' ' animals was increased 
with CGP7930 pre-treatment (t [6] = 3.7,/? < 0.05 *) although no change was found in 
the seizure score. In wild-type mice given the vehicle control group, the largest 
proportion o f the observation period was equal for both partial and generalised clonus, 
this shifted to just generalised clonus with CGP7930 pre-treatment (Figure 4.8). 
Whereas, with GABAgia^ mice all animals died with both vehicle control and 
CGP7930, therefore the largest proportion o f the observation period was death for both 
pre-treatments. GABAgib^ mice showed the largest changes, from tonic-clonic 
seizures having the largest proportion with vehicle control to generalised clonus with 
CGP7930 pre-treatment. These finding suggests CGP7930 decreases severity in 
GABAgib  ^ mice, with no changes in wild-type and GABAgia ^  mice.
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Figure 4.6 -  Time spent at each seizure level was altered in GABAeia \  
GABAeib ’ and wild-type mice with baclofen treatm ent.
Wild-type, GABAeia’^ ' and GABAeib'^’ mice were injected with vehicle control (saline) 
or baclofen (6 or 12 mg/kg) prior to PTZ (60 mg/kg). Mice displayed hypoactivity 
(level 1), partial seizures (level 2), generalised seizures (level 3), tonic-clonic seizures 
(level 4) and death (level 5). The proportion o f the observation period (45 minutes) to 
the onset of seizure levels was calculated. The majority of time was spent at level 3 for 
wild-type and GABAsib'' mice with the vehicle control and shifted to higher seizure 
level with baclofen pre-treatment. GABAbla’^ ’ mice spent the majority of time at level 
5 for the vehicle control group and shifted for lower seizure levels with baclofen. 0 
mg/kg n = 5, 6 mg/kg n = 5 and 12 mg/kg n = 4.
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Figure 4.8 -  CGP7930 lowered seizure levels in GABAeib ’ mice.
Wild-type, GAB Asia"' and GABAsib"' mice were injected with vehicle control 
(DMSO/Tween) or CGP7930 (30 mg/kg) prior to PTZ (60 mg/kg). Mice displayed 
hypoactivity (level 1), partial clonus (level 2), generalised clonus (level 3), tonic-clonic 
seizures (level 4) and death (level 5). The proportion of the observation period (45 
minutes) to the onset o f seizure levels was calculated. The majority of time was spent 
equally at level 2 and 3 for wild-type with vehicle control and just in level 3 for 
CGP7930 pre-treatment. GABAeia  ^ mice had a large proportion of the observation 
period spent in level 5 with both vehicle control and CGP7930 treatment. GABAeib 
mice spent majority o f time at level 4 for control and decreased to level 3 with 
CGP7930. 0 mg/kg n = 4 and 30 mg/kg n = 4.
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4.4 Discussion
Spontaneous seizures were observed in GABAeia^ mice but were not seen in either 
wild-type or GABAeib  ^ animals. In addition, GABAeia'' mice displayed greater PTZ- 
induced seizure severity compared with both wild-type and GABAeib'^' mice. 
Intervention with baclofen reduced the seizure score in GABAeia'^ mice and 
conversely increased the score in GABAeib^ animals. However, pre-treatment with 
CGP7930 produced a reduction in seizure score o f GABAeib  ^ animals and no change 
in GABAeia'' and wild-type mice.
For this investigation the seizure score equation created by Ferraro cr a/. (1997; 1999) 
was adapted to use the time following onset of behaviour to each seizure level as a 
fraction o f the total observation time, with death as an additional level. Using the 
original equation data showed a large range between data points within the same group 
(not shown), this was due to the implementation o f the reciprocal of latency to each 
seizure level. It was found that by using latencies as fractions of total observation time 
that the data were more consistent with a lower variance.
Spontaneous seizures were observed in the GABAeia^ animals in agreement with 
reported findings from investigation in these mice (Vienne gt a/., 2010). The seizure 
phenotypes observed during the spontaneous seizures were associated with generalised 
activity. However, as the electroencephalography (EEG) recordings preformed by 
Vienne g/ a/. (2010) were across a single hemisphere there are no findings to indicate 
whether the initial seizure activity was &om partial seizures with secondary 
generalisation or generalised seizures alone. Both increased expression of the 
GABAeia (Wu gr a/., 2007) and the complete knockout of the GABAei subunit 
(Schuler gf a/., 2001) resulted in atypical absence seizures. Classification of seizures 
from their phenotype is complicated in these mice as atypical absence seizures can 
occur with partial consciousness and voluntary movement (Cortez gf 6z/., 2001). 
Therefore, the classification of the seizure activity in the GABAeia  ^ animals needs to 
be determined using bilateral EEG recordings.
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These GABAei isofbrm knockouts have also been transferred to a C57BL/6 mouse 
line, in these mice seizures were observed at a younger age than seen in this study and 
had a shortened lifespan compared to BALB/c mice (personal communications with Dr 
D. van der Veen, University o f Surrey). This suggests that the selection of background 
mouse strain for this knockout is important for spontaneous seizure prevention with the 
deletion o f the GABAgia isofbrm. These observations are consistent with the 
differences between the background strains seen with the GABABi'^' knockout 
mutation where BALB/c mouse (Schuler gt a/., 2001) demonstrated a greater seizure 
resistance compared to 129Sv/J (Prosser g/ a/., 2001) and C57BL/6 mice which had a 
maximum lifespan between 3 and 8 weeks (Queva g^  a/., 2003; Haller gr a/., 2004). 
These findings suggest that the absence of the GABAgia isofbrm in GABAgr^' mice is 
key to seizures and development of epilepsy in the G A BA si'' animals. Interestingly, 
BALB/c mice have been shown to have greater susceptibility to PTZ-induced seizures 
compared to B57BL/6, which were the most resistant of the mouse strains tested 
(Kosobud gf a/., 1992). This difference is suggested to be due to a faster accumulation 
of PTZ in the brain of BALB/c mice compared to C57BL/6 animals (Kosobud et al ,  
1992). BALB/c mice have been reported to show a higher resistance to kainic acid- 
induced seizure compared to other mouse strains (McLin and Steward, 2006). 
However, both BALB/c and B57BL/6 strains show resistance to kainic acid-induced 
cell death in the hippocampus (Schauwecker, 2002; McLin and Steward, 2006). These 
data suggest that mouse strain resistance to chemoconvulsants is not indicative o f their 
resistance to seizures from genetic modiEcation.
GABAsia  ^ mice displayed an increase in seizure activity induced from the convulsant 
PTZ compared to both GABAgib  ^ and wild-type mice. The mechanism of PTZ- 
induced generalised seizures is through antagonism at the GABAA receptors to reduce 
inhibition and thereby enhance excitation (Fisher, 1989; De Deyn g/ a/., 1992). The 
current study showed that the threshold to PTZ-seizures is reduced in GABAgia ^  mice, 
this is possibly due to the loss of gluatmatergic heteroreceptors as seen in the limbic 
system and which may promote the spread of activity to other brain regions (Shaban g/ 
a/., 2006; Vigot g/ a/., 2006; Ulrich g^  a/., 2007; Guetg gr a/., 2009).
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Kainic acid produced no differences between the genotypes, which suggests that the 
GAB As 1 isofbrms do not play a critical role in the seizures evoked from this 
chemoconvulsant compared to PTZ. However, inter-animal variations in responses 
were large compared to those seen with PTZ and may mask differences between the 
genotypes. Reponses to kainic acid have been reported to vary in rats of different 
strain, age, gender and body weight -  possibly due to changes in the bioavailability of 
kainic acid from systemic administration (Sperk, 1994). Focal injection of kainic acid 
into the hippocampus induces histological changes and recurrent seizures similar to 
those seen in temporal lobe epilepsy. In this model, an acute and permanent reduction 
in GABAg receptor expression was reported in the CAl with a long term up regulation 
o f the GABAs receptors in the dentate gyrus (Straessle gr a/., 2003), also seen in tissue 
resected from human temporal lobe epilepsy patients (Princivalle g/ a/., 2003). This 
suggests a compensatory inhibitory mechanism &om an increase in GABAsia 
heteroreceptors at glutamatergic terminals (Vigot g /a/., 2006; Guetg g /a /., 2009).
Baclofen is reported to induce absence seizures via GABAs-mediated IPSCs in the 
thalamocortical relay neurons (Kim gf^  a/., 2001). However induction o f this seizure 
activity requires a concentration o f baclofen higher than used in the current 
investigation. In agreement, baclofen treatment fbr 45 minutes in the absence o f PTZ 
did not induce seizures in this study and no escalation of PTZ-induced seizure activity 
was observed in wild-type mice with baclofen pre-treatment. In addition, baclofen was 
not reported to induce seizures in other studies when peak physiological effects were 
observed (Malcangio gr a/., 1991; Balerio and Rubio, 2002a; Jacobson gf^  a/., 2006a). 
Furthermore, the concentrations of baclofen used fbr the current experiment have also 
been used fbr motor control investigations using the same mutant mouse line and no 
seizures have been observed (personal communications with Miss C. Mann, University 
o f Surrey).
GABAg receptor subtype expression has been shown to alter during post-natal 
development. At birth GABAgia is the predominant receptor subtype, however, its 
expression decreases while GABAgib expression increases to be the predominant 
GABAgreceptor subtype in adulthood (Fritschy g/ a/., 1999). As the receptor subtypes 
are known to have different roles in the synaptic compartment (Vigot gr a/., 2006), it
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suggests that the developing brain may have greater requirements fbr GABAg- 
mediated heterosynaptic inhibition compared to the adult brain. This notion is also in 
agreement with the finding of anti-seizure properties of baclofen in the neonatal rat 
compared with adult animals (Veliskova gr <3/., 1996) and may indicate that these anti­
seizure activities are due to greater activation of the GABAgia receptor subtype. 
However, the current study fbund that GABAgiy'' mice, expressing only GABAgia, 
had an increase in seizure activity with baclofen, whereas the GABAgia" ' mice showed 
a decrease in seizure activity with baclofen pre-treatment. Baclofen has been shown to 
be potent at suppressing PTZ-induced tonic-clonic seizures when injected into the 
globus pallidus (Chen gf a/., 2004), but the current investigation showed no decreases 
in tonic-clonic seizures with systemically administered baclofen. Indeed, the decrease 
in seizure activity in GABAgia" ' mice was mainly due to a reduction in mortality in the 
mice. This effect may be due to the muscle relaxant effects of baclofen, seen in both 
GAB Agi isofbrm knockouts (Jacobson gz^  a/., 2006a), thus preventing asphyxia from 
prolonged contraction of the intercostal muscles during the tonic-phase of the tonic- 
clonic seizures. Interestingly, an increase in seizure activity was seen in GABAgiy" " 
mice with baclofen, however, a decrease was seen with CGP7930. These differences 
may be due to differential mechanisms o f action. As baclofen activates all GABAg 
receptor, whereas, CGP7930 wdll only positively modulate receptors when GABA is 
also bound. The results from this study may suggest that universal GABAgia receptor 
activation has a disinhibitory action producing a pro-seizure effect. Whereas, increased 
activity of GABAgia receptors activated by endogenous GABA has an inhibitory 
action and produces an anti-convulsive effect, this effect may result h"om modulation 
o f receptors in the globus pallidus (Chen g/ a/., 2004).
This study has shown fbr the first time that the GABAgia isofbrm is essential fbr 
maintaining a threshold to PTZ-induced seizures. However, the observation of 
spontaneous seizures indicates that GABAgia receptors are likely to have a critical role 
in epileptogenesis. This mechanism may be due to impeding the spread o f seizure 
activity by GABAg heteroreceptor activity. Activation of GABAgia receptor subtype 
by the agonist baclofen may cause disinhibition, whereas activation by the positive the 
allosteric receptor modulator CGP7930 is inhibitory.
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5 General Discussion
5.1 GABAb receptor subtypes within the dentate gyrus
Investigations conducted fbr this thesis fbund that the glutamatergic terminals of the 
associational/commissural pathway within the dentate gyrus and the mossy fibre 
terminals in the hippocampal CA3 demonstrated positive staining fbr the GABAB(ia, 2) 
receptor subtype. However, it was determined that the perforant path-dentate gyrus 
granule cell synapse lacks functional GABAg heteroreceptors. The perforant path- 
dentate gyrus synapse seems to be an exception to the current idea that the GABAg(ia, 
2) subtype is common in glutamatergic terminals (Perez-Garci a/., 2006; Shaban g/ 
a/., 2006; Vigot g/ a/., 2006; Ulrich gr <2/., 2007; Guetg gf a/., 2009). On the other hand, 
a small GABAg heteroreceptor-mediated inhibition was fbund in the absence of 
GABAA-mediated inhibition, therefore the absence of this GABAg effect may be due 
to masking by feed-forward inhibition into the dentate gyrus. Further examination of 
feed-forward inhibition in the dentate gyrus is required to confirm this hypothesis.
Activation of either GABAgia or GABAg ib produces predominantly disinhibition 
within the dentate gyrus. In agreement, the inhibitory basket cells o f the dentate gyrus 
expressed both the GABAgia and GABAgib isofbrms and suggest that both may act as 
autoreceptors. The postsynaptic inhibition observed was solely via the GABAg(ib, 2) 
receptor subtype, which is in agreement with findings from the hippocampus (Vigot gt 
a/., 2006) and the cortex (Perez-Garci gt <2/., 2006). GABAg heteroreceptors on the 
associational/commissural recurrent excitation pathway are exclusively composed of 
the GABAgia subtype. The overall increased expression of both GABAg 1 isofbrms 
observed in epileptic patients, could lead to increased or decreased network excitation 
depending on the synaptic locations of these receptors (Princivalle gr a/., 2003). For 
example, upregulation of either GABAgia or GABAgly containing autoreceptors would 
be expected to enhance disinhibition and promote excitation. Whereas, greater 
expression o f the GABAg(ia, 2) subtype on the associational/commissural pathway 
should increase heteroreceptor-mediated inhibition and GABAgib at postsynaptic sites 
will lead to enhanced IPSCs, resulting in decreased excitation. Activation of the 
GABAg receptors in epileptic rats reduces spontaneous activity recorded in the dentate 
gyrus (Sokal and Large, 2001). However, it can be speculated that this reduction in the 
spontaneous activity in the dentate gyrus may also involve GABAg receptors
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elsewhere in the limbic system. This investigation fbund that GABAg receptor 
activation was predominantly disinhibitory rather than inhibitory, indicating that 
increased expression o f GABAg receptors could result in excitation rather than 
inhibition.
5.2 Spontaneous Seizures and the Localisation of the GABAg(ia, 2) Subtype 
This study observed spontaneous seizures in the GABAgia'^' mice in agreement with
findings from another investigation using these animals (Vienne gt a/., 2010),
indicating that the GABAgia containing receptors may have a critical role in
epileptogenesis. Both spontaneous partial and generalised seizures were observed in
the complete GABAgi knockout mice (Schuler gt a/., 2001), suggesting that the
spontaneous seizures observed in the GABAgia'' animals may be either partial or
generalised. At present the classification of these seizures in the current investigation
remains unclear. All seizures observed were generalised, therefbre it is essential to be
determined whether the initial activity was partial with secondary generalisation or the
result o f generalised seizure activity alone. Additional investigation using bilateral
EEG recordings in these mice are needed in order to identify whether the initial
activity is partial or generalised. Immunohistochemical labelling o f the GABAgi and
GABAg2 subunits demonstrated a predominance in expression o f the GABAg(ia, 2)
subtype in the amygdala and the caudate putamen. Collectively, the exclusive
expression o f the GABAgia containing subtype at glutamate terminals in the amygdala
(Shaban gr a/., 2006) and hippocampal fbrmation (Vigot gr a/., 2006; Guetg gf a/.,
2009) suggests a greater susceptibility o f the GABAgia'^' mice to seizure activity in the
limbic system, thus having a greater susceptibility to partial seizures. However, the
GABAgia containing subtype is also present at glutamatergic input sites to the
inhibitory intemeurons in the thalamus (Ulrich gf <2/., 2007) therefbre their loss may
increase synchronised firing of the inhibitory intemeurons and invoke absence seizures
or allow fbr the generalisation of the partial seizure activity (Cassidy and Gale, 1998).
5.3 Chem oconvulsant Induced Generalised Seizures and Function of the 
GABAg Receptor Subtypes
This study fbund that the GABAgia'^' animals had a greater seizure score in PTZ- 
induced generalised seizures, which may indicate that these animals have a greater
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susceptibility to generalised seizures. Immunhistochemical labelling o f the GABAg 
receptor subunits within the fbrebrain identified the thalamus as having a predominant 
expression of the GABAg(ib, 2), suggesting a stronger GABAg effect in the thalamus of 
the GABAgia'^' animals. However, as the GABAgia subtype acts at presynatpic 
glutamatergic terminals in the thalamus (Ulrich gr a/., 2007), hippocampus (Vigot g/ 
a/., 2006; Guetg gr a/., 2009), amygdala (Shaban gr aZ., 2006) and cortex (Perez-Garci 
gf a/., 2006), the GABAgia'^' mice will lack GABAg heteroreceptor-mediated 
inhibition. The loss o f this subtype enhanced excitation, thus strongly suggesting that 
this increase is due to the loss of the GABAg heteroreceptor-mediated inhibition.
Baclofen pre-treatment in the GABAgia'^' mice reduced seizure severity, suggesting 
that activation of all GABAgib receptors indiscriminately had a net inhibitory effect on 
seizure activity. This is possibly due to the fact that the postsynaptic inhibition is 
mediated via the GABAgib containing receptors in the dentate gyrus, CAl (Vigot gr 
a l, 2006) and cortex (Perez-Garci e t a l, 2006). In agreement, local injection of 
baclofen into the globus pallidus suppressed tonic-clonic seizures via activation of the 
postsynaptic receptors (Chen gr aZ., 2004). Although the current study fbund the 
expression o f both GABAg receptor subtypes to be equal in the globus pallidus, 
activation o f the GABAgib containing receptors at postsynaptic sites may decrease the 
excitability o f globus pallidal neurons and invoke a decrease in tonic-clonic seizures in 
the GABAgia" ' mice with baclofen pre-treatment.
Decreased seizure activity seen with pre-treatment o f the GABAg positive allosteric 
modulator, CGP7930, in the GABAgib"' '^ mice results from enhanced GABAgia 
containing receptors activity by endogenous GABA release. Therefbre, inhibition may 
be mediated by the selective increase in function of the physiologically activated 
GABAgia heteroreceptors to produce a net inhibitory effect. This may be due to 
selective enhancement of the inhibition by the GABAg heteroreceptors in the 
amygdala (Shaban gZ aZ., 2006), the cortex (Perez-Garci gZ aZ., 2006), the CAl (Vigot 
gZ ^Z., 2006), the CA3 (Guetg gZ aZ., 2009) and the thalamus (Ulrich gZ aZ., 2007). The 
absence o f CGP7930 induced alteration in seizure scores in the GABAgia'^' suggests 
that enhancement of the physiologically activated GABAgib may not produce 
sufficient inhibition, unlike that seen with baclofen. In addition, CGP7930 may not 
produce disinhibition as seen with the full agonist baclofen. However, CGP7930 has
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been shown to invoke disinhibition -  in preference to inhibition -  in C A l, suggesting 
greater activation of the autoreceptors (Chen gZ a/., 2006). Activation of the 
autoreceptors in the midline thalamus may reduce GABA release and suppress seizure 
activity (Miller gZ aZ., 1989; Miller and Ferrendelli, 1990). However, the effect of 
CGP7930 on disinhibition in the thalamus needs to be investigated further to reveal 
how autoreceptors may be modulated.
5.4 Chem oconvulsant Induced Partial Seizures and the Location of the GABAg 
Receptor Subtypes
The loss o f the GABAg heteroreceptors within the limbic system of GABAgia'^' mice 
may increase their susceptibility to partial seizures (Shaban gZ aZ., 2006; Vigot gZ üfZ., 
2006; Guetg gZ aZ., 2009). In addition, the changes in GABAergic function within the 
midline thalamic nuclei may increase the likelihood o f seizures activity spreading to 
other regions (Cassidy and Gale, 1998). Loss of GABAg(ib, 2) expression within the 
thalamus of the GABAgib'^' mice may increase generalisation of partial seizures 
activity. However, no differences was observed between GABAgia % GABAgib" ' and 
wild-type animals using the acute kainic acid model. Findings from this study suggest 
that the GABAg receptors are unlikely to be critical in the control or suppression of 
partial seizure activity. However, the GABAg receptors may have a more important 
role in development o f partial epilepsy. Investigations into the thresholds of seizure 
onset using electrical or chemical kindling models of mTLE in these transgenic 
animals may be useful to further characterise the roles of GABAg subtypes in 
epileptogensis.
5.5 Conclusions
GABAg(ia, 2) is the predominant GABAg receptor subtype expressed in the amygdala, 
and caudate putamen. Whereas, GABAg(ib, 2) is the main subtype in the thalamus. The 
current study provides the Erst evidence that dentate gyrus inhibitory intemeurons 
express both the GABAgia and the GABAgib isofbrms and that both receptor subtypes 
evoke disinhibition. In contrast to previous research (Lanthom and Cotman, 1981; Ault 
and Nadler, 1982, 1983a) no GABAg heteroreceptors were identiEed on the perfbrant 
pathway-granule cell synapse. Furthermore, the Endings presented in this thesis 
demonstrate for the Erst time that postsynaptic inhibition in the dentate gyrus is
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mediated exclusively by the GABAg(ib, 2) subtype. Also, the loss o f GABAgia 
containing receptors increases susceptibility to generalised seizures. In addition, the 
absence of the GABAgia isofbrm was responsible fbr the development of recurring 
spontaneous seizures in agreement with previous Endings, (Vienne gZ aZ., 2010). 
Therefbre, it can be suggested that the loss o f the GABAgia isofbrm is cntical fbr the 
development o f seizures observed in disorders involving the GABAg 1 receptor -  
autoimmune encephalitis (Lancaster gZ z^Z., 2009; Boronat gZ arZ., 2011) and 
polymorphism (Xi gZ arZ., 2011). Ultimately the novel Endings presented in this thesis 
could lead to the design o f pharmacological agents targeting the GABAgia isofbrm in 
the treatment o f seizures.
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